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Abstract 
 
Paget's disease of bone (PDB) is a systemic disease characterized by increased 
bone resorption and formation, causing gradual destruction of parts of the skeleton and 
subsequent reconstruction of a more fragile bone. PDB has an overall incidence of 2% 
in the population over 55 years. PDB is a complex disease with multiple genes 
implicated in its pathogenesis, but in its monogenic form, only one gene (SQSTM1) has 
been linked to PDB. 
To identify novel genes causing familial PDB, we performed whole exome 
sequencing (WES) in six individuals from a Portuguese multiplex family composed of 
five PDB cases, two unaffected individuals and one individual with unclear diagnosis. 
Given the uncertain diagnosis for one family member, we conducted two analyses: 
model 1, in which this individual is considered affected and model 2 where he is 
unaffected. DNA was captured using the SureSelect Target Enrichment System kit and 
sequenced using Hiseq2000 (Illumina’s Solexa). We identified three variants (c.C4786T 
(KIAA1875), c.C53T (NLRC3) and c.T566C (SRL)) in model 1 and one variant 
(c.G180A (SERINC2)) in model 2 that were present in all affected and absent from the 
unaffected in next-generation sequencing (NGS) data. Validation of these mutations by 
Sanger sequencing in all family members revealed that all model 1 mutations were 
present in all individuals, while the model 2 mutation was present in all family members 
except the individual with unclear diagnosis. None of these variants were present in a 
second Portuguese PDB multiplex family. 
In conclusion, our findings support the notion that bioinformatics analyses of 
NGS data is a process requiring optimization. We found four novel variants which may 
cause PDB in this family with an autosomal dominant pattern of inheritance and 
incomplete penetrance. Further studies in other PDB families are warranted to 
determine the pathogenic potential of these genes/variants. 
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Sumário 
 
Os ossos são um tecido importante do corpo humano com diversas funções, tais 
como, a protecção dos órgãos, armazenamento de minerais e reservatório para diversas 
células. Três células essências contribuem para que o tecido ósseo seja continuamente 
remodelado, preservando a homeostase mineral. Essas células são os osteoclastos, 
responsáveis pela reabsorção óssea, os osteoblastos, responsáveis pela formação óssea, 
e os osteócitos, responsáveis pela manutenção da integridade da matriz óssea. Em 
condições normais, a interacção entre as três células mantém a remodelação óssea 
equilibrada. No entanto, quando há um desequilíbrio na remodelação óssea podem-se 
desenvolver doenças, tais como a doença óssea de Paget (DOP). 
A DOP é uma doença sistémica em que a taxa de reabsorção e formação óssea 
estão aumentadas, causando uma destruição gradual de partes do osso, e uma 
consequente reconstrução de um osso mais frágil e desorganizado. A DOP é uma 
doença complexa com uma incidência de aproximadamente 2% na população com mais 
de 55 anos. 85% dos indivíduos afectados não manifesta qualquer sintoma, recebendo o 
diagnóstico para a DOP quando faz exames médicos de rotina. A percentagem de 
pacientes com sintomas manifesta dores, osteoartrite, fracturas, surdez, entre outros. 
Estudos sugerem que a doença surgiu no Reino Unido tendo-se depois 
dispersado para outras partes do mundo, provavelmente devido a fenómenos 
migratórios. A DOP é assim mais comum no Reino Unido, Austrália, Nova Zelândia, 
África do Sul, Ásia e em Portugal onde se verifica um foco de indivíduos afectados no 
Alentejo, mas não se conhece ainda uma causa para esse facto.  
A etiologia da DOP para a maioria dos casos é desconhecida. Pensa-se que a 
combinação de variantes comuns e/ou raras em conjunto com factores ambientais que 
despoletam a manifestação da doença. Dos factores ambientais estudados, o mais 
defendido como desencadeador da DOP é a infecção pelo paramamyxovirus, tendo-se 
observado no núcleo e citosol dos osteoclastos partículas parecidas com 
nucleocapsídeos de paramyxovirus. Os osteoclastos de doentes com DOP manifestam 
um fenótipo diferentes dos indivíduos não afectados, tendo mais núcleos por célula, 
resistência à apoptose e reabsorção óssea aumentada. No entanto, os factores ambientais 
requerem a co-expressão de factores genéticos para o desenvolvimento da doença. 
xiv 
 
Até ao momento, o SQSTM1 é o único gene identificado responsável pelo 
desenvolvimento da DOP familiar. No entanto, estudos de linkage e associação apontam 
para um risco aumentado para o desenvolvimento de DOP idiopática em indivíduos 
com polimorfismos nos genes CSF1, OPTN, TNFRSF11A, TM7SF4, NUP205, RIN3, 
PML e GOLGA6A. Contudo, são necessários mais estudos para identificar outras 
variantes causais que explicam a restante variabilidade genética. 
O nosso objectivo é identificar o(s) gene(s) que causa a DOP numa família 
Portuguesa com vários indivíduos afectados com DOP oriunda do Alentejo. Para tal, foi 
solicitado à Beijing Genomics Institute (BGI) Hong Kong que fizesse a sequenciação do 
exoma (whole-exome sequencing [WES]) dos seis familiares usando next-generation 
sequencing (NGS). NGS é uma técnica de sequenciação que produz dezenas de 
fragmentos de DNA (entre 100 a 500 pares de base) num curto período de tempo, que 
tem vindo a ser aplicada no estudo de diversas doenças monogénicas e complexas. WES 
é um método robusto para a identificação de variantes raras associadas a doenças 
complexas visto que o exoma (1-2% do genoma que codifica proteínas) representa uma 
grande parte do genoma onde é possível identificar variantes que produzem efeitos 
funcionais. O DNA foi capturado usando o kit SureSelect Target Enrichment System e 
sequenciado usando a plataforma Hiseq2000 (Illumina’s Solexa). 
Após verificarmos que a análise bioinformática da BGI continha diversos erros 
realiza-mos uma nova análise seguindo a pipeline do Broad Institute (Genome Analysis 
Toolkit (GATK) Best Practices workflow) optimizada para DNA humano, utilizando 
algumas ferramentas complementares. A pipeline encontra-se dividida em três fases, o 
processamento dos dados (alinhamento dos fragmentos de DNA com a sequência 
referência e remoção dos duplicados), a detecção das variantes, e por último a anotação 
e análise das funções das variantes usando ferramentas in silico (SIFT e PolyPhen-2). 
Por fim, os dados foram divididos em polimorfismos nucleótidicos simples (SNPs) e 
inserção e delecção de nucleótidos (InDels), contendo as variantes encontradas para 
cada indivíduo na região codificante. Para a análise dos SNPs, dividiram-se as variantes 
em não-sinónimas, sinónimas, ganho de um codão stop (stop-gain) e perda de um codão 
stop (stop-loss). Para a análise dos InDels dividiram-se as variantes em frameshift 
insertion/deletion, non-frameshift insertion/deletion, frameshift/non-frameshift block 
substitution, ganho de um codão stop (stop-gain) e perda de um codão stop (stop-loss). 
Analisámos ainda as variantes presentes nas regiões regulatórias mas não as validámos. 
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Assumindo que a mutação que causa a DOP nesta família é privada e nova 
excluímos todas as variantes presentes em bases de dados públicas (dbSNP e 1000 
Genomes Project). Como não foi possível obter até à conclusão desta tese o diagnóstico 
final de um dos familiares, criámos dois modelos de análise distintos, em que para o 
modelo 1 o indivíduo é considerado afectado e no modelo 2 é considerado não afectado.  
Pretendemos assim identificar as variantes na região codificante que estão 
presentes nos indivíduos afectados e ausentes no(s) indivíduo(s) não afectado(s). 
Validar as variantes identificadas por sequenciação de Sanger não só nos indivíduos 
sequenciados por WES, mas também nos restantes membros da família e numa nova 
família oriunda do Alentejo e ver a sua segregação. Estamos interessados em analisar 
variantes novas (ou seja, que não estão descritas em nenhuma base de dados) visto já 
existerem diversos estudos em variantes comuns que apenas explicam uma parte da 
variabilidade genética para a doença.  
Três novas variantes (c.C4786T (KIAA1875), c.C53T in (NLRC3) e c.T566C 
(SRL)) foram identificadas utilizando o modelo 1. No modelo 2 identificámos duas 
novas variantes, c.G180A (SERINC2) e uma delecção no PLEKHG5 (c.2163_2168del). 
As funções destes genes parecem estar associadas com o metabolismo ósseo, no entanto 
são necessários mais estudos para confirmar esta associação. 
A validação destas variantes por sequenciação de Sanger revelou que as três 
variantes identificadas para o modelo 1 (c.C4786T, c.C53T, and c.T566C) estavam 
presentes em todos os indivíduos afectados da família 1. No entanto, estas variantes 
também estavam presentes nos dois indivíduos controlo. Para o modelo 2, verificou-se 
que a variante c.2163_2168del insere-se numa posição diferente do genoma quando 
comparado com os resultados de WES, estando já reportada em bases de dados (estando 
presente em todos os indivíduos afectados e nos dois controlos da família 1, de acordo 
com a sequenciação de Sanger). Para o modelo 2, a variante c.G180A está presente em 
todos os indivíduos afectados e nos dois controlos, no entanto está ausente do individuo 
controlo adicional (incluído apenas no modelo 2). Numa segunda família multiplex 
Portuguesa com DOP nenhuma destas mutações foi detectada em nenhum membro da 
família.  
Podemos concluir que nenhuma destas variantes tem uma segregação perfeita do 
tipo autossómico dominante com penetrância completa, o que está de acordo com o 
descrito na literatura. O potencial patogénico destas mutações não pode ser excluído se 
tivermos em conta que alguns indivíduos da família podem não ter sido ainda 
xvi 
 
diagnosticados clinicamente por não apresentarem sintomas ou por ainda não terem 
idade para manifestar a DOP. 
Estudos adicionais devem incluir variantes com uma frequência do alelo menor 
inferior a 5% e descritas no dbSNP ou 1000 GP. Há várias variantes localizadas em 
zonas regulatórias que apontam para uma possível associação com a PDB, sendo 
necessário mais estudos que incluam variantes que se encontram nestas regiões. O 
número de indivíduos e famílias no estudo devería de ser maior, de modo a melhorar a 
identificação das variantes causais, e os indivíduos controlo a estudar deveriam de ter 
uma idade superior à de risco (acima dos 50 anos). 
A identificação de novas variantes genéticas associadas à DOP pode ajudar a 
compreender melhor as vias celulares envolvidas na sua patogénese. Deste modo 
poderão, eventualmente, advir novas terapias mais eficazes e porventura preventivas. 
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1. Introduction 
 
1.1 Paget’s disease of bone  
 
The human body is supported and shaped by the bones, which are a complex and 
highly organized tissue with several functions: organ protection, anchor points for 
muscles, tendons and ligaments, storage for minerals, and a reservoir for a broad range 
of cells (such as stem cells of the mesenchymal and hematopoietic cell lineages)
1,2
. 
Three essential cells, osteoclasts (OCL, bone-resorbing), osteoblasts (bone-forming), 
and osteocytes (maintenance of the bone matrix health), all contribute for the bone 
tissue to be continuously remodeled preserving mineral homeostasis, and to maintain its 
robustness. The damaged or old bone is resorbed by OCL during remodeling, and then, 
osteoblasts migrate to this resorbed area to form new bone. Once the new bone is 
formed, osteoblasts are entrapped in the newly mineralized bone matrix and called 
osteocytes. The latter are able to sense the fluctuations in mechanical load and in 
hormone levels, amongst others, forming a large signaling network to communicate 
with each other, lining cells on the bone surface and with bone marrow stromal cells. In 
normal circumstances, the interaction of all the cells mentioned, through stimuli such as 
growth factors, hormones, and cytokines, maintains the bone remodeling balanced. 
However, when there is an unbalance in bone remodeling, diseases can develop ranging 
from mild to severe. One example is osteoporosis, in which the bone resorbing process 
exceeds the bone formation process. When there is an unbalance in the bone formation 
process, this can result in sclerosing bone dysplasias namely osteopetrosis - Van 
Buchem disease and Camurati-Engelmann disease. Additionally, there are several 
metabolic bone diseases caused by defects in both bone resorption and formation 
processes. One of the most frequent from this last group is Paget’s disease of bone 
(PDB), but there are also a number of rare conditions showing similarities to PDB:  
- familial expansile osteolysis (FEO),  
- expansile skeletal hyperphosphatasia (ESH),  
- early-onset PDB (eoPDB),  
- juvenile PDB (JPD),   
- syndromal PDB condition named “inclusion body myopathy combined with 
PDB and frontotemporal dementia” (IBMPFD)2. 
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Sir James Paget first described PDB (MIM 602080) in the 19
th
 century as 
“osteitis deformans”, a chronic inflammation of bone resulting in deformities. It is the 
second most common metabolic bone disease, after osteoporosis, with a prevalence of 2 
to 5% in Caucasians over 55 years old. It affects more men than women, likely due to 
the larger mechanical loads on the bones of males
2–6
. PDB has a very unusual 
geographic distribution, presenting a different prevalence across different ethnicities, 
with the highest prevalence in European descent patients
2
. Within Europe, the highest 
prevalence belongs to United Kingdom, Spain, Italy, and France. It is also relatively 
common in people of European descent who have migrated to Australia, Canada, New 
Zealand, South Africa, and United States
7,8
. PDB occurs rarely in other parts of the 
world such as Africa, Middle East, and Asia
2
. PDB most likely originated in Britain and 
spread to other parts of the world as the result of migration and genetic admixture
7
. 
Furthermore, the incidence of PDB appears to be decreasing over the last 25 years, 
partly due to changes in the ethnic makeup of the population that result from the influx 
of migrants from low-prevalence regions such as the Indian subcontinent and the Far 
East. 
Several PDB patients are diagnosed incidentally when being examined for other 
reasons since it is asymptomatic in approximately 80% of cases
2
. The characteristic 
focal bone lesions with accelerated bone turnover can be detected on bone scans using 
radionuclide-labeled bisphosphonates or on radiologic film with dual emission 
radiograph absorption, being the most sensitive method to detect pagetic lesions
2,8
. This 
method can be used to follow the activity of the disease in these patients
8
. Biochemical 
changes related to PDB include high levels of bone resorption markers (eg. urinary 
NTX [N-terminal telopeptide excretion]) and elevated levels of bone formation markers 
(eg. serum alkaline phosphatase), which are routinely used in clinical practice to make a 
diagnosis
2,9
. PDB diagnosis is performed based on the search for typical radiological 
features, measurement of serum alkaline phosphatase and a bone scintigraphy
10,11
. 
PDB develops in three consecutive phases. Initially (phase 1) there is an 
increased bone resorption (accelerated bone turnover) that gives an osteolytic 
appearance. Secondly (phase 2), mixed osteolytic and sclerotic features occur. Lastly 
(phase 3), sclerotic marks in the affected bone appear, which have a disorganized bone 
appearance (named “woven bone” or “cotton-like bone”). This affected bone has a 
reduced mechanical strength, placing patients at increased risk of developing bone 
deformities and pathologic fractures
2,7
. These lesions can occur in either just one bone 
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(mono-ostotic) or multiple bones (poly-ostotic) localized mainly in axial bones. In the 
majority of cases, the skin surface of the affected site present redness and warmth, since 
these lesions are highly vascular, and once a lesion is formed new lesions rarely 
develop. The most frequently affected bones are the pelvis, femur, (lumbar) spine, skull, 
and tibia. Additionally, and to a lesser extent, the knee, elbow, phalanges, and calcaneus 
can also be affected
2
.  
Complications can develop in PDB patients, including, fractures, bone pain, 
secondary osteoarthritis, deafness, spinal stenosis, nerve compression syndromes, and 
also heart failure due to the increased blood flow during active PDB (which leads to the 
patient death). Also, a subset of PDB patients develop osteosarcoma, suggesting that 
these patients may have an increased risk for the development of this malignancy when 
compared to the general population
2,12
. 
The genetic architecture of PDB is not yet fully understood for the majority of 
cases, however, it is consider to be a multifactorial complex disorder resulting from the 
combination of environmental and multiple genetic factors that, individually or 
epistatically, contribute the disease etiology
7
.  
 
1.2 Environmental factors 
 
Several environmental factors have been suggested as possible triggers for PDB, 
including low dietary calcium intake during childhood, vitamin D deficiency, exposure 
to environmental toxins, repetitive mechanical loading of affected bones, a rural as 
opposed to an urban lifestyle, exposure to cattle, and chronic infection with measles, 
canine distemper or respiratory syncytial virus
2,5,7
.  
The most widely studied environmental exposure is paramyxoviral infection, 
although evidence of a viral etiology for PDB remains controversial
7
. Involvement of 
viral factors arose from the observation of paramyxoviral-like nucleocapsid particles 
(e.g. inclusion bodies) in the nucleus and cytosol of pagetic OCL
2
. Additionally, it has 
been suggested in 1960 that the introduction of immunization programs for measles and 
canine distemper virus is a possible reason for the reduction in PDB’s incidence. 
However, this not only occurred too recently to account for a reduction in prevalence 
and severity of PDB patients born in the 1930s and 1940s (assuming that a slow viral 
infection picked up in childhood was indeed the cause of the disease), but also this 
would not be possible since the disease has a late age-at-onset
7
. 
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In addition, there are reports of PDB cases that are due to arsenic acid (abundant 
in the water of a mill), which in turn resulted in a higher prevalence of PDB in 
inhabitants from Lancashire (Britain)
2,5
.  
Known genetic mutations associated to PDB appear to predispose individuals to 
this disease but require co-expression of an environmental factor in OCL precursors for 
the development of a robust “pagetic phenotype”. In support of this hypothesis, Gennari 
et al. recently reported that there is a strong association between environmental factors 
(probably associated with a persistent animal contact) and the development of severe 
PDB in patients with a genetic predisposition to this disease (genes that increase the risk 
to familial PDB), again supporting PDB to be a complex disorder
13
. 
  
1.3 Genetic factors 
 
In a subset of PDB patients, genetic risk factors play an important role in 
pathogenesis
14–16
. Familial clustering is frequently observed since 15 to 40% of patients 
have at least one affected first-degree relative
4,5,17,18
. Also, individuals with affected 
first-degree relatives have a sevenfold increased risk of developing PDB
14,19–21
. Since 
PDB is frequently asymptomatic prevalence of a familial aggregation could be 
underreported. However, it has been described that patients with a positive family 
history have a higher probability to manifest symptoms, deforming bone diseases and/or 
bone pain, when compared with patients with a negative family history
14,19,20
. 
Additionally, an earlier onset of PDB has been reported in family members when 
compared to sporadic cases
20
. One possible explanation for this is that relatives are more 
aware of PDB symptoms and seek medical attention at earlier ages
14
. Patients with a 
known family history will be called from now on as “familial PDB” and those with a 
negative family history as “sporadic PDB”2. 
Siris et al. reported a higher risk in siblings when the mother was affected versus 
an affected father, nonetheless a previous study could not find evidence for this
14,20
. One 
possible explanation for this higher risk is that there might be maternally transmitted 
factors, which could be either environmental factors (e.g. a virus), cytoplasmic factors, 
or imprinting of susceptibility genes
14
. 
In PDB families, segregation analysis showed that more than half of family 
relatives over the age of 55 had inherited the disease. Moreover, PDB has an equal 
incidence in males and females. Both these evidences point for PDB to be inherited in 
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an autosomal dominant fashion with highly variable penetrance, which is consistent 
with previous reports
8,15,21,22
.  
Several studies have shown that PDB might be caused by a combination of rare, 
high-penetrance variants in genes, such as SQSTM1, and other common variants in 
genes such as CSF1, TNFRSF11A, and TM7SF4 (amongst others, see Table 1 and 2). 
These individually are not sufficient to cause the disease but can act together to increase 
the risk of developing it
7,23,24
. Also, the risk of developing PDB increases with an 
increased number of risk alleles carried
25
. 
 
Table 1. Summary of genes and loci identified using linkage analysis in PDB. 
 
 
Table 2. Summary of associated genes and loci in PDB. 
 
 
 
 
 
Locus 
name 
Gene  
Chromosome 
band 
Type of 
original study 
Associated 
SNP 
Reference 
PDB1 HLA 6p21.3 Linkage  . Tilyard et al.
26
 
PDB2 TNFRSF11A 18q22.1 Linkage  rs3018362 Cody et al.
27
 
PDB3 SQSTM1 5q35 Linkage  . Laurin et al.
19
 
PDB4 . 5q31 Linkage  . Laurin et al.
19
 
PDB5 . 2q36 Linkage  . Hocking et al.
4
 
PDB6 OPTN 10p13 Linkage  rs1561570 Hocking et al.
4
 
PDB7 . 18q23 Linkage  . Good et al.
28
 
. VCP 9p13.3 Linkage  rs565070 Kovach et al.
29
 
Gene 
Chromosome 
band 
Type of 
original study 
Associated 
SNP 
Reference 
CSF1 1p13 GWAS rs484959 Albagha et al.
24
 
CaSR 3q21.1 Candidate gene . Dónath et al.
30
 
ESR1 6q24-q27 Candidate gene . Dónath et al.
30
 
NUP205 7q33 GWAS rs4294134 Albagha et al.
23
 
TM7SF4 8q22 GWAS rs2458413 Albagha et al.
23
 
TNFRSF11B 8q24 Candidate gene . Wuyts et al.
31
 
RIN3 14q32 GWAS rs10498635 Albagha et al.
23
 
PML 15q24 GWAS rs5742615 Albagha et al.
23
 
GOLGA6A 15q24 GWAS . Albagha et al.
23
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PDB is characterized by focal and disorganized increases in bone turnover, with 
highly localized areas of increased bone resorption (lytic phase) coupled with a high 
rate of bone formation with the primary cellular abnormality residing in OCL. This is 
accompanied by other abnormalities, such as marrow fibrosis and increased vascularity 
of bone
7,32,33
. OCLs, the primary affected cells in PDB, are increased in number and 
size, and express a “pagetic phenotype” that distinguishes them from normal OCLs33. 
“Pagetic” OCLs contain nuclear inclusion bodies, which are microcylindrical structures 
that have been linked to viral nucleocapsids. Although the identity of these inclusions 
has not been established until now, another hypothesis is that these inclusions might 
represent protein aggregates that are not degraded, similar to those observed in neurons 
from patients with neurodegenerative diseases. This is supported by the increasing 
evidence that PDB may be associated with a protein degradation system of autophagy 
dysregulation and the fact that OCL nuclear inclusions almost identical to those seen in 
PDB patients have been observed in mice carrying the SQSTM1 (sequestosome 1) 
P394L mutation (equivalent to the human P392L mutation)
7
.  
Histologically, OCL are the primary affected cells in this disease. They are 
numerous, enlarged, hypermultinucleated, resistant to apoptosis and hyperactive, 
probably due to hypersensitivity for RANKL (receptor activator of nuclear factor-kB 
ligand), 1,25–(OH)2D3 (1,25–dihydroxyvitamin D3), and TAFII17 (TATA-binding 
protein–associated factor [17 kDa], a vitamin D receptor binding protein)2,34. The 
1,25(OH)2D3 hyper-responsivity results from elevated levels of VDR (Vitamin D 
Receptor) coactivator and TAF12 (formerly TAFII-17) in OCL
33
. Nuclear and 
cytoplasmatic inclusion bodies can be found in pagetic OCL
2
. OCL in PDB secrete high 
levels of IL-6 (Interleukin 6), which are detectable in marrow plasma and peripheral 
blood from PDB patients
33
.  
In sporadic PDB, mutations in SQSTM1 cause a severe phenotype, with more 
affected bone and an earlier age of onset, than in patients without this mutation. 
However, similar phenotypes were observed in familial PDB with and without 
mutations in this gene. Furthermore, it was recently seen that PDB osteoclasts (with or 
without P392L mutation) from patients have the same phenotype including more nuclei 
per cell, apoptosis resistance and increased resorption activity. This raises the possibility 
that other factors (e.g. environmental and other genes) are involved in PDB 
susceptibility
2
. 
 
Family Genetics of Paget’s Disease of Bone                                                       1. Introduction  
 
7 
 
1.4 Polymorphisms 
 
Genetic variation or polymorphism occurs where there is a variation in the 
deoxyribonucleic acid (DNA) sequence, being classified into several categories, 
including single-nucleotide polymorphisms (SNPs), insertions and deletions (InDels) 
and structural variants
35,36
. It is believed that genetic variation is the major factor that 
contributes to human diversity
36
.   
A SNP is a genetic variation that occurs in a single base of a DNA sequence, and 
where one of the four nucleotides is substituted for another. The minor allele frequency 
(MAF) must be greater than 5% in a given population to be considered a SNP (if the 
frequency is less than 1% it is called a rare variant). This is the most frequent type of 
variation in the human genome
36,37
.  
Insertions and deletion (InDels) are genetic variations where there is an insertion 
or deletion of at least one base from the reference DNA sequence. Several InDels have 
been detected over the past decade in the human genome, however their number is 
smaller than the number of SNPs and small InDels (ranging from 1 to 10 000 base 
pairs) cause similar phenotypic effects than SNPs
35
. Similar to SNPs, some InDels are 
localized in functionally important loci, likely to influence proteins and/or their 
regulation, and ultimately lead to human traits and diseases. However, InDels are more 
difficult to detect, validate and genotype, when compared to SNPs and so they are less 
studied
35
. 
 
1.5 Genetic variants that contribute to PDB risk 
 
1.5.1 Linkage studies 
 
Linkage is a genetic phenomenon described as the tendency of genes or other 
DNA segments at a specific genomic region to be inherited together on the same 
chromosome, as a consequence of their physical proximity
38
. 
Linkage analysis is designed to identify regions of the genome that contain 
genes that predispose to a trait/disease, testing for cosegregation between a well-
characterized polymorphic genetic marker and an unknown locus influencing the 
disease susceptibility, using Affected Sibling Pairs (ASP) or extended families
38,39
. 
Genetic linkage methods can be parametric (model-based) and non-parametric (model 
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free). The former is used when the genetic model of the disease is specified, being more 
often used in Mendelian diseases, whereas the latter is used when there is no clear mode 
of inheritance of the disease (such as with many complex disorders), or when I do not 
know the allele frequencies and/or penetrances are not known
38
. 
The logarithm of the odds (LOD) score, proposed by Morton in 1955, is a 
function of the recombination fraction or chromosomal position measured in 
centimorgans (cM), being a useful measure of linkage. High LOD scores constitute 
evidence for linkage and low scores represent evidence against. It was suggested that 
linkage is excluded when the LOD is less than -2, and a LOD score of 3 or higher 
indicate a significant evidence for linkage
38
. However, in complex diseases, like PDB, 
where several genes could contribute to increase the risk of the disease, the stringency 
of the criteria should be different, and a modest maximum LOD score is expected and 
should not be ignored
38
. The limited success of linkage analysis for complex diseases is 
in part due to studies being too small to detect genes of modest effect. The sample size 
necessary to detect linkage to genes with a genotype relative risk of less than 2 could be 
unachievable
38
.  
Linkage analysis can only identify large regions and even if there is a strong 
causal gene within the linkage peak, such regions frequently contain hundreds of genes, 
many of them biologically reasonable candidates in a complex disease. A good 
approach to narrow the region of interest is to perform association analysis to fine-map 
the linkage peak
38
. 
Suggestive evidence for linkage in PDB was first reported by Tilyard et al. for 
HLA at 6p21.3 (also named PDB1 locus) – Table 126. However, no other study has 
confirmed the HLA linkage with PDB, indicating that the linkage signal may have been 
a false positive or the gene may be of minor importance in the disease etiology
14,19,40,41
. 
Based on a study for FEO (a bone disorder similar to PDB previously 
mentioned), where evidence of linkage has been shown at 18q21.2-21.3, Cody et al. 
performed a linkage study in this region in two PDB families in which the authors found 
evidence for linkage with that same locus
27,42
. TNFRSF11A (PDB2 locus) maps within 
this region, and encodes a receptor activator of nuclear factor κB (RANK) that regulates 
OCL activity
16
. However, subsequent reports are contradictory. Some studies report a 
strong linkage signal at 18q
27,43
 while other studies found no evidence of linkage at this 
locus
19,22,4,19
. In addition, a whole-genome linkage study performed in a large pedigree 
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did not show any evidence for linkage at PDB2, identifying a novel susceptibility locus 
at 18q23 (PDB7) near of TNFRSF11A
28
. 
Laurin et al. conducted a whole genome linkage study in 24 large French- 
Canadian families with PDB, detecting evidence for linkage at both 5q35 (PDB3) and 
5q31 (PDB4)
19
. The former contains SQSTM1, which is the only disease-causing gene 
consistently reported for PDB. Mutations in this gene are reported in 40-50% of familial 
PDB and 2.5-10% of sporadic PDB, usually following an autosomal dominant mode of 
inheritance
2,7,17
.  
SQSTM1 is a multifunctional protein with 440 amino acids, distributed by nine 
protein-interacting domains. The main functions of SQSTM1 are proteasomal 
degradation of proteins, acting as scaffold protein in the RANKL, IL1, nerve growth 
factor and TNFα-induced NFκB signaling pathways, autophagy, and apoptosis. 
Moreover, SQSTM1 is an important protein in the RANKL/RANK/OPG-NFκB axis. At 
least 28 mutations in SQSTM1 have been reported in about one third of PDB families as 
well as in about 9% of sporadic PDB
2,25
. All mutations identified in SQSTM1 are 
located within and around the ubiquitin-associated (UBA) domain of the protein. The 
most frequent mutation found in familial and sporadic PDB is p62
P392L
, a mutation 
causing an amino acid substitution from a proline (P) to a leucine (L) at position 392 of 
the coding sequence
2,33,44
. This mutation induces the activation of human osteoclasts
44
. 
Additional linkage studies performed by Hocking et al. demonstrate evidence for 
linkage at 2q36 (PDB5), 10p13 (PDB6), and also 5q35 
4
. OPTN (optineurin), a homolog 
of NFκB (nuclear factor kappa B) essential modulator (NEMO) implicated in the NFκB 
signaling pathway and autophagy, is located in PDB6
2,7
. 
In families reported to have linkage in PDB2 and PDB7 regions, most of the 
patients also carried SQSTM1 mutations
40,41
. Furthermore, when Lucas et al. reanalyzed 
linkage data excluding patients with SQSTM1, mutations there was only evidence for 
linkage at 10p13 (PDB6), while at 2q36 (PDB5) the linkage signal disappeared almost 
completely. There are two possible explanations for this: first, PDB2, PDB5 and PDB7 
loci contain modifier genes that interact with SQSTM1 to cause the disease or secondly, 
the former results are false positives
40,41
. 
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Another linkage study performed by Kovach et al. in a family with PDB showed 
linkage at 9p13.3. Later, a genome-wide association study (GWAS) confirmed the 
association between VCP (valosin-containing protein), localized in this region, and 
PDB
12,29
. This gene expresses a protein that has been linked to the autophagy 
mechanism and may be involved in cellular and structural functions of muscle and/or 
bone cells
12,29
. 
To sum up, all these findings reinforce the notion that PDB is genetically 
heterogeneous and multifactorial
19,27
. 
 
1.5.2 Association studies 
 
From 1970 to 1990, linkage analysis was the dominant approach in the 
investigation of genetic risk variants in families, however association studies are more 
powerful in the detection of genes with a modest/small effect
37,45
.  
Figure 1. RANKL/RANK NFκB signaling pathway. 
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Association studies allow the identification of susceptibility genes, detecting 
common variants with weak/moderate effect on the phenotype at the population level
45
. 
These common genetic variants, in particular SNPs, usually have a MAF above 5%
46
.  
Evidence for association between a marker and PDB exists if there is linkage 
disequilibrium (LD) between that marker and the causative functional variant or if the 
marker itself corresponds to the causal gene variant
47
. LD is a genetic phenomenon 
described as two or more genetic variants that are inherited together on the same 
haplotype more often than expected by chance alone in the population under study
38
.  
There are many sampling approaches to perform an association study, being the 
most common either a case-control or a family-based format. In the case-control 
approach, an unrelated group of patients is compared to a group of matched controls. In 
the family-based studies patients and their family members are collected and 
compared
47–49
. Family-based studies are more robust because they are less affected by 
population stratification, whereas case-control studies are more powerful, easier to 
collect and genotype
48
.   
Association studies can be performed on a candidate gene basis or as a 
GWAS
7,12
. In the first approach, genes are selected based on their function (e.g. role in 
bone metabolism or a relationship to bone diseases for PDB). The genome-wide 
approach uses variants across the entire genome independently of gene function, 
increasing the probability of discovering novel unbiased susceptibility variants
12
.  
GWAS carried out for PDB identified six potential susceptibility loci (Table 2): 
1p13 (CSF1)
24
, 7q33 (NUP205)
23
, 8q22 (TM7SF4)
23
, 9p13.3 (VCP)
12
, 14q32 (RIN3)
23
, 
and 15q24 (this region contain two genes, PML and GOLGA6A)
23
.  
The function of these genes appears to be related with PDB. CSF1 encodes for 
the macrophage-colony stimulating factor (M-CSF), which plays a key role in osteoclast 
formation and survival
2,7,24
. NUP205 encodes the nucleoporin 205 kDa protein, which 
has a role in the nucleus to cytosol transport of proteins such as ALFY (Autophagy-
Linked FYVE domain-containing protein/WD repeat and FYVE domain containing 3), 
which interacts with SQSTM1
2,23
. TM7SF4 (transmembrane 7 super-family member 4) 
encodes the dendritic cell-specific transmembrane protein (DC-STAMP), which 
functions in the fusion of OCL precursors to form mature OCL
2,23
. RIN3 regulates the 
vesicular trafficking via interaction with small GTPases, and could have a function in 
the bone resorption since small GTPases have an important role in vesicular trafficking 
and in OCL function
2,23
. PML (promyelocytic leukemia gene) plays an important role in 
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the TGF-β (tumor growth factor-β) signaling pathway, which regulates bone remodeling 
suggesting that PML may have an influence on the coupling between bone resorption 
and bone formation through TGF-β2,23. GOLGA6A (golgin A6 family member A) is 
located on the same associated regions as PML and its function in bone metabolism is 
not yet known, but other mutations in other golgin proteins have been associated with 
skeletal dysplasia and a severe form of osteoporosis. GOLGA6A protein has a known 
function in the Golgi apparatus and in membrane fusion
2,23
.  
There are also other association studies based on candidate genes, which report 
an association of CaSR
30
, ESR1
30
 and TNFRSF11B
31,50
 in genetic susceptibility for 
PDB.  
CaSR has an important role in the regulation of extracellular calcium that could 
be important for the changes that occur in the bones of PDB patients
30
. TNFRSF11B 
encodes osteoprotegerin (OPG), a key regulator of osteoclastic bone resorption. OPG is 
a member of the TNF (tumor necrosis factor) receptor superfamily that lacks an 
intracellular domain and acts as a decoy receptor for RANKL, thereby inhibiting 
osteoclast differentiation and bone resorption
7
. In addition, TNFRSF11B seems to be 
sex-related, being more associated to women in a Belgian population study
51
. In the 
Donáth et al. study there is also a sex specific effect (women more affected than men) 
possibly due to polymorphisms in ESR1 (estrogen receptor 1)
30
.  
Several reports suggest that abnormalities of OCL formation in PDB could be 
due, in part, to the cytokine IL-6. Elevated levels of IL-6 were detected in plasma and in 
conditioned media from pagetic bone marrow cultures when compared with control 
cultures
2,12,40,52
. Moreover, the vitamin D receptor (VDR) gene has a function in calcium 
and bone metabolism, since vitamin D is needed for a normal bone mineralization, 
absorption of calcium from the gut, control of calcium and phosphate homeostasis and 
regulation of parathyroid hormone secretion
30
. Finally, TNFSF11 encodes RANKL, 
having an important role in NFκB-induced osteoclastogenesis12. However, no SNPs in 
IL6
12
, VDR
30
 or TNFSF11
12
 were found to be associated with PDB
2,12,40
. 
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Figure 2. Genes that predispose to PDB play key roles in osteoclast differentiation and function. 
OCL differentiation has multiple steps with several genes involved in its pathway. CSF1 is essential for 
OCL and macrophage differentiation. TNFRSF11A and TNFRSF11B encode RANK and OPG, 
respectively, playing both an important role in OCL differentiation and function. TM7SF4 is needed for 
OCL precursors fusion; SQSTM1, VCP and OPTN have an important function in the regulation of NFκB 
signaling and autophagy
7
. 
 
Linkage and association data altogether indicate that CSF1, OPTN, 
TNFRSF11A, TM7SF4, NUP205, RIN3, PML and GOLGA6A are putative players in  
PDB genetic risk
2,17
. However, more studies are warranted to identify other causal 
variants that explain the missing heritability in PDB risk. 
 
1.6 Next-generation sequencing (NGS) 
 
GWAS helped to identify more than 2,000 common variants that play a role in 
complex disease susceptibility and provided many new clues about disease biology. 
However, common variants tipically explain a small proportion of the genetic variance 
and much of the genetic contribution remains unexplained. Partially, this might be due 
to rare variants (MAF < 5%) that are not detected with GWAS but that could play an 
important role in human diseases
25,46
. These rare variants may be independent of each 
other and confer a detectable risk of developing a disease
25
. Many diseases are caused 
by a combination of highly penetrant rare variants and common variants. Reports show 
that rare variants have an important role in complex diseases
53
. NGS enables the 
detection of these rare variants, complementing the investigation in the complex 
diseases field
25,46,53
. 
NGS is a high-throughput parallel-sequencing approach that produces hundreds 
of thousands/millions of short-reads (approximately 100-500 bp) in a short time
46
. 
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These short reads are then aligned against a reference genome to identify where 
sequenced individuals vary
46
.  
There are two main types of NGS: Whole-genome sequencing (WGS) and 
whole-exome sequencing (WES). The first has a greater cost and an inherent 
complexity in analysis. WES is a robust strategy for discovering novel rare variants 
associated to complex diseases since the exome (1-2% of the genome, which encodes 
for proteins) represents a highly enriched subset of the genome, in which to search for 
variants with large effect sizes
46,54–56
.  
A large fraction of rare, protein-altering variants, such as non-synonymous 
(NSV) or stop-gain/loss single-base substitutions or small InDels, are predicted to have 
functional consequences and/or to be deleterious
56
. First successful cases of NGS 
carried out in rare monogenic disorders were Miller syndrome
57
, Freeman-Sheldon 
syndrome
58
 and Schinzel-Giedion syndrome
59
. There is an increasing number of studies 
using WES to identify genes associated with complex diseases
46,60
. Although WES is a 
robust approach to search for disease-related variants, it has a high error rate
61
.   
WES analysis has several technical constrains when identifying risk alleles, 
depending on their mode of inheritance. Genes that cause recessive and de novo 
dominant diseases are easier to identify due to low number of genes shared between 
affected individuals, decreasing the number of possible candidate genes
55
. Identification 
of genes that cause dominant diseases is more challenging due to several reasons such 
as a small number of family members and consequently a higher number of candidate 
heterozygous variants, or the absence of disease-causing variants in the mapped 
region
55
. In other cases, no variants are identified since the causal mutation resides 
outside the exome. 
So far, polymorphisms in a total of 13 genes (Table 1 and 2) have been 
associated to increased PDB risk. Since SQSTM1 mutations can only explain PDB 
heritability in a small subset of patients, the search for novel rare causal variants is now 
warranted. Unraveling the genetic background of PDB will be essential to understand its 
pathogenesis, and it might make early detection and treatment for individuals at risk a 
reality
2
. 
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2. Objectives 
 
Our goal is to identify the gene(s) that cause PDB in an extended Portuguese 
multiplex family from Alentejo. 
More specifically, the project was divided in the following tasks: 
 
1. Whole-exome sequencing (WES) of six family members; 
2. Bioinformatic analysis of WES data based on the Genome Analysis Toolkit 
(GATK) Best Practices workflow from Broad Institute, for human exome 
sequencing; 
3. Selection of candidate variants - present in the affected relatives and absent 
in the unaffected relatives – as well as analysis of their potential functional 
impact using in silico methods (e.g. SIFT, PolyPhen); 
4. Technically validate the candidate variants by Sanger sequencing and test 
their segregation in all available family members; 
5.  Test the presence and segregation of these mutations in a second PDB 
multiplex family also from Alentejo. 
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3. Methods 
 
3.1 DNA collection and extraction 
 
7.5 mL of whole blood was collected using sodium Ethylenediaminetetraacetic 
Acid (EDTA) tubes. For each individual, the medical team collected two blood EDTA 
tubes, one for DNA extraction and another for pellet isolation. This was the preferred 
DNA source for the study performed since it was the source already available, and also 
it allows the extraction of large amounts of DNA required to perform genomic assays
62
.  
DNA extraction was carried out using Genomic DNA Extraction kit (RBC 
Bioscience Corp., New Taipei City, Taiwan) that is designed to purify genomic DNA 
from 50 μL to 10 mL of blood.  
When I started my master project, family 1 DNA samples (except for individuals 
III.4-080001 and IV.3-090095) were already extracted. The kit used was Nucleo Spin 
Blood XL kit (Macherey-Nagel, Germany) according to the manufacturer’s protocol. I 
only collected and extracted the blood samples from family 1 III.4-080001 and IV.3-
090095 and family 2 individuals. 
 
In summary, the protocol consisted in: 
 
1. Pipet up to 400 μL of whole blood to a 2.0 mL microcentrifuge tube; 
2. Add three times the sample volume of RBC lysis buffer (to remove red 
blood cells) and mix by inversion 10-15 times (no vortex); 
3. Incubate for 10 minutes at room temperature; 
4. Centrifuge at 3.000 g for 7 minutes; 
5. Remove the supernatant, but retain about 50 μL of residual buffer to 
resuspend the white cell pellet by vortexing; 
6. Add up to 400 μL cell lysis buffer (to lyse cell membrane) to the tube and 
mix by vortexing; 
7. Incubate at 60ºC for 20 minutes, until the sample lysate was more or less 
clear. During incubation invert the tube every 4/5 minutes; 
8. Add 125 μL of protein remove buffer  (to digest proteins) to the sample 
lysate and mix immediately by vortexing for 10 seconds; 
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9. Incubate on ice for 10 minutes; 
10. Centrifuge at 13.000 rpm for 5 minutes; 
11. Transfer the supernatant from Step 11 to a 1.5 mL microcentrifuge tube; 
12. Add 400 μL isopropanol  (for DNA precipitation) and mix well by inverting; 
13. Centrifuge again at 13.000 rpm for 5 minutes; 
14. Discard the supernatant and add 400 μL of 70% ethanol (to improve DNA 
precipitation) to wash the pellet; 
15. Centrifuge at 13.000 rpm for 5 minutes; 
16. Discard the supernatant and air-dry the pellet for 20 minutes; 
17. Add 50-100 μL of water and incubate at 60ºC for 30-60 minutes to dissolve 
the DNA pellet. During incubation, tap the bottom of tube to promote DNA 
rehydration. 
 
For individual IV.9-090044, DNA extraction was made from the pellet since the 
whole blood sample was no longer available. This required two additional steps before 
the DNA extraction. First, the blood sample was centrifuged to split the white blood 
cells from the rest of the cells. Then, it was added PBS (Phosphate buffered saline, to 
ressuspend the pellet) up to 7.5 mL. 
 
3.2 DNA quantification 
 
DNA concentrations were quantified using the NanoDrop 2000. Briefly, 1 μL of 
each sample was pipetted onto an optical pedestal (receiving fiber). Another fiber is 
then brought into contact with the first one by closing the NanoDrop’s arm, forcing the 
1 μL solution to fill the gap between the two fiber optic ends in order to be measured. A 
source light is then directed to the sample, and the spectrometer analyses the light after 
passing through the solution based on the amount of radiation absorbed. The data is then 
stored using a computer NanoDrop 2000/2000c software. Before measuring the 
samples, 1 μL of MilliQ water is used as a blank measurement. This spectrophotometer 
uses a spectra range from 190 to 840 nm, giving accurate estimates of the template 
concentration in ng/μL. DNA has optimal absorption at 260 nm, due to the structure of 
the aromatic rings of their bases
63
. Thus, DNA concentration can be estimated based on 
the amount of absorbed radiation at 260 nm
62,64
. The Lambert-Beer equation is applied 
to correlate the absorbance with concentration 
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A = ε.l.C 
where A is the absorbance, ε is the wavelength-dependent molar absorptivity coefficient 
(ng
−1
cm
−1μL), l is the path length (cm), and C is the nucleic acid concentration (ngμL−1) 
64
. Standard values for the molar absorptivity coefficient of double- and single-stranded 
DNA (0.020 ng
−1
cm
−1μL and 0.027 ng−1cm−1μL respectively, when exposed to Ultra 
Violet light (UV) at 260nm) were applied for the concentration estimation
64
.  
The purity of the sample can then be roughly determined using the A260/A280 
ratio. The DNA is considered pure if this ratio is 1.8
62,63
. For RNA, it is considered pure 
when the A260/A280 ratio is 2.0
62,63
. If this ratio is significantly different from 1.8, then 
the DNA sample is contaminated, either by RNA (if the ratio is closer to 2.0) or by 
proteins or other contaminants (if it is below 1.8), since the latter will absorb radiation 
at 280 nm
62,63
. 
For the WES and validation assays, all DNA samples were diluted to a final 
concentration of 40 ng/uL (minimum concentration required for Beijing Genomics 
Institute – BGI and 10 ng/uL, respectively (working solutions). 
 
3.3 Electrophoresis 
 
Gel electrophoresis was mainly used to examine DNA quality, fragment size and 
PCR product specificity. The DNA fragments always migrate from the cathode 
(negative pole) to the anode (positive pole), because DNA carries a negative charge due 
to its phosphodiester backbone. As the DNA migration in the gel matrix occurs, the 
fragments are separated according to size - small fragments migrate faster and run 
further in the gel compared to larger ones. For optimal resolution the agarose 
concentration varied from 1-3% depending on the size of the PCR products, allowing 
for maximum fragment separation. The gels were made by dissolving agarose powder 
(NZYTech, Lisboa, Portugal) in 1x Tris-Acetate-EDTA (TAE) (Sigma, Missouri, 
United States of America), followed by heating the mix in a microwave until it becomes 
transparent (meaning that the agarose powder is fully dissolved). GreenSafe Premium 
(NZYTech, Lisboa, Portugal) was added at a final volume of 6 μL in 100 mL of agarose 
gel. The whole solution was poured into a sealed plate and allowed to cool and set. 
Once the gel was set, the gel was immersed in a 1x TAE buffer solution. Loading buffer 
(3.5 μL) was added to each sample (6 μL) and these were loaded into the wells with a 
molecular weight ladder running in parallel (6 μL of 1x NZYDNA Ladder VI 
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[NZYTech, Lisboa, Portugal]). This ladder provided an approximate quantification of 
the fragment’s size. Moreover, we used a negative control (using all PCR reagents but 
instead of DNA we added water) to guarantee that there was no contamination. The 
voltage was set at a constant value (usually at 100 V) for the length of time required 
(which can be visually checked by the migration of the loading buffer). As the products 
migrate the GreenSafe intercalates with the DNA, and consequently allowing its 
visualization using an UV transilluminator (GenoSmart gel documentation system, 
VWR International) and photographed. 
 
3.4 Bioanalyzer  
 
The bioanalyzer system is an electrophoretic assay based on traditional gel 
electrophoresis principles that have been transferred to a chip format. This platform 
provides sizing, quantitation and quality control of DNA, dramatically reducing 
separation time as well as sample and reagent consumption. 12 samples (three PDB 
patients and nine positive controls since the PDB DNA samples were older) were run 
using bioanalyzer. This analysis was carried out in this platform to make sure that the 
DNA had high quality for the WES assay, which is more sensitive than Sanger 
sequencing. 
The total amount of DNA must be between 0.5-50 ng/μL for an accurate 
determination of DNA concentration with the Bioanalyzer. The chip accommodates 
sample wells, gel wells and one well for an external standard (ladder). During chip 
preparation, the micro-channels are filled with a sieving polymer and fluorescence dye, 
once the wells and channels are filled, the chip becomes an integrated electrical circuit. 
The 16-pin electrodes of the cartridge are arranged so that they fit into the wells of the 
chip. Each electrode is connected to an independent power supply that provides 
maximum control and flexibility, such that DNA is electrophoretically driven by a 
voltage gradient. The molecules are separated by size (smaller fragments migrate faster 
than larger ones) due a constant mass-to-charge ratio and the presence of a sieving 
polymer matrix. Dye molecules intercalate into DNA strands and the complexes formed 
are detected by laser-induced fluorescence. Data is translated into gel-like images 
(bands) and electropherograms (peaks). A standard curve of migration time versus 
fragments size is plotted with the help of a ladder that contains components of known 
sizes, and size is calculated from the migration times measured for each fragment in the 
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sample. Two markers are run with each of the samples bracketing the overall sizing 
range. The “lower” and “upper” markers are internal standards used to align the ladder 
data with data from the sample wells, to compensate for drift effects that may occur 
during the course of a chip run
65
.  
 
3.5 Whole Exome Sequencing (WES) 
 
The exome of six family members (from family 1) with multiple PDB patients 
was sequenced using WES outsourced at BGI (Hong Kong, 
http://www.genomics.cn/en/index). This technique is highly complex, and involves 
multiple steps that may be divided into (1) genomic enrichment (selection of all exons 
with an additional 200 bp up and downstream of each target region), (2) sequencing 
(including library preparation), and (3) bioinformatics analysis
66
.  
The genomic enrichment step (step 1) is a multi-step procedure (Figure 3).  
Briefly, the qualified DNA sample is randomly sonicated into fragments with a base 
pair peak of 150 to 200 bp (in our case the fragments had 100 bp approximately). 
Afterwards, adapters are ligated to both ends of the resulting fragments. The adapter-
ligated templates are purified by the AgencourtAMPure SPRI beads and fragments with 
insert sizes of about 200 bp are excised. Extracted DNA is amplified by ligation-
mediated polymerase chain reaction (LM-PCR), purified and hybridized using the 
SureSelectBiotinylated RNA library (BAITS) for enrichment of the exonic regions. 
Hybridized fragments are bound to the strepavidin beads whereas non-
hybridized fragments are washed out after 24h. Captured LM-PCR products are 
subjected to Agilent 2100 Bioanalyzer to estimate the magnitude of enrichment. 
Because the aim of this analysis is to sequence the protein-coding part of the genome 
(exome), such targeted sequencing includes the enrichment of the target sequences
54
. 
Each captured library is then loaded on Hiseq2000 (Illumina’s Solexa) platform. 
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Figure 3. Steps of the exome capture used to sequence PDB family 1 
(http://ncifrederick.cancer.gov/atp/genetics-and-genomics/laboratory-of-molecular-
technology/lmt-protocols-and-resources/sureselect/background/). 
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Afterwards, high-throughput sequencing (step 2) was performed with an average 
fold-coverage of 60x approximately (recommended coverage value). Raw image files 
are processed by Illumina base calling software 1.7, using base calling default 
parameters that vary between 2 and 41 (these are standard values used by BGI). This 
base quality value (denoted as Q) allows for the calculation of the sequencing error rate 
(denoted as E, 𝑠𝑄 = −10 log10 𝐸, Table 3).  
 
Table 3. Relationship between the sequencing error rate (E) and the quality value (Q). 
Three examples of sequencing error rates and the corresponding sequencing quality 
values (calculated using the formula above) are shown. 
 
Sequencing error rate (E, %) Sequencing quality value (Q) 
5 13 
1 20 
0.01 30 
 
 
The sequences of each individual are then generated with 90 bp paired-end 
reads. Illumina´s technology is based on clonally amplified templates coupled with 
cyclic reversible termination method with four fluorescent colors. First, one 
fluorescently modified nucleotide complementary to the template sequence is 
incorporated. After washing and imaging for detection of the incorporated nucleotide, a 
cleavage step removes the fluorescent dye and a novel incorporation step is performed. 
These steps are done in a cyclic manner, 72 or 100 times. It is possible to sequence from 
both extremities of the DNA template (paired-end sequencing
a
)
54
.  
The final steps (step 3, bioinformatics analysis - see Figure 4) are the genome 
alignment, variant calling and data analysis. 
The Hiseq 2000 is one of the most robust platforms with lower false positive 
rates, detecting the signal produced by the incorporation of nucleotides. Thus, for 
sequencing platforms using single molecule templates, the amount of starting DNA is 
                                                          
a
 Paired-end sequencing allows sequencing both ends of a strand by the ligation of adapters, containing 
attachment sequences, and sequencing primer sites (forward and reverse) into exonic DNA. Single-end 
sequencing on the other hand only allows sequencing of one strand because it only uses one sequencing 
primer (forward or reverse). In our study we used paired-end reads always to improve the confidence of 
our results.  
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lower and there is no PCR amplification step that could create artificial mutations and 
AT or GC-rich amplification bias. Templates, primers and polymerase enzymes are 
immobilized on a solid support before the sequencing reaction
54
.  
WES is already a useful alternative or complementary technique for molecular 
diagnosis. Its routine use leads to a rapid screening and fast identification of mutations 
in rare genetic disorders through sequencing of the coding region
54
. 
 
3.5.1 Bioinformatics analysis 
 
We followed the Genome Analysis Toolkit (GATK) Best Practices workflow 
(Figure 4), from the Broad Institute, optimized for our human data (all the scripts used 
are in Appendix A). However, some tools were added to the pipeline to improve the 
analysis (such as Freebayes and Samtools mpileup used for the variant calling). 
WES data enters a bioinformatics pipeline that includes data pre-processing (e.g. 
sequence aligned using BWA), variant discovery, and ultimately a variant annotation 
(e.g. in silico evaluation of variant function) (Figure 4). All data has been stored 
redundantly at IMM. We adhered to the Minimum Information about a Genome 
Sequence (MIGS) specification (http://gensc.org). 
 
3.5.1.1 Alignment 
 
The bioinformatics analysis begins with the sequencing data (raw data), which 
was generated from the Illumina pipeline. BGI eliminated reads that contained the 
sequence of the adapter, the low-quality reads (which have long stretches of “N”s) and 
reads in which unknown bases are more than 10%. This step produced the “clean data”, 
originating “clean” FASTQ files used in the bioinformatics analysis. The generated 
reads (FASTQ files) were aligned to the human reference genome hg19/GRCh37 
(available at http://hgdownload.cse.ucsc.edu/goldenPath/hg19/bigZips/) using the 
Burrows-Wheeler Aligner tool (BWA – version 0.6.1) leading to binary alignment files 
(BAM) (http://bio-bwa.sourceforge.net/). This tool identifies the best position where the 
reads match and then does a linear scan through all the potential hits for both paired-end 
reads. 
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Figure 4. Bioinformatics analysis workflow. This pipeline is divided in three main sections: 
Data pre-processing, variant discovery and variant annotation. The first section is the alignment 
and base recalibration, starting with the FASTQ files and ending with the BAM files ready for 
further analysis. The second section is the variant calling, originating the VCF files which are 
used in the annotation phase. In the third section, we make the variant annotation using two 
different tools (SnpSift and VEP ensembl). Quality control of the FASTQ files and BAM files 
was made with FastQC and Qualimap, respectively, which were added steps to improve the 
confidence of our results. 
  
BWA estimates the insert size distribution of both paired-end reads mapped and 
pairs them. After that, it aligns the unmapped reads whose mate pairs are already 
respectively aligned with higher confidence
67
. For each mapped read, BWA generates a 
mapping quality score (MAPQ), which varies between 0 and 60
67
.  The higher the 
MAPQ score is, the smaller the probability of the alignment being incorrect. Finally, 
BWA records the results for each read as a CIGAR string (Figure 5)
67
. The BAM 
format files are needed to do other processes, such as fixing mate information of the 
alignment, adding read group information, marking duplicate reads and InDel 
realignment.   
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Figure 5. CIGAR string example. The POS indicates that the read aligns starting at position 2 
in the reference. The CIGAR string indicates that the first three bases in the read sequence align 
with the reference. The next base in the reference does not exist in the read (one deletion). Then 
two bases align with the reference. The next base in the read does not exist in the reference (one 
insertion) and then one more base aligns with the reference. 
 
3.5.1.2 Quality control (QC) 
 
The sequencing reads were aligned with the reference genome sequence using 
BWA (explained above). Also, the duplicated reads (redundant information produced by 
PCR) were removed using Picard (http://picard.sourceforge.net/command-line-
overview.shtml - version 1.111). This tool sort the reads present in the dataset according 
to chromosomal position and marks as duplicates all the CIGAR strings that match for 
alignments in the same position, except for the best read that has the highest sum of 
base qualities (Q ≥ 15). Also, for an internal quality control, FastQC (version 0.10.1) 
was used to analyze the FASTQ files and Qualimap (version 0.7) to analyze the BAM 
files generated by BWA. 
After these quality control steps, the BAM files were re-aligned with the GATK 
IndelRealigner. This step is crucial because InDels could lead to errors in the alignment 
itself originating mismatches. Local realignment around InDels reduces the number of 
mismatching bases.  
Lastly, a base recalibration was performed using the GATK base quality 
recalibration tool. This identifies the number of mismatches in the sequence and uses 
the known variants (present in Mills and 1000 Genomes Project (GP) gold standard – a 
stringently curated list of InDels) to only take into account the novel genetic variation, 
and so discard most of the known genetic variation, identifying the probability of error 
for each base with a higher confidence for variants in databases. BAM files are at this 
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point ready for further analyses. A list of SNPs and InDels was derived from the BAM 
files based on unique matches with the reference genome. Two lists were created for 
analysis, one for SNP and another for InDels variants. 
The quality of the genetic variants was also inspected visually using IGV 
(Integrative Genomics Viewer - http://www.broadinstitute.org/igv/ - version 2.3.32). 
IGV is a software that allows the visualization and interactive exploration of genomic 
data, including NGS data
68
. This tool permits the visualization of data in multiple 
genomic regions simultaneously in adjacent panels, “a scale of genome resolution from 
whole genome to base pairs”68. It also provides several reference genomes for different 
species, and provides the option of importing other genome references (but only 
FASTQ files containing chromosome or contig sequences)
68
. IGV supports several read 
alignment file formats, including SAM and BAM files. 
 
3.5.1.3 Variant calling – SNPs and InDels 
 
For the variant calling four of the most popular tools from academic and 
industrial settings were used
69
:  
1) GATK Unified Genotyper (http://www.broadinstitute.org/gatk/gatkdocs/ 
org_broadinstitute_sting_gatk_walkers_genotyper_UnifiedGenotyper.html - 
version 2.4.3 and 3.1.1); 
 2) GATK Haplotype Caller (http://www.broadinstitute.org/gatk/ gatkdocs/ 
org_broadinstitute_sting_gatk_walkers_haplotypecaller_HaplotypeCaller.html - version 
2.4.3 and 3.1.1); 
 3) Freebayes (https://wiki.gacrc.uga.edu/wiki/Freebayes - version 0.9.14); 
 4) Samtools mpileup (http://samtools.sourceforge.net/mpileup.shtml - version 
0.1.19). 
The differences between the two GATK tools are that Unified Genotyper calls 
separately SNPs and InDels by considering each variant locus independently, whereas 
in Haplotype Caller SNPs and InDels calls are performed with a local de novo 
assembly. Only bases that fulfill the criteria specified in the program are included, 
namely a minimum base quality value required to consider a base for calling and a good 
confidence call
70
. To determine the most likely combination of genotypes at each 
position in the genome, Freebayes uses short-read alignments for any individual and a 
reference genome (in our case GRCh37/hg19)
71
. Finally, Samtools mpileup needs the 
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bcftools to make the variant call because it is only capable of collecting the information 
of BAM files, computing the likelihoods of data given each possible genotype and 
stores the scores in the binary format (.bcf file). Then, Bcftools (from Samtools) makes 
the variant calling applying the prior likelihoods obtained by Samtools and doing the 
actual calling
72
.  
Briefly, all four tools used (GATK Unified Genotyper, GATK Haplotype Caller, 
Freebayes and Samtools) use a Bayesian formulation for picking the base that 
maximizes the posterior probability with the highest Phred quality score (this is the Q 
parameter previously described, which characterize  the quality of each base call)
71,73,74
. 
In addition, for each individual, a combined analysis was performed, where the variants 
that are not common between the four variant calling tools were filtered out.  
Transitions (Ti - A – G, C – T) are twice as frequent as transversions (Tv - A – 
C, G – T, A – T, C – G), so false positive SNPs should have Ti/Tv 
(Transition/Tranversion)  around 0.5 for randomly assigned variations, such results 
could be the consequence of systematic sequencing errors, alignment artifacts and data 
processing failures
75
. For evaluating the specificity of novel SNP calls, the Ti/Tv ratio, a 
critical metric for assessing the amount of false positive SNPs present in the data, was 
used. The expected Ti/Tv ratio for WES data in the literature varies between 3.0-3.3
75
. 
A combination of residual false positive makes the Ti/Tv ratio lower at new sites when 
compared to known sites. 
The Ti/Tv ratios for the six samples were calculated using VCFtools (version 
0.1.12a) for each of the four variant calling tools and for the combined analysis in order 
to decide the approach that has a lower rate of false positive SNPs. 
The GATK VariantRecalibrator tool was used to evaluate the probability that 
each call is real. This tool uses known sites (from databases such as dbSNP, Mills and 
1000 GP gold standard and HapMap) to estimate the relationship between SNP call 
annotations and the probability that a SNP is a true genetic variant versus a sequencing 
error or data processing artifact
76
. 
Lastly, all the variants in the call set were QC evaluated based on seven 
annotations parameters (Quality by Depth [QD], MAPping Quality [MAPQ], read 
DePth [DP], Fisher Strand [FS], Mapping Quality Rank Sum Test [MQRankSum], 
Haplotype Score and ReadPosRankSum). Briefly: 
1) QD is another quality parameter calculated by GATK, which indicates the 
confidence in a variant (based on the QUAL score), at a given site, over the coverage of 
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the reads that do not match a given site before being filtered. This parameter is 
normalized by read length (the higher the length, the more confident is the QD score). 
Low scores (below 10) are indicative of false positives calls and artifacts
77
.  
2) MAPQ is a quality parameter calculated by alignment tools (in our case, 
BWA) that measures the quality of the alignment for the sequencing reads
78
. BWA 
aligns the sequencing reads with a reference genome (we used hg19) and confers a score 
between 0 and 60, in which 0 indicates a low mapping quality (less confidence in the 
alignment) and 60 represents the maximum confidence in the alignment (all the bases 
are correctly mapped with the reference)
60
. When no cut-off is available for the MAPQ 
score it is recommended to draw the distribution of mapping quality scores and examine 
this distribution of outliers
79
. The author of BWA introduced the Base Alignment 
Quality (BAQ) score, based in the Hidden Markov Model, and implemented it into 
Samtools as a default parameter. Since InDels often lead to alignment artifacts BAQ 
score decrease the base quality scores for bases around insertion and deletion events in 
the sequence reducing the false positive SNP calls. However, a study lead by Guo et al. 
has shown that if BAQ and GATK’s local realignment are used consecutively, this 
increases the false positive SNP calls
79
. This is due to the fact that both tools intend to 
correct false SNPs caused by insertion and deletions, so, when applying this two tools 
consecutively will cause an over-correction
79
. 
3) Coverage or read depth (DP) is a quality parameter that indicates the number 
of times that each read was sequenced. However, this could be skewed easily by the 
high-depth regions during exome sequencing, in a phenomenon called unspecific biding 
where certain regions of the genome have much higher depth than usual. In order to 
obtain a more realistic value, we used the DP parameter calculated by GATK, that 
describes the total depth of the reads, for each variant, that passed the caller’s internal 
quality control metrics, like MAPQ > 10, for example
80
. For our data, the range for this 
parameter varies between 4 and 255. 
4) FS is a quality parameter that detects the strand bias in the reads, which 
means it will identify the number of reference and/or alternative alleles were seen on the 
forward and reverse strand. This score is calculated with the Fisher’s exact test to obtain 
the p-value and calculate the Phred-scale score (FS = −10 log10(p − value)). The p-
value is calculated creating a contingency table (2 x 2) with the number of strands 
(negative and positive) for the reference and alternate alleles. Higher scores are 
indicative of false positive calls. The recommended value for this parameter for SNPs 
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and InDels variants are below 60 and 200, respectively. One example of the Fisher 
Strand bias calculation is described in Appendix B. 
5) MQRankSum is a quality parameter that measures the mapping quality of 
heterozygous calls (reads with reference allele versus alternate allele). It uses the 
Wilcoxon Rank Sum test to test if two samples are or not the same. The score indicates 
how many times the standard deviation is distant from the mean. The recommended 
value for this parameter for SNPs variants are above -12.5. 
6) Haplotype Score is a quality parameter that measures the consistency of the 
site with two segregating haplotypes. This score is calculated for each consensus 
haplotypes against one of the consensus haplotypes found in a prior set, for each read. 
The haplotype score is the mean of haplotype scores of all reads for each locus (in a 
window of 21 bp). It generates one or two consensus haplotypes with the best quality 
scores (that is the lowest score). The recommended value for this parameter for SNPs 
variants is below 13. 
7) ReadPosRankSum is a quality parameter that measures the distance from the 
end of the read, for reads with the alternate allele. If the alternate allele is only seen near 
the extremities of the read it is indicative of an error. It uses the Wilcoxon Rank Sum 
test to test if two samples are or not the same. The score indicate how many times the 
standard deviation is distant from the mean. The recommended value for this parameter 
for SNPs and InDels variants are above -8 and -20, respectively. 
For SNPs, all variants with a QD < 2.0, FS > 60.0, MAPQ < 40.0, 
HaplotypeScore > 13.0, MQRankSum < -12.5, ReadPosRankSum < -8.0, and DP < 4 
were filtered out. For InDels variants, all variants with a QD < 2.0, FS > 200.0, 
ReadPosRankSum < -20.0, and a DP < 4 were filtered out.  
In addition, all variants present in the X, Y and mitochondrial chromosomes 
were filtered out. At the end of all these steps of the variant discovery process twelve 
VCF (variant call format) files were obtained per individual sequenced: six VCF files 
for SNP variants and six VCF files for InDel variants were created for each of the six 
family members under study (III.2-080004, III.4-080001, III.6-080005, IV.1-080002, 
IV.3-090095 and IV.6-090044). Moreover, QC is present in the whole pipeline. 
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3.5.1.4 Variant annotation 
 
Many bioinformatics tools are available to functionally annotate genetic variants 
detected in the human genome as well as their effect prediction. Examples of these are 
ANNOVAR (functional annotation of genetic variants from high-throughput 
sequencing data), SNPSift (http://snpeff.sourceforge.net/SnpSift.html - version 3.6b; a 
collection of tools to manipulate VCF files that is part of SNPeff) and VEP ensembl 
(Variant Effect Predictor - http://www.ensembl.org/info/docs/tools/vep/index.html - 
version 75). The last two tools were used to make the annotation of the final variant 
results that had a Q above 50. Both tools require an input file containing the 
chromosome, start/end positions, reference nucleotide and observed nucleotides for a 
given a list of variants.  
SNPSift was used with three specific aims: identify variants that are present in 
databases, predict whether an amino acid substitution affects the protein function, and 
give a conservation score.  
VEP ensembl was used to make gene-based annotation (identifies if single 
nucleotide variants (SNVs) cause protein coding changes and which are the amino acids 
affected), and region-based annotations (which identifies variants in specific 
genes/genomic regions). If there are several transcripts in a specific position, VEP 
choses the variant by the canonical, biotype status and length of the transcript (along 
with the ranking of the consequence type per variation). 
dbSNP 141 (http://www.ncbi.nlm.nih.gov/SNP/) and 1000 GP 
(http://www.1000genomes.org/) were used to obtain the SNP identification and allele 
frequencies, respectively. The dbSNP single-nucleotide polymorphism database  is a 
repository for common SNPs and small InDels
36
. The 1000 Genomes Project is a public 
reference database for DNA polymorphisms which has a 95% completeness of variants 
allele frequency
81
  We also used two functional prediction tools (SIFT and PolyPhen-2) 
and one conservation tool (GERP++). 
SIFT (Sorting Tolerant From Intolerant - http://sift.jcvi.org/) and PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2/) integrate and predict the effect of coding NSVs 
on protein function, based on the degree of conservation of amino acid residues in 
sequence alignments derived from closely related sequences.  
SIFT scores range between 0 and 1, and scores below 0.05 are predicted to affect 
protein function
82
. This tool assumes that important positions in a protein sequence have 
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been conserved through evolution and therefore substitutions at these positions may 
greatly affect protein function, thus assessing the effect of the amino acid substitution
82
. 
Polyphen-2 uses the characterization of the substitution site as a feature, 
comparing the ancestral (reference) allele with the mutant (alternate) allele
36,83
. In this 
tool a variant is classified as “probably damaging” if its probabilistic score is above 
0.85, as “possibly damaging” if its probabilistic score is above 0.15, and the remaining 
variants are classified as benign
83
. Also, PolyPhen-2 maps the non-synonymous SNPs 
with a known 3D structure, using the Dictionary of Protein Secondary Structure (DSSP) 
database to obtain informative features of the protein structure and to see if the 
substitution is likely to destroy important protein features, such as the hydrophobic 
membrane
36,83
.  
Regions that remain conserved over large evolutionary time scales are likely to 
be involved in key biological processes, unlike the less conserved sites, which 
accumulate more mutations
84
. To assess the level of constraint (sites that show fewer 
substitutions than would be expected to occur with neutral evolution) at a site or region 
of the genome, GERP++ (Genomic Evolutionary Rate Profiling) software tool was 
used. This tool aligns the DNA sequences of many divergent species and identifies sites 
under evolutionary constraint, aggregating these sites into longer, potentially functional 
sequences
84,85
. GERP++ scores vary between -12.36 and 6.18 - the higher the score, the 
more conserved is the site. This score is based on the alignment of 35 mammalian 
species sequences
86
. 
 
3.6 SNP selection and validation 
 
For filtering and scoring the variants and detection of disease-causing mutations, 
there are several possible strategies depending on the mode of inheritance and on the 
number of affected/non-affected individuals sequenced. Sequencing several affected 
and non-affected individuals from the same family dramatically improves the filtering 
process. Potentially functional variations (NSVs and/or variants with a probable splice 
site effect) present in all affected individuals and absent in the unaffected relative(s) 
were prioritized. In the identification of disease-related alleles, the main challenge is to 
identify the causal alleles among the background of non-pathogenic polymorphisms and 
sequencing errors
56
. Several strategies for allele discovery using NGS also rely on the 
mode of inheritance of a trait, the pedigree, population structure, whether it is a de novo 
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or inherited variant, and the extent of locus heterogeneity for the trait under study. 
Moreover, the sample size needed to provide adequate power to detect trait-associated 
alleles, and the selection of the most successful analytical framework are influenced by 
these factors
56
. 
Data was divided in two main categories: SNPs and InDels. These categories 
contain several types of alterations in the coding DNA sequence (CDS) region. The 
SNP category includes non-synonymous, synonymous, stop-gain and stop-loss variants. 
The InDel category encompasses frameshift insertions/deletions, non-frameshift 
insertions/deletions, stop-gain and stop-loss variants. Variants in the CDS region were 
the focus of this research because this is the portion of DNA that encodes for proteins. 
For SNPs, NSVs were analyzed first (because they lead to different amino acids that 
could be damaging for protein function, thus a probable cause for the disease) and also 
stop-gain/stop-loss variants. For InDels, were analyzed frameshift insertions/deletions, 
non-frameshift insertions/deletions, frameshift/non-frameshift block substitution and 
stop-gain/stop-loss variants. For both SNPs and InDels, the search was expanded for 
other regulatory regions (3’UTR, 5’UTR, upstream, downstream, intronic, intergenic 
and regulatory) that were identified but did not validate. 
For the filtering process were used two different filters. The first filter applied to 
the variants under study aims to identify variants that are absent from the unaffected 
relative and present in all affected individuals, to highlight novel alleles shared only 
among affected family members.  
Next, assuming that the PDB causative variant in the family under study is novel 
and not described in public databases, variants present in dbSNP141 and 1000 GP 
databases were filtered out.  
SIFT and Polyphen-2 scores were used to assess if the variants are possibly 
damaging to the protein function
87
. 
After the filtering steps, validation of the selected mutations of interest was 
performed using traditional Sanger sequencing at the Sequencing Unit of Instituto 
Gulbenkian de Ciência (IGC). 
The standard nomenclature recommendations of the HGVS (Human Genome 
Variation Society) were followed to name variants. Standard mutation nomenclature 
based on coding DNA reference sequences requires prefixes “c.” and numbering starts 
with number 1 for the first nucleotide in the sequence
88
.  
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3.7 Primer design & preparation 
 
PCR and sequencing primers were designed using Primer3 
(http://bioinfo.ut.ee/primer3-0.4.0/primer3/)
89
. This programme  considers possible 
combinations for reverse and forward primers to look for the best primer pairs
89
. 
Primer3 takes into consideration parameters such as sequence specificity, similar 
melting temperatures (Tm) of primer pairs, low GC content and pairing of primers with 
low probability of forming loops
89
. Primers were on average 20 nucleotides long for 
specific targeting and amplification, and spanning a specific region of interest (Table 4). 
To confirm the uniqueness of each primer sequence Blast-Like Alignment Tool 
(BLAT) program (http://genome.ucsc.edu/cgi-bin/hgBlat?command=start) was used, a 
local alignment tool from University of California–Santa Cruz (UCSC) database. This 
tool compares each DNA sequence against the whole human genome and scores it 
giving a percentage of identity. Also, the uniqueness of the forward and reverse primer 
for each region that wants to amplify was confirmed via in silico PCR 
(http://genome.ucsc.edu/cgi-bin/hgPcr?command=start), which searches how specific 
each pair of primers is, and gives the PCR product and its characteristics. 
Lyophilized primers were re-suspended in MilliQ water, making final 100 μM 
stock solutions. In turn, these were diluted to 8.27 μM (working solution) and stored at  
-20 
o
C. 
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Table 4. Primers used to Sanger sequence candidate mutations and quality control variants. 
CDS change Gene Chr Ref allele 
Obs 
allele 
Primer sequence (5' --> 3') 
Primer 
length 
(bp) 
PCR 
fragment 
(bp) 
c.G180A SERINC2 1 G A 
TATATGACCCAGCCTCCCTCT (f) 21 
460 
AGATCATCAGTGCACCCAAAC (r) 21 
c.2163_2168del PLEKHG5 1 TTCCTCC T 
CCCACAGTGTTCATGACAAGAG (f) 22 
379 
AGATTAGGGAGATGCTGGTCAC (r) 22 
c.C2264T NUP210 3 G A 
CACACTCACCACCTGCTTGT (f) 20 
204 
CTGTTCACTGTGCCCTACCA (r) 20 
c.C871T MLL3 7 G A 
TTACAACATTTGTTATTTTC (f) 20 
332 
TACTTGTGATATACAGAGAGT (r) 21 
c.C4786T KIAA1875 8 C T 
GATGAGACTGAGGGGTGAGTG (f) 21 
394 
CCTGCAGAAAGAAATTCTCTGG (r) 22 
c.C8800T CUBN 10 G A 
AGTCAAGAGGACCACTGACAGA (f) 22 
152 
TGATGACTTTTTGTTCCCACA (r) 21 
c.T1933C PML 15 T C 
CCAAGGTGAGGTCTCTAGATGG (f) 22 
350 
GGAATTCCCACAGCCTGTTAAT (r) 22 
c.C53T NLRC3 16 G A 
AGACAGCTTCTTGGAGTCTCGT (f) 22 
444 
GACAGGAAGGAAGAATGAGGTG (r) 22 
c.T566C SRL 16 A G 
TCTCCCAAAGAGTTGGGATC (f) 20 
417 
CACCAGGCATATACACATGCTT (r) 22 
c.C478G EMR2 19 G C 
CTGCTTTGGAGGACCTGACT (f) 20 
150 
AACACCCTCGGCAGCTACAC (r) 20 
 
Chr.: Chromosome; CDS change: Coding DNA sequence change; Ref.: Reference; Obs.: Observed; PCR: Polymerase chain reaction; bp: Base pair; f: Forward; r: Reverse. 
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3.8 Polymerase Chain Reaction (PCR) 
 
The first step in Sanger sequencing is the amplification of the regions of interest 
by the PCR method. PCR is an enzymatic process in which a specific DNA region is 
replicated over and over again to yield many copies of a particular sequence of interest. 
This process involves heating and cooling samples in a precise thermal cycling pattern 
over ~30 cycles. During each cycle, a copy of the target DNA sequence is generated for 
every molecule containing the target sequence. The oligonucleotide primers, that are 
complementary to the 5´- and 3′-ends of the sequence of interest, define the boundaries 
of the amplified product. Theoretically, after 30 cycles, approximately one billion 
copies of the target region (DNA template) have been generated. This PCR product 
(‘amplicon’) is then in sufficient quantity to be easily quantified and verified by a 
variety of techniques
90
. 
The PCR reaction requires a genomic template, deoxyribonucleotide 
triphosphates (dNTPs), magnesium chloride (MgCl2), primers, buffer and a polymerase 
enzyme. The PCR reaction typically contained final concentrations of 0.2 mM of each 
dNTP, 0.625 U/μL AmpliTaq Gold, 1.5 mM MgCl2, 1x AmpliTaq Gold buffer, 0.5 mM 
of each primer (forward and reverse) and 10 ng/μL of template DNA. All these reagents 
were supplied by NZYTech, apart from the primers that were from Invitrogen and the 
DNA. The final PCR volume was 12.5 μL (Table 5). The PCR reaction was performed 
on a PCR 2720 Thermal Cycler (Applied Biosystems).  
 
Table 5. Components for the PCR reaction. 
 
Component Volume in a 12.5 μL reaction (μL) 
Water 2.25 
NZYTaq Colourless Master Mix (2 x) 6.25 
Forward primer (0.5 mM) 0.50 
Reverse primer (0.5 mM) 0.50 
DNA (10 ng/μL) 3.00 
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Generally a PCR cycle includes three steps: 
1. Denaturation at 94
o
C (the double DNA strand melts to single stranded DNA). 
2. Annealing at approximately 60
o
C (the primers bind specifically to their 
complementary sequence in the single stranded DNA; the annealing temperature usually 
depends on the Tm of the expected duplex). 
3. DNA synthesis (extension of the complementary strand is initiated by the 
annealed primer and occurs most efficiently at 72
o
C). 
Each cycle is repeated 25-35 times and is finished by a longer final extension at 
72
o
C to complete all synthesis of the amplified region. 
 
A PCR stepdown program was used to amplify the candidate variants because 
this is a robust method that prevents primers to amplify non-specific regions. PCR 
initiates with an annealing temperature above the optimum annealing temperature, 
which decreases in each cycle, helping to ensure a competitive advantage for the right 
target sequence. Thus, in the initial cycles, the PCR primers will mostly hybridize with 
the region of interest, increasing the specificity substantially. Then, in subsequent 
cycles, the temperature decreases, diminishing the specificity, while increasing the 
amplification efficiency
91,92
. 
Optimization of PCR conditions was carried out by changing/adjusting the 
annealing temperature and/or number of cycles, as appropriate, until the optimal 
conditions were achieved. When the successful amplification of the targeted region was 
obtained, 6 μL of product was analyzed on an agarose gel by electrophoresis for product 
size confirmation (as previously described in sub-chapter 3.3). The conditions that 
provided optimal results were then used to amplify the remaining samples, and are 
specified for each primer pair in Appendix D. When the amplification was suboptimal, 
further systematic optimization of the PCR conditions was attempted. The KAPA2G 
Robust HotStart (Kapa Biosystems, Woburn, USA) was used in four variants 
(c.C4786T, c.C53T, c.G180A and c.2163_2168del). This kit is suited for the 
amplification of DNA templates with a high GC or AT content. It contains a DNA 
polymerase combined with a proprietary antibody that inactivates the enzyme until the 
first denaturation step, which eliminates spurious amplification products resulting from 
non-specific priming events during reaction setup and initiation, and increases overall 
reaction efficiency
93
. KAPA Enhancer 1 improves the amplification of difficult 
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templates by increasing primer specificity. KAPA2G GC Buffer helps the amplification 
of sequences with high GC content (Table 6).   
 
Table 6. PCR reaction using KAPA2G Robust HotStart kit. 
 
Component Volume in a 25 μL reaction (μL) 
Water 5.30 
KAPA2G GC buffer (5 x) 5.00 
MgCl2 (25 mM) 0.50 
KAPA Enhancer 1 (5 x) 5.00 
dNTP mix (10 mM) 0.50 
Forward primer (10 μM) 1.25 
Reverse primer (10 μM) 1.25 
DNA (90 ng/ μL) 6.00 
KAPA2G Robust Hotstart DNA polymerase (5 units/ μL) 0.20 
 
 
3.9 Sanger sequencing 
 
After the amplification of regions of interest, traditional Sanger sequencing was 
performed to validate the candidate variants in family 1 and 2. This process involves the 
incorporation of dideoxyribonucleotide triphosphates (ddNTPs) as chain terminators 
followed by a separation step capable of single nucleotide resolution. There is no 
hydroxyl group at the 3′-end of the DNA nucleotide with a ddNTP and therefore chain 
growth terminates when the polymerase incorporates a ddNTP into the synthesized 
strand. Extendable dNTPs and ddNTP terminators are both present in the reaction mix 
so that some portions of the DNA molecules are extended. At the end of the sequencing 
reaction a series of molecules are present that differ by one base from one another
90
.  
Each DNA strand is sequenced in separate reactions with a single primer. Either 
the forward or reverse PCR primers are used for this purpose. Four different colored 
fluorescent dyes are attached to each four ddNTP. Thus, ddTTP (thymine) is labeled 
with a red dye, ddCTP (cytosine) is labeled with a blue dye, ddATP (adenine) is labeled 
with a green dye, and ddGTP (guanine) is labeled with a yellow dye although it is 
typically displayed in black for easier visualization. These are similar dyes for Short 
Tandem Repeat (STR) polymorphisms detection. Fluorescent dye labels have simplified 
DNA sequencing as have the widespread use of automated detection systems and 
capillary electrophoresis
90
. 
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After obtaining successful PCR products and confirming them on a 2% agarose 
gel, products are prepared for the sequencing reaction and purified prior entering the 
sequencing platform. The Cycle Sequencing BigDye Terminator v1.1 protocol was 
used. Briefly, to each 1 μL PCR product (90 ng/μL) was added 4 μL of MilliQ water, 2 
μL of buffer, 2 μL of Terminator Ready Mix Dye and 1 μL of primer (3.2 pmol). The 
sequencing reactions were performed in the 2720 Thermal Cycler (Applied Biosystems) 
using caps and heated lids, with the following conditions: 
 
96ºC for 1 min 
96ºC for 10 sec 
50ºC for 5 sec      
60ºC for 1.15 min 
Rapid thermal ramp (1ºC/sec) to 4ºC and hold until ready to 
purify 
 
It was added to each tube 10 μL of MilliQ water, 2 μL of 3M sodium acetate 
(AcNa, pH 4.6), 50 μL of 95% ethanol and 10 μL of the PCR product obtained. The 
samples were then centrifuged at maximum speed (13.200 rpm) for 30 min (4ºC), the 
supernatant carefully discarded and 250 μL of 70% ethanol added. Samples were briefly 
vortexed and centrifuged at maximum speed (13.200 rpm) for 15 min (4ºC). Lastly, the 
pellet was dried at room temperature and then was frozen until being shipped for IGC to 
process. 
 
3.10 Sequence analysis 
 
Sequence files generated at IGC were imported to the Staden package (Pregap4, 
Trev and Gap4)
94
 and checked individually for variation by comparison with a reference 
sequence. 
Pregap4 prepare trace data for assembly, such as trace format conversion and 
quality analysis. The configuration modules selected for analysis are 1) estimation of 
base accuracy (estimates a confidence value for the base called), 2) initialize experiment 
files (for the sequence assembly), 3) quality clip (to determine the regions where the 
sequence has low quality to use for reliable assembly), 4) interactive clipping (to “call” 
25 cycles 
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the Trev program to see the chromatogram files) and 5) Gap4 shotgun assembly 
(assembles the processed sequences into Gap4 using its own assembly engine)
94
. 
Trev exhibits the original sequence, the confidence value for each base call, and 
allows editing the chromatogram data prior to assembly into a Gap4 database. 
Gap4 mainly carries out the sequence assembly and checking, contig ordering 
based on read pair data, and editing. It provides a graphical view of the contigs, readings 
and traces. Both primer pairs were aligned and compared to the reference and the 
position of the relevant variants and/or novel SNPs/InDels was highlighted. This 
programme also provides a confidence measure for each allele call per position.  
 
3.11 Reagents and buffers 
 
 MilliQ water 
 Isopropanol 
 EtOH 70% and 95% 
 RBC Lysis Buffer (RBC Bioscience Corp., New Taipei City, Taiwan) 
 Cell Lysis Buffer (RBC Bioscience Corp., New Taipei City, Taiwan) 
 Protein Remove Buffer (RBC Bioscience Corp., New Taipei City, 
Taiwan) 
 NZYTaq 2x Colourless Master Mix (NZYTech, Lisboa, Portugal) 
 TAE 1x 
 Agarose powder (NZYTech, Lisboa, Portugal) 
 Loading dye (NZYTech, Lisboa, Portugal) 
 GreenSafe Premium (NZYTech, Lisboa, Portugal) 
 1x NZYDNA Ladder VI (NZYTech, Lisboa, Portugal) 
 KAPA2G Robust HotStart (Kapa Biosystems, Woburn, USA) 
 AcNa 3M (Sigma-Aldrich, inc, St. Louis, USA)  
 BigDye (BigDye Terminator v1.1 Cycle Sequencing Kit, Applied 
Biosystems by Life Technologies, California, USA) 
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4. Results 
 
4.1 Family collection 
 
The study was carried out using two Portuguese multiplex PDB families from 
Alentejo. Multiplex families are families with multiple affected individuals. Both 
families were acertained at Instituto Português de Reumatologia (IPR) by Doctor José 
Vaz Patto and Doctor Filipe Barcelos, two rheumatologists with a special interest in 
PDB. 
All participants received an explanation of the study and signed an appropriate 
informed consent, ensuring their voluntary participation in our study. Blood samples of 
eight individuals from the family 1 (Figure 6) and six individuals from the family 2 
were collected (Figure 7). The participant’s clinical and demographic information was 
collected using a standardized questionnaire and the data was subsequently stored in an 
in-house secure database (BCgene - https://bcgene.igc.gulbenkian.pt/bcos/index.html). 
This study has been approved by the ethics committee of IPR (Appendix E). 
 
4.1.1 Characterization of the PDB family 
 
The genogram of families 1 and 2 are depicted in Figure 6 and 7, respectively. 
Diagnostic tests have been made, in particular the total serum alkaline 
phosphatase measurement, which is an important biomarker aiding the physician in 
establishing the diagnosis of PDB. The medical information of the families obtained is 
summarized in Tables 7 (family 1) and 8 (family 2). At the end of the validation 
analysis we did not know if the individual ID IV.3-090095 (from family 1) was affected 
or not. 
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Figure 6. Genogram of the PDB family 1. This genogram was constructed using CeGat Pedigree Chart Designer (version 2.1). The arrows indicate the 
individuals selected for WES (III.2-080004, III.4-080001, III.6-080005, IV.1-080002, IV.3-090095 and IV.9-090044). 
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Figure 7. Genogram of the PDB family 2. This genogram was constructed using CeGat Pedigree Chart Designer (version 2.1). All individuals from whom 
DNA were available (II.1-140033, II.2-140030, II.3-140029, III.1-140031, III.2-140034 and IV.1-140032) were used for validation.
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Table 7. Clinical and demographic characterization of the Portuguese multiplex PDB family 1. 
F: Female; M: Male; l: left; r: right; NA: Not available. 
Family 
relative ID 
Gender 
Year of 
birth 
Affection status 
Age at 
onset 
N
o
 of affected 
bones 
Localization of 
lesions 
Symptoms 
III.1-080003 F 1928 Patient 58 12 
Cranium, scapula (r), 
sacrum, pelvis (r), both 
femurs, patela (r), both 
tibia, fibula (r) 
Skeletal pain, skeletal deformities, 
fractures (fissure fracture, chalk-stick 
fracture),  hearing deficit,  generalized 
atherosclerosis  
III.2-080004 F 1928 Patient 62 9 
Cranium, humerus (l),  
pelvis (l), both femurs,  
patella (l), tibia (l), 
both fibulas  
Skeletal pain, skeletal deformities, 
secondary osteoarthritis, hearing deficit, 
generalized atherosclerosis 
III.4-080001 F 1933 Patient 55 7 
Cranium, sacrum, 
pelvis (l), femur (l), 
both tibia, tarsus (r)  
Skeletal pain, skeletal deformities, 
fractures (fissure fracture, chalk-stick 
fracture), secondary osteoarthritis, 
hydrocephalus, slight pericardial 
effusion 
III.6-080005 F 1931 Patient 62 3 
Cranium, clavicle (r), 
pelvis (r) 
Skeletal pain, secondary osteoarthritis, 
hearing deficit  
III.8-090043 F NA Unaffected - - - - 
IV.1-080002 F  1965 Unaffected - - - - 
IV.3-090095 M  1954 Unclear 52  2 Femur (r), tibia (l) Skeletal pain 
IV.9-090044 F  1963 Patient 30 4 
Cranium, sacrum, 
humerus (r), pelvis (r) 
Skeletal pain, secondary osteoarthritis 
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Table 8. Clinical and demographic characterization of the Portuguese multiplex PDB family 2. 
F: Female; M: Male; l: left; r: right. 
Family 
relative ID 
Gender 
Year of 
birth 
Affection status 
Age at 
onset 
N
o
 of affected 
bones 
Localization of lesions Symptoms 
II.1-140033 M 1928 Unaffected -  - - - 
II.2-140030 F  1935 Patient 59 18 
Cranium, both clavicles, 
vertebral column, both 
humerus, both hand carpals, 
both hand metacarpals, 
both hand phalanges 
pelvis (r), both  
patella, both foot tarsals,  
both foot metatarsals,  both 
foot phalanges 
Skeletal pain, skeletal deformities, 
fractures (fissure fracture, chalk-stick 
fracture), secondary osteoarthritis, 
vascular cerebral accident, 
hypertension,  hyperparathyroidism, 
lupus, rheumatoid arthritis 
II.3-140029 F 1937 Patient 56 9 
Cranium, both clavicles, 
both humerus, both pelvis,  
patella (r), foot phalanges 
(r) 
Skeletal pain, skeletal deformities, 
fractures, secondary osteoarthritis, 
hearing deficit, generalized 
atherosclerosis, hyperparathyroidism 
III.1-140031 F  1960 Unclear - 3 
Vertebral column, both 
hands phalanges 
Skeletal pain, secondary osteoarthritis,  
hypertension, gouty diathesis 
III.2-140034 F 1953 Unclear - 8 
Both humerus, both hand 
phalanges, both  patella, 
both foot phalanges 
Skeletal pain, secondary osteoarthritis,  
hyperparathyroidism, diabetes 
IV.1-140032 M  1979 Unaffected -  - - - 
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4.1.1.1 Sample selection criteria for the WES assay 
 
The use of pedigree information can substantially narrow the genomic search 
space for candidate causal alleles. Depending on the frequency of the disease-causing 
allele and the nature of the relationship between the individuals within the family under 
study one chooses the most informative individuals to further analyze
56
.  
Sequencing multiple affected individuals from within one family to identify 
genes with novel variants in a shared region of the exome is the most efficient strategy 
in our case, since we can substantially reduce the exonic search space by choosing the 
relatives that share half or less than half of the genetic information between them. Thus, 
we can reduce the genetic information that is shared between the family relatives 
increasing the probability of find the risk variants. Siblings from the third generation 
(III.2-080004, III.4-080001, III.6-080005) were selected since in the case of rare alleles 
the probability of identity-by-descent given identity-by-state is high, even among 
distantly related individuals
56
. This is also the case for first cousins that were also 
selected to study (IV.1-080002, IV.3-090095 and IV.9-090044) in order to substantially 
restrict our exonic search.   
The DNAs from the six selected individuals from family 1 were therefore sent to 
BGI for WES. Few weeks later, we received from BGI the raw sequencing data as well 
as their bioinformatics analysis. 
 
4.2 Quality control of the WES data 
 
To validate the WES data and bioinformatics analysis from BGI, four variants 
with varying quality scores were selected for validation by Sanger sequencing. To 
ensure that a good concentration of DNA was obtained to proceed to the WES analysis 
and validation (by Sanger sequencing) all the DNA samples were quantified and run in 
an agarose gel to confirm DNA quality. 
Moreover, three samples (III.4-080001, III.6-080005 and IV.3-090095) were run 
in the bioanalyzer to make sure that the DNA had high quality for the WES assay, 
which is a more sensitive technique. Only three of the six samples (sent to BGI) were 
run in the bioanalyzer because this was the first time that this analysis was performed 
and for that reason it was necessary to run positive controls from the lab (DNA samples 
recently extracted), in order to be sure that we obtained optimal results. This is a crucial 
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step because the WES assay is sensitive to slightly degraded DNA, so it was needed to 
ensure that our samples (which have been stored for five years) had a similar quality of 
DNA samples recently extracted. 
All 14 samples had an excellent quality and their concentration was above the 
required (> 40 ng/μL) for the WES and validation assays. In the bioanalyzer gel (Figure 
F.1. A, Appendix F), none of the three PDB samples seemed degraded unlike the 
sample 090022 (a control sample of the lab), which had a band at 7000 bp indicating 
that the DNA was slightly degraded. Also, there is no peak between the two markers 
(Figure F.1. B, Appendix F) indicating that the genomic DNA of the three PDB samples 
is not fragmented. 
Six quality parameters were used to check BGI’s SNPs and InDels results: (1) 
MAPQ (MAPping Quality), (2) GQ (Genotype Quality), (3) DP (read DePth), (4) AD 
(Depth Allele by sample), (5) QUAL (QUALity score) and (6) QD (Quality by Depth). 
Briefly: 
1) MAPQ is a quality parameter that measures the quality of the base alignment. 
The highest score is 60, which indicate that the read matches rightly with the reference 
genome.  
2) GQ (or Phred-scale confidence) is another quality parameter calculated by 
GATK that indicates if the inferred genotype for each variant is the real genotype, this 
means, if they are estimated with high/low confidence level
95
. GQ ranges between 0 and 
100%. 
3) DP is a quality parameter that indicates for each position how many times 
each variant passed the internal quality control (such as a MAPQ > 10)
60
. A base with a 
DP of four indicates that this base was read four fold. This first three quality parameters 
are described in more detail in the sub-chapter 3.5.1.3.  
4) AD value is the number of reference (ref) and alternate (alt) alleles observed 
in each variant read. The total sum of ref and alt alleles is then equal to the DP value 
calculated, providing complementary information on our data
96
. 
5) QUAL is a quality score that indicates the probability of a variant (ref/alt) 
exists at a certain site, given sequenced data (Table 2). This score grows with the 
amount of NGS data analyzed in the variant calling step
95
.  
6) Finally, QD is a quality parameter that indicates the variant’s confidence at a 
given site. Low scores are indicative of false positive calls.  
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 To show an example of the interpretation of all six quality parameters, an 
example for variant c.C1165A is shown in Table 9. 
 
The table 9 indicates that: 
- the quality score (QUAL) is 802.92, indicating approximately 1 in 10
80
 chances 
of error; 
- the MAPping Quality (MAPQ) is 60, indicating a good confidence in the 
alignment; 
- the Quality by Depth (QD) is 13.16 (QD above 10 is consider a variant with a 
good confidence call); 
- the genotype value (GT) is 0/1, which means this individual is heterozygous at 
this locus;  
- the depth allele by sample (AD) shows a total number of reference nucleotide 
(G) is 33 and the alternate nucleotide (T) is 28;  
- the read DePth (DP) is 61, which means that this variant as a coverage of 61 
fold;  
- the genotype quality (GQ) is 99%;  
- the genotype likelihood (PL) presents three different values who correspond to: 
0/0 (homozygous) = 833; 0/1 (heterozygous) = 0; 1/1 (homozygous) = 939, so the 
genotype is 0/1, because the value of genotype likelihood is equal to zero. 
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Table 9. Example of WES QC parameters for the non-synonymous variant (NSV) c.C1165A in CUBN. 
 
 
 
 
 
CDS change: Coding DNA sequence change; NSV: Non-synonymous variant; Chr: Chromosome; bp: Base pair; Ref: Reference; Obs: Observed; MAPQ: MAPping Quality; QD: 
Quality by Depth; GT: GenoType; AD: Depth Allele by sample; DP: read DePth; GQ: Genotype Quality; PL: Genotype Likelihood. 
 
CDS 
change 
Gene 
Mutation 
type 
Chr 
Start/End 
(bp) 
Ref Obs QUAL MAPQ QD GT AD DP GQ PL 
c.C1165A CUBN NSV 10 
17.147.521/ 
17.147.521 G T 802.92 60.00 13.16 0/1 33;28 61.00 99.00 833,0,939 
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Based on the BGI bioinformatics analysis one variant (c.C8800T) with good 
quality (MAPQ ~60, and DP of ~36x), two variants (c.C2264T and c.C871T) with a 
medium quality (one with low MAPQ ~36, and another with a mean DP ~25x), and one 
variant (c.C478G) with bad quality (low MAPQ ~24.94 and DP ~10x) were selected for 
quality control (Table 10). For each variant one PDB patient and one control from 
family 1 were randomly sequenced to confirm BGI’s results as either real or false 
positive/negative. 
In addition, for each variant were counted how many reference and/or observed 
alleles were seen in the reverse and/or forward strand to verify if the alternate allele is 
disproportionately represented on one strand migh be indicative of a false positive 
variant (Fisher strand bias – Table 11). 
At this point, the PCR for the “bad” quality variant (c.C478G) was not optimized 
because this is inserted in a repetitive region, and was very difficult to amplify the 
region of interest (even after several attempts). This is reflected on the BGI results, 
since the MAPQ attributed to this variant is very low (MAPQ = 24.94), corresponding 
to a low confidence in mapping the read with the reference genome. The same applies to 
the DP (DP = 10x), which means that just a few reads were actually counted.  
Two PCRs (one from a “good” quality variant – c.C8800T - and another from 
the variant with “medium” quality – c.C2264T) are represented in Figure 8. The 
respective sequencing chromatograms are represented in Figures 9B and 10B for one 
PDB patient and one control. 
Afterwards, these four regions were visualized using IGV to enquire if the BGI 
results corresponded to the results obtained for the “good” (Figure 9), “medium” 
(Figures 10 and 11) and “bad” quality variants (Figure 12) both in IGV and our Sanger 
sequencing results.  
The results visualized in IGV for the two variants (c.C8800T and c.C2264T) are 
consistent with the results obtained by BGI (Figure 9A and 10A). However, contrary to 
the results obtained by BGI, variants c.C871T and c.C478G are also present in the 
control IV.1-080002 (Figure 11A and 12A). 
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Table 10. Selected variants for the QC parameters assessment. These variants were chosen mainly following two main quality control parameters (DP and 
MAPQ) and are organized in three quality categories (Good, medium and bad). 
CDS 
change 
Gene Chr 
Start/End 
(bp) 
Ref 
Allele 
Obs 
Allele 
SNP ID 
Variants 
quality 
DP MAPQ QUAL AD QD GQ 
c.C8800T CUBN 10 
16.930.521/ 
16.930.521 
G A . Good 36.00 60.00 493.61 16;20 13.71 99.00 
c.C2264T NUP210 3 
13.399.786/ 
13.399.786 
G A rs6795271 
Medium 
25.00 60.00 250.47 15;10 10.02 99.00 
c.C871T MLL3 7 
151.970.931/
151.970.931 
G A rs56850341 84.00 36.98 1204.08 23;50 16.49 99.00 
c.C478G EMR2 19 
14.877.799/ 
14.877.799 
G C rs12976472 Bad 10.00 24.94 75.48 0;10 7.55 9.03 
CDS change: Coding DNA sequence change; Chr: Chromosome; Ref: Reference; Obs: Observed; bp: Base pair. 
Note: All variants are exonic NSVs. 
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Table 11. Strand bias for the QC variants selected. For each variant, was visualized how many reference and/or alternate alleles were seen in the reverse 
and/or forward strand using IGV and was calculated the Fisher Strand bias (when FS = 0 there is no bias and FS > 0 indicates bias, so the higher the score 
more bias is present).  
CDS change: Coding DNA sequence change; Ref: Reference; Obs: Observed; FS: Fisher Strand. 
Note: Individual IV.1-080002 presented variants c.C871T (MLL3) and c.C478G (EMR2) using IGV in our analysis, but in BGI results they were absent
  III.4-080001 IV.1-080002 III.2-080004 III.6-080005 IV.9-090044 IV.3-090095 
CDS change Strand Ref Obs FS Ref Obs FS Ref Obs FS Ref Obs FS Ref Obs FS Ref Obs FS 
c.C8800T 
Positive . . 
. 
. . 
. 
8 5 
0.00 
8 6 
0.00 
5 6 
0.00 
. . 
. 
Negative . . . . 18 10 23 17 10 14 . . 
c.C2264T 
Positive 16 14 
0.00 
. . 
. 
15 9 
3.98 
8 18 
9.24 
10 12 
4.63 
. . 
. 
Negative 2 2 . . 0 1 2 0 3 1 . . 
c.C871T 
Positive 10 72 
11.33 
13 45 
6.24 
19 44 
0.00 
15 50 
0.00 
18 49 
5.87 
22 66 
0.95 
Negative 6 13 7 12 4 8 5 19 8 11 7 19 
c.C478G 
Positive 26 2 
8.28 
26 2 
0.00 
0 10 
0.00 
1 4 
3.43 
0 7 
0.00 
. . 
. 
Negative 9 3 9 1 0 1 0 6 0 5 . . 
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A 
B 
 
 
 
 
 
 
 
 
 
1 – NZYDNALadder VI  
2 and 11– Negative Controls 
3 – III.4-080001               
4 – IV.1-080002 
5 – III.1-080003               
6 – III.2-080004 
7 – III.6-080005            
8 – IV.3-090095 
9 – III.8-090043 
10 – IV.9-090044 
              
 
 
 
 
 
 
 
 
 
 
 
Figure 8. PCR amplification of the c.C8800T (A) and c.C2264T (B) variants in individuals 
from family 1. The NZYDNALadder VI was loaded in the first lane of a 2% agarose gel and 
the PCR products are running at the expected location for 152 bp (A) and 204 (B) fragments, 
respectively. 
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A 
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G G G T A A T T T G [G/A] A G A A A T G A T G T A 
 
 
 
 
 
 
 
 
 
 
Figure 9. “Good” quality variant (c.C8800T) according to IGV (A) and chromatograms 
obtained via Sanger sequencing (B). A - c.C8800T variant with the mutated A allele in patient 
III.6-080005, and absent in the control (IV.1-080002), depicted between the dashed black lines 
using IGV. The reads are depicted as grey arrows aligned by base and above them there is a 
histogram that reflects the coverage per base. Polymorphisms are highlighted in the respective 
read and the deletions are represented as a black line. Also, the reference sequence (hg19) and 
respective amino acids are also shown below, when possible. B - Here one can see the peak for 
the mutated A allele for c.C8800T variant in patient III.6-080005 (arrow), and absent in the 
control (IV.1-080002). 
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A 
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G A C A G G C [G/A] C G A G G G T G A 
 
 
 
 
 
 
 
 
 
 
Figure 10. “Medium” quality variant (c.C2264T) according to IGV (A) and 
chromatograms obtained through Sanger sequencing (B). A - c.C2264T variant with the 
mutated A allele in patient III.2-080004, and absent in the control (IV.1-080002). B - Here one 
can see the mutated A allele for c.C2264T variant in patient III.2-080004 (above, black arrow). 
It is also present in the control IV.1-080002 (below, black arrow). 
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G C T C C A A [G/A] G T G C T T  
 
 
 
 
 
 
 
 
 
Figure 11. “Medium” quality variant (c.C871T) according to IGV (A) and chromatograms 
obtained via Sanger sequencing (B). A - The c.C871T variant with the mutated A allele in 
patient III.9-090044 is here depicted, also present in the control (IV.1-080002). B - Here one 
can see the mutated A allele for the c.C871T variant in patient IV.9-090044 (above, black 
arrow). This variant is also present in the control IV.1-080002 (below, black arrow). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. “Bad” quality variant (c.C478G) according to IGV. Here one can see the 
c.C478G variant with the mutated C allele in patient III.2-080004, also present in the control 
(IV.1-080002).  
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A perfect match was obtained between the alleles reported in the BGI WES 
analysis and the Sanger sequencing performed for the “good” quality variant c.C8800T 
(Figure 9). As shown in Figure 9, patient III.6-080005 is heterozygous having both the 
reference (G) and alternate (A) alleles at 16.930.521 bp position in chromosome 10, 
which is in agreement with the BGI result. The control (IV.1-080002) does not have the 
mutation as expected. 
For the “medium” quality variants (c.C2264T and c.C871T) it can be seen the 
alternate allele in the control (IV.1-080002), which was not reported in the BGI analysis 
(Figures 10 and 11).  
In Figure 10, it is highlighted that the patient III.2-080004 is heterozygous 
having the reference (G) and alternate (A) alleles for the 13.399.786 bp position in 
chromosome 3 corresponding to the result reported by BGI. However, in the control 
(IV.1-080002) the variant was present, although it was supposed to be absent. 
In Figure 11, one can see that the patient IV.9-090044 is heterozygous having 
the reference allele (G) and alternate (A) alleles for the 151.970.931 bp position in 
chromosome 7 corresponding to the result reported by BGI. However, in the control 
(IV.1-080002) the variant was supposed to be absent and again it was identified in 
Sanger sequencing. More, when this position was observed in IGV (Figure 11A) the 
variant is present in the control, re-confirming these findings and supporting that the 
results given by the BGI are wrong. Additionally, the strand bias is higher in the 
“medium” and “bad” quality variants than in the “good” quality variants. 
In Table 12 is summarized the inconsistencies between the BGI BAM files, BGI 
bioinformatics analysis and Sanger sequencing. 
 
Table 12. Differences inspected between IGV, BGI bioinformatics analysis and Sanger 
sequencing in the QC variants. Here is shown the genotype present for both affected and 
unnafected individuals when we visualized the BGI BAM files in IGV, the BGI bioinformatics 
analysis and Sanger sequencing. Discordant results are highlited in bold. 
CDS change Family relative ID 
BGI bioinformatics 
analysis 
IGV 
Sanger 
sequencing 
c.C8800T 
III.6-080005 GA GA GA 
IV.1-080002 GG GG GG 
c.C2264T 
III.2-080004 GA GA GA 
IV.1-080002 GG GG GA 
c.C871T 
IV.9-090044 GA GA GA 
IV.1-080002 GG GA GA 
c.C478G 
III.2-080004 GC GC GC 
IV.1-080002 GG GC NA 
CDS change: Coding DNA sequence change; NA: Not available 
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As the BGI bioinformatics results were analyzed, were found several errors such 
as old and different versions of dbSNP between files for the same individual, a high rate 
of non-calling variants and errors in calculations such as the SIFT values. In addition, 
BGI used GATK Unified Genotyper that has a higher error rate when compared with 
GATK Haplotype Caller. The latter does a de novo realignment of the read data 
decreasing the error rate of the variants call. Consequently, we decided to perform a 
new updated bioinformatics analysis based on the Best Practices workflow, from the 
Broad Institute, optimized for human data, using only the raw FASTQ files from WES 
sent by BGI.  
 
4.3 New bioinformatics analysis of raw WES data 
 
In the first phase of the bioinformatics re-analysis (Data Pre-processing – Figure 
4), FastQC and Qualimap tools were used to perform a quality control of the twelve 
FASTQ files (six FASTQ files from the positive strand and another six FASTQ files 
from the negative strand) and the six BAM files. The FastQC and Qualimap were used 
to annotate the number of reads for each of the six individuals, the GC percentage, 
mapping and duplication rate (Table 13 and Figure G.1, Appendix G). In addition, was 
used the graphs sent by BGI to assess the sequencing depth of the target bases and see if 
there was no variation between samples (Figure G.2, Appendix G). 
 
Table 13. WES data and alignment statistics. This information was generated with the 
FastQC and Qualimap programmes. The GC, mapping rate and duplicate rate were selected as 
the most important parameters since they can affect the subsequent analysis. 
 
Data and 
alignment statistics 
III.4-
080001 
IV.1-
080002 
III.2-
080004 
III.6-
080005 
IV.9-
090044 
IV.3-
090095 
Number of reads  63.713.598 58.536.898 59.194.990 50.515.208 58.252.244 75.206.380 
Data size  6.371.359.800 5.853.689.800 5.919.499.000 5.051.520.800 5.825.224.400 7.520.638.000 
fq1 GC(%)  47.00 47.00 47.00 48.00 46.00 45.00 
fq2 GC(%)  47.00 47.00 47.00 48.00 46.00 45.00 
Mapping rate (%) 97.83 99.23 98.81 99.21 99.10 98.60 
Duplicate rate (%) 22.92 30.90 24.45 27.00 22.51 18.19 
   fq1 – FASTQ 1 file (positive strand); fq2 – FASTQ 2 file (negative strand) 
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In the second phase of the bioinformatics analysis (Variant Discovery) to 
improve the variant calling results, the Ti/Tv ratio was calculated for each of the four 
variant calling tools (Table 14). Reference values in the literature for Ti/Tv ratio vary 
between ~2.0 – 2.1 for WGS and ~3.0 – 3.3 for WES75. Also, a combined analysis was 
performed in which all variants that do not match between the four tools were filtered 
out. The combined analysis achieved a higher Ti/Tv score (2.30) than any of the variant 
calling tools individually suggesting a lower false positive rate with this analysis. 
Therefore, the results obtained with the combined analysis were used in the subsequent 
in SNPs/InDels analyses. 
 
Table 14. Ti/Tv scores. Ti/Tv is a ratio between the number of transitions (A – G, C – T) and 
the number of transversions (A – C, G – T, A – T, C – G), and is used to assess the false 
positive rate. This score was calculated for each of the four variant calling tools as well as for a 
combined analysis. The scores obtained for each tool is an average of the ratios calculated for 
each of the six individuals sequenced by WES. 
 
 
 
 
 
 
 
 
 
 
 
Additionally, it was assessed if the QC filters applied to obtain the final lists of 
SNPs and InDels present in each individual presented optimal results. For this we 
compared our SNP data with respective data collected for European Americans in the 
Bamshad et al. report
56
 (Table 15). The mean number of novel SNPs present in our 
dataset was 259, approximately the same number obtained in the dataset for the 
European Americans (novel SNPs = 307). Also, it was calculated the Ti/Tv score per 
individual to assess the false positive SNP rate (Table 16). A global Ti/Tv score of 
approximately 2.37 (average score, Table 16) was achieved. This indicates an improved 
mean error rate when compared to previous calculations and closer to the reference 
value for WES (3.0). Also, the Ti/Tv score for novel SNPs showed a high error rate 
when compared to the global Ti/Tv score indicating that these variants could be 
increasing the global false positive rate.  
Variant Calling tool Ti/Tv score 
UnifiedGenotyper GATK 1.91 
HaplotypeCaller GATK 2.19 
Freebayes 2.00 
Samtools mpileup 1.96 
Combined analysis 2.30 
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Table 15. Mean number of novel and known SNPs obtained in the WES re-analysis. 
Known variants are those found in dbSNP and 1000 GP. 
 
Variant type 
Mean number of variants (± SD) 
in our dataset 
Mean number of variants (± SD) 
in European Americans56 
Novel variants     
NSV 150 (± 13) 192 (± 21) 
Stop-gain and stop-loss 3 (± 0.6) 5 (± 2) 
Synonymous 89 (± 10) 109 (± 16) 
Splice 17 (± 3) 2 (± 1) 
Total 259 (± 16) 307 (± 33) 
Known variants     
NSV 8782 (± 160) 9319 (± 233) 
Stop-gain and stop-loss 68 (± 4) 89 (± 6) 
Synonymous 9968 (± 59) 10.536 (± 280) 
Splice 1685 (± 27) 32 (± 3) 
Total 20579 (± 219) 19976 (± 505) 
Total variants     
NSV 8967 (± 118) 9511 (± 244) 
Stop-gain and stop-loss 72 (± 4) 93 (± 6) 
Synonymous 10098 (± 103) 10645 (± 286) 
Splice 1702 (± 27) 34 (± 4) 
Total 20838 (± 219) 20283 (± 523) 
SD: Standard Deviation; NSV: Non-synonymous Variants 
Note: For the European Americans the dbSNP version used was dbSNP131. For our dataset the dbSNP 
version used was dbSNP141.  
 
 
 
Table 16. Ti/Tv ratio obtained for the six family members sequenced by WES. This score 
was calculated for each of the six individual sequenced by WES and a mean Ti/Tv score of all 
six individuals.  
 
 
 
 
 
 
 
 
 
 
 III.4-
080001 
IV.1-
080002 
III.2-
080004 
III.6-
080005 
IV.9-
090044 
IV.3-
090095 
Average 
Ti/Tv 
Ti/Tv 2.37 2.37 2.38 2.43 2.36 2.31 2.37 
Novel Ti/Tv 2.11 2.00 2.01 2.29 2.01 2.25 2.11 
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4.4 Validation by Sanger sequencing 
 
After filtering out the low quality variants and performing the annotation (final 
steps of the bioinformatics pipeline [Figure 4 – Methods]), six VCF files for the SNP 
variants and another six VCF files for InDel variants present in the six individuals were 
generated. Since variants in the CDS region are those of interest in this project, the 
NSVs and also stop-gain/stop-loss variants for the SNP variants category have been 
analyzed (Table 17, C.1 and C.3, Appendix C). For InDels category, frameshift 
insertion/deletion, non-frameshift insertion/deletion, frameshift/non-frameshift block 
substitution and stop-gain/stop-loss variants have been analyzed (Table 17, C.2 and C.4, 
Appendix C). The results for each individual were divided by SNPs and InDels in Table 
17. 
For both SNPs and InDels, the search has been expanded for other regulatory 
regions (3’UTR, 5’UTR, upstream, downstream, intronic, intergenic and splicing 
regions – Table 17, C.1, C.2, C.3 and C.4, Appendix C) that which were not validated 
due to time constrains. 
After all the QC and filtering analysis, variants that are absent from the 
unaffected relative and present in all affected individuals have been identified, so 
mutations in the same genes shared only among affected family members can be 
highlight, obtaining a final list of variants to further pursue in validation. However, we 
did not have a final diagnosis until the end of this thesis of one family member from 
family 1 (individual IV.3-090095), so two different analyses were created: 
- Model 1: one unaffected relative (IV.1-080002) and five affected individuals 
(III.2-080004, III.4-080001, III.6-080005, IV.3-090095 and IV.9-090044); 
- Model 2: two unaffected relatives (IV.1-080002 and IV.3-090095) and four 
affected individuals (III.2-080004, III.4-080001, III.6-080005 and IV.9-090044). 
Assuming that the mutation causing PDB in family 1 is novel, it is not included 
in the dbSNP or 1000 GP databases. Therefore, all polymorphisms/mutations present in 
1000 GP and dbSNP141 were filtered out from our list of variants. 
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Table 17. SNP and InDel statistics. After our bioinformatics analysis the results obtained for 
each individual were divided into SNPs (top) and InDels (bottom) variants. 
SNPs 
 III.4-
080001 
IV.1-
080002 
III.2-
080004 
III.6-
080005 
IV.9-
090044 
IV.3-
090095 
Total variants 107487 105285 105058 91948 109182 163163 
1000 GP and dbSNP 101969 100504 99697 88545 103326 153613 
1000GP 101969 100504 99697 88545 103326 153613 
dbSNP 106433 104210 104053 91038 107998 161669 
Novel 1054 1075 1005 910 1184 1494 
Hom 55452 51727 51663 40023 53940 94250 
Het 52035 53558 53395 51925 55242 68913 
Synonymous 10368 10251 10355 10541 10461 10416 
NSV 9079 8972 9090 9314 9027 9180 
Stop-gain 58 61 57 58 66 54 
Stop-loss 12 13 13 13 11 14 
Exonic 19518 19298 19516 19927 19565 19665 
Exonic and splicing 50 50 52 43 47 61 
5’UTR 1869 1788 1779 1891 1764 1862 
3’UTR 3603 3537 3530 3616 3692 4433 
Upstream 4438 3940 4081 3017 4158 7561 
Downstream 2995 2791 2746 1904 2848 5823 
Intronic 62028 61231 61154 55448 64701 93275 
Intergenic 7863 7794 7258 1897 7452 23280 
SIFT 1433 1417 1443 1444 1406 1452 
InDels 
Total variants 7467 8770 7723 6981 7841 9579 
1000 GP and dbSNP 4174 4656 3412 3963 4380 5381 
1000GP 4174 4656 3412 3963 4380 5381 
dbSNP 7212 8451 7468 6761 7619 9307 
Novel 255 319 255 220 222 272 
Hom 4210 5119 4347 3742 4472 5610 
Het 3257 3651 3376 3239 3369 3969 
Frameshift insertion 78 72 76 73 70 74 
Non-frameshift insertion 98 90 97 106 83 94 
Frameshift deletion 71 70 72 69 60 72 
Non-frameshift deletion 118 105 119 115 117 102 
Frameshift block 
substitution 
0 0 0 0 0 0 
Non-frameshift block 
substitution 
0 0 0 0 0 0 
Stop-gain 0 0 0 0 0 0 
Stop-loss 3 3 2 2 2 3 
Exonic 385 357 383 381 349 361 
Exonic and splicing 16 20 17 18 14 13 
5’UTR 209 156 172 181 159 174 
3’UTR 378 347 360 372 388 431 
Upstream 295 390 318 246 278 413 
Downstream 189 268 185 134 204 305 
Intronic 5435 5984 5493 5267 5687 6832 
Intergenic 339 989 548 174 518 770 
Hom: Homozygous; Het: Heterozygous; NSV: Non-synonymous Variants; SIFT: Sorting Tolerant From Intolerant; 
Ti/Tv: Transition/Transversion ratio; UTR: Untranslated region. 
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According to model 1, three novel NSVs, c.C4786T in KIAA1875, c.C53T in 
NLRC3 and c.T566C in SRL co-segregated with the disease in family 1 (Table 18). 
SIFT and PolyPhen-2 scores indicate that variants c.C4786T and c.T566C are probably 
damaging for the protein function. In addition, GERP++ scores showed that these two 
variants are inserted in conserved sites, which means that they are likely to be involved 
in key biological processes, not tolerating mutations. Only variant c.C53T is predicted 
to be not damaging for the protein function and also it is inserted in a less conserved site 
indicating that will tolerate mutations. However, these in silico tools are only predictive, 
so all three variants were validated. The MAPQ for these variants achieved the highest 
score (MAPQ ~60) indicating a good confidence in the alignment performed. As for 
coverage, these variants have enough coverage (DP > ~30), however for the c.T566C 
there is a slight strand bias between the reference and alternate alleles observed in the 
positive and negative strand (Table 19).  
For model 2 one novel NSVs - c.G180A in SERINC2 - and one novel non-
frameshift deletion - c.2163_2168del in PLEKHG5 -  co-segregated with the disease in 
family 1 (Table 20). SIFT and PolyPhen-2 scores showed ambiguous results for variant 
c.G180A. The former indicated that the mutation is deleterious and the latter that is 
benign for the protein function. GERP++ scores highlighted that this variant is inserted 
in a conserved site, which means that this is inserted in a site that does not tolerate 
mutations. For InDels there are no in silico tools to predict the impact of the mutation. 
The MAPQ for the two variants achieved the highest score (MAPQ ~60) indicating a 
good confidence in our alignment. The c.2163_2168del had sufficient coverage (DP 
~54) however for c.G180A the coverage is lower (DP ~13). Additionally, there is a 
slight strand bias between the reference and alternate alleles observed in the positive 
and negative strand for c.2163_2168del in individuals III.4-080001, III.6-080005 and 
IV.9-090044 (Table 21). 
All mutations for both models were found in the heterozygous state consistent 
with an autosomal dominant model, since the phenotype is expressed with presence of 
both reference and alternate alleles. 
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Table 18. Model 1 top three variants, selected from SNPs and InDels categories from the WES data. These variants are absent from the unaffected 
relative (IV.1-080002) and present in all five affected individuals (III.2-080004, III.4-080001, III.6-080005, IV.3-090095 and IV.9-090044), and not described 
in 1000 GP and dbSNP databases. 
CDS 
change 
Gene 
Mutation 
type 
SIFT 
score 
PolyPhen-2 
score 
GERP++ Chr 
Start/End 
(bp) 
Ref 
allele 
Obs 
allele 
DP MAPQ Genotype 
c.C4786T KIAA1875 NSV 0.000 0.996 4.46 8 
145.171.113/ 
145.171.113 
C T 27.00 60.00 0/1 
c.C53T NLRC3 NSV 0.920 0.000 -3.62 16 
3.627.162/ 
3.627.162 
G A 31.00 60.35 0/1 
c.T566C SRL NSV 0.000 0.948 5.10 16 
4.245.598/ 
4.245.598 
A G 113.00 59.84 0/1 
NSV: Non-synonymous Variants; CDS change: Coding DNA sequence change; Chr: Chromosome; bp: Base pair; Ref: Reference; Obs: Observed; SIFT: Sorting Tolerant From Intolerant; 
Genotype: 1/1 (homozygous for the observed allele); 0/1 (heterozygous). 
 
 
 
 
 
 
 
 
Family Genetics of Paget’s Disease of Bone                                                                                                                                                               4. Results 
 
64 
 
 
 
 
Table 19. Strand bias for the variants selected according to model 1. The number of reference and alternate alleles seen in IGV in the forward and reverse 
strand as well as the calculated Fisher strand bias are shown for each model 1 variant and for each individual sequenced by NGS.  
CDS change: Coding DNA sequence change; Ref: Reference; Obs: Observed; FS: Fisher Strand. 
 
 
 
 
 
 
 
 
 
  III.4-080001 IV.1-080002 III.2-080004 III.6-080005 IV.9-090044 IV.3-090095 
CDS 
change 
Strand Ref Obs FS Ref Obs FS Ref Obs FS Ref Obs FS Ref Obs FS Ref Obs FS 
c.C4786T 
Positive 18 20 
1.55 
. . 
. 
11 12 
0.00 
13 21 
1.62 
10 19 
0.00 
15 14 
0.00 
Negative 5 3 . . 2 2 2 6 2 4 1 2 
c.C53T 
Positive 17 13 
0.00 
. . 
. 
13 12 
1.85 
13 14 
0.00 
12 8 
0.00 
5 5 
0.00 
Negative 9 6 . . 2 4 5 5 6 3 3 3 
c.T566C 
Positive 29 38 
3.57 
. . 
. 
38 36 
0.73 
47 32 
7.88 
34 43 
4.81 
38 40 
2.35 
Negative 22 21 . . 19 20 30 11 22 18 20 26 
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Table 20. Model 2 top three variants, selected from SNPs and InDels categories from the WES data. These variants are absent from the two unaffected 
relatives (IV.1-080002 and IV.3-090095) and present in four affected individuals (III.2-080004, III.4-080001, III.6-080005 and IV.9-090044), and not 
described in 1000 GP and dbSNP databases. 
CDS change Gene 
Mutation 
type 
SIFT 
score 
PolyPhen-2 
score 
GERP++ Chr 
Start/End 
(bp) 
Ref allele 
Obs 
allele 
DP MAPQ Genotype 
c.G180A SERINC2 NSV 0.030 0.068 4.92 1 
31.896.668/ 
31.896.668 
G A 13.00 60.00 0/1 
c.2163_2168del PLEKHG5 NFD . . . 1 
6.529.182/ 
6.529.188 
TTCCTCC T 54.00 59.96 0/1 
NSV: Non-synonymous Variants; CDS change: Coding DNA sequence change; Chr: Chromosome; bp: Base pair; Ref: Reference; Obs: Observed; SIFT: Sorting Tolerant From Intolerant; 
Genotype: 1/1 (homozygous for the observed allele); 0/1 (heterozygous). 
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Table 21. Strand bias for the variants selected according to model 2. The number of reference and alternate alleles seen in IGV in the forward and reverse 
strand as well as the calculated Fisher strand bias are shown for each model 2 variant and for each individual sequenced by NGS. 
CDS change: Coding DNA sequence change; Ref: Reference; Obs: Observed; FS: Fisher Strand.
  III.4-080001 IV.1-080002 III.2-080004 III.6-080005 IV.9-090044 IV.3-090095 
CDS change Strand Ref Obs FS Ref Obs FS Ref Obs FS Ref Obs FS Ref Obs FS Ref Obs FS 
c.G180A 
Positive 5 4 
0.00 
. . 
. 
2 2 
2.76 
5 8 
1.53 
6 6 
0.00 
. . 
. 
Negative 7 6 . . 7 2 7 7 5 6 . . 
c.2163_2168del 
Positive 10 12 
7.86 
. . 
. 
15 9 
0.00 
13 8 
2.50 
11 13 
5.91 
. . 
. 
Negative 23 11 . . 14 10 21 9 16 9 . . 
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For each variant it was confirmed if the region of interest was amplified - 
Figures 13, 14, 15, 16 and 17 for both models. Then, the variants for both models were 
observed in all family members through IGV (Figure 18A, 19A, 20A, 21A and 22A). 
This way it has been confirmed if the variants were really present in the BAM files 
(originated after the alignment process) and check the coverage for each mutation.  
Afterwards, the validation of these candidate variants were performed by Sanger 
sequencing and tested the segregation in the remaining family 1 relatives and in family 
2. All chromatograms for both models are present in Figures 18B, 19B, 20B, 21B, 22B, 
23, 24, 25, 26 and 27 for one strand (complementary strand depicted in Appendix H). 
For c.C4786T, one can see that all six patients (family 1) are heterozygous 
having the reference allele (C) and alternate (T) alleles for the 145.171.113 bp position 
in chromosome 8 supporting the results obtained by WES analysis (Figure 18B). 
However, in the control IV.1-080002 the variant was absent in the WES results which is 
not confirmed as we could see the alteration. In addition, this variant is present in 
control III.8-090043. 
For c.C53T, one can see that all six patients (family 1) are again heterozygous 
having the reference allele (G) and alternate (A) alleles for the 3.627.162 bp position in 
chromosome 16 confirming our results (Figure 19B). However, in the control IV.1-
080002 the variant was supposed absent in our results but that is not confirmed here as 
we can see the alteration. In addition, this variant is present in control III.8-090043. 
For c.T566C, we can see that all six patients (family 1) are once again 
heterozygous having the reference allele (A) and alternate (G) alleles  for the 4.245.598 
bp position in chromosome 16 again confirming the results obtained by us (Figure 20B). 
However, in the control IV.1-080002 the variant was supposed to be absent according to 
the bioinformatics analysis, but that was not confirmed by Sanger sequencing. In 
addition, this variant is present in control III.8-090043. 
For c.G180A, we can see that five patients (family 1) are heterozygous as well, 
having the reference allele (G) and the alternate (A) alleles for the 31.896.668 bp 
position in chromosome 1 supporting our results (Figure 21B). In the control IV.3-
090095 the mutation was not present as it was expected. However, in the control 
individual IV.1-080002 the variant was supposed to be absent, but that was not 
confirmed by our sequencing. In addition, this variant is present in control III.8-090043. 
For c.2163_2168del we observed that was amplify three instead of one region of 
interest in the four affected relatives (family 1 - III.1-080003, III.2-080004, III.4-
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080001, III.6-080005 and IV.9-090044) and also in the control (IV.1-080002, Figure 
23). In the case of family 2, more than one region was also amplified, however looking 
at the agarose gel picture (Figure 17) the distance between the PCR fragments is smaller 
when compared to the PCR fragments in family 1. Still, this variant was validated, since 
this contains our region of interest and we want understand what other regions are being 
amplified. This is discussed in more detail in sub-chapter 5.1.4 One can see in the 
chromatograms obtained (Figure 22B) that all four patients (family 1) have the deletion 
and also the control III.8-090043. However, the deletion reported by the WES analysis 
(TCCTCC – 6.529.182/6.529.188 bp) does not match with the deletion found by Sanger 
sequencing (CTCCTC – 6.529.184/6.529.190 bp). Additionally, in the control IV.3-
090095 the mutation was absent as it was expected. In the control individual IV.1-
080002 it was supposed not find the deletion, but that was not confirmed by our 
sequencing.  
Even though the five candidate mutations under study did not segregate as 
expected with PDB affection status in the Sanger sequencing validation, the presence of 
these mutations was tested in family 2 to assess their pathogenic potential by replication 
in an independent family. None of these mutations was detected in any of the family 2 
members (Figures 23, 24, 25, 26 and 27). However, a deletion for the 
6.529.187/6.529.190 bp position (CTC) in chromosome 1 was observed in the controls 
(IV.1-140032 and II.1-140033), absent in the patients (II.2-140030 and II.3-140029) 
and in the unclear individuals (III.1-140031 and III.2-140034). 
 
1 – NZYDNALadder VI             10 – Negative Control 
2 – III.4-080001               11 – II.3-140029 
3 – IV.1-080002              12 – II.2-140030 
4 – III.1-080003  13 – III.1-140031 
5 – III.2-080004  14 – IV.1-140032 
6 – III.6-080005  15 – II.1-140033 
7 – IV.3-090095  16 – III.2-140034 
8 – III.8-090043 
9 – IV.9-090044 
Figure 13. PCR amplification of the c.C4786T variant (model 1). This product was 
run in a 2% agarose gel and is running at the expected location for 349 bp fragments. 
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1 – NZYDNALadder VI             10 – IV.9-090044 
2 and 11 – Negative Controls 12 – II.3-140029 
3 – III.4-080001           13 – II.2-140030 
4 – IV.1-080002  14 – III.1-140031 
5 – III.1-080003  15 – IV.1-140032 
6 – III.2-080004  16 – II.1-140033 
7 – III.6-080005  17 – III.2-140034 
8 – IV.3-090095 
9 – III.8-090043 
Figure 14. PCR amplification of the c.C53T variant (model 1). This PCR was run in 
a 2% agarose gel and is running at the expected location for 444 bp fragment. 
 
 
 
1 – NZYDNALadder VI             10 – Negative Control 
2 – III.4-080001               11 – II.3-140029 
3 – IV.1-080002              12 – II.2-140030 
4 – III.1-080003  13 – III.1-140031 
5 – III.2-080004  14 – IV.1-140032 
6 – III.6-080005  15 – II.1-140033 
7 – IV.3-090095  16 – III.2-140034 
8 – III.8-090043 
9 – IV.9-090044 
Figure 15. PCR amplification of the c.T566C variant (model 1). This product was 
run in a 2% agarose gel and is running at the expected location for 417 bp fragment. 
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1 – NZYDNALadder VI  9 – III.4-080001 
2 – II.3-140029  10 – IV.1-080002 
3 – II.2-140030  11 – III.1-080003 
4 – III.1-140031  12 – III.2-080004 
5 – IV.1-140032  13 – III.6-080005 
6 – II.1-140033  14 – IV.3-090095 
7 – III.2-140034  15 – III.8-090043 
8 – Negative Control  16 – IV.9-090044 
  
Figure 16. PCR amplification of the c.G180A variant (model 2). This product was 
run in a 2% agarose gel and is running at the expected location for 460 bp fragment. 
 
1 – NZYDNALadder VI             10 – Negative Control 
2 – III.4-080001               11 – II.3-140029 
3 – IV.1-080002              12 – II.2-140030 
4 – III.1-080003  13 – III.1-140031 
5 – III.2-080004  14 – IV.1-140032 
6 – III.6-080005  15 – II.1-140033 
7 – IV.3-090095  16 – III.2-140034 
8 – III.8-090043 
9 – IV.9-090044 
Figure 17. PCR amplification of the c.2163_2168del variant (model 2). This product 
was run in a 5% agarose gel and is running at the expected location for 379 bp fragment. 
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T G G C C T A T G C C C C C G [C/T] G C C C C G C T G C C C C C G – Family 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. c.C4786T variant according to IGV (A) and chromatograms obtained through 
Sanger sequencing (forward strand - B). A – Here is shown the mutated allele present in five 
patients (III.2-080004, III.4-080001, III.6-080005, IV.3-090095 and IV.9-090044) and absent in 
control (IV.1-080002), via IGV. B – Here one can see the mutated T allele for the c.C4786T 
variant in patients (III.1-080003, III.2-080004, III.4-080001, III.6-080005, IV.3-090095 and 
IV.9-090044), also present in the controls (IV.1-080002 and III.8-090043). The complementary 
strands chromatograms are depicted in Appendix H. 
Family Genetics of Paget’s Disease of Bone                                                          4. Results 
 
72 
 
A 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A C C T C C C G G G C C T C [G /A] A T G C T G G C T C C A G G – Family 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. c.C53T variant according to IGV (A) and chromatograms obtained through 
Sanger sequencing (reverse strand - B). A – Here one can see the mutated allele present in 
five patients (III.2-080004, III.4-080001, III.6-080005, IV.3-090095 and IV.9-090044) and 
absent in control (IV.1-080002), through IGV. B – Here is shown the mutated A allele for the 
c.C53T variant in patients (III.1-080003, III.2-080004, III.4-080001, III.6-080005, IV.3-090095 
and IV.9-090044), also present in the controls (IV.1-080002 and III.8-090043). The 
complementary strands chromatograms are presented in the Appendix H. 
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A T G C C T G G T G T A T C C [A/G] C A A A A G T G A C C C T C – Family 1 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. c.T566C variant according to IGV (A) and chromatograms obtained through 
Sanger sequencing (reverse strand - B). A – Here is shown the mutated allele present in five 
patients (III.2-080004, III.4-080001, III.6-080005, IV.3-090095 and IV.9-090044) and absent in 
control (IV.1-080002), through IGV. B – Here is shown the mutated G allele for the c.T566C 
variant in patients (III.1-080003, III.2-080004, III.4-080001, III.6-080005, IV.3-090095 and 
IV.9-090044), also present in the controls (IV.1-080002 and III.8-090043). The complementary 
strands chromatograms are presented in the Appendix H. 
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G G T G T C C A T C A T T A T [G/A] C T G A G C C C G G G C G T – Family 1 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. c.G180A variant according to IGV (A) and chromatograms obtained through 
Sanger sequencing (reverse strand - B). A – Here one can see the mutated allele present in 
four patients (III.2-080004, III.4-080001, III.6-080005, and IV.9-090044) and absent in controls 
(IV.1-080002 and IV.3-090095), via IGV. B – Here is shown the mutated A allele for the 
c.G180A variant in patients (III.1-080003, III.2-080004, III.4-080001, III.6-080005 and IV.9-
090044), also present in the controls (IV.1-080002 and III.8-090043). The variant is absent in 
the unclear individual IV.3-090095. The complementary strands chromatograms are presented 
in the Appendix H. 
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C C T C C T C C T C C T C C T [C C T C C T C / C] T T C C T C C T C C T G C T – Family 1 
 
 
Figure 22. c.2163_2168del variant according to IGV (A) and chromatograms obtained 
through Sanger sequencing (forward strand - B). A – Here is shown the deletion present in 
four PDB patients (III.2-080004, III.4-080001, III.6-080005 and IV.9-090044) and absent in 
two controls (IV.1-080002 and IV.3-090095), through IGV. B – Here is shown the deletion 
CTCCTC for the 6.529.184/6.529.190 bp position in chromosome 1 in patients (III.1-080003, 
III.2-080004, III.4-080001, III.6-080005 and IV.9-090044), also present in the controls (IV.1-
080002 and III.8-090043). The deletion is absent in the unclear individual IV.3-090095. The 
complementary strands chromatograms are presented in the Appendix H. 
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 T G G C C T A T G C C C C C G [C/T] G C C C C G C T G C C C C C G – Family 2 
 
 
Figure 23. Chromatograms for the c.C4786T variant (forward strand) for family 2. Here 
one can see the ancestral C allele for the c.C4786T variant in patients (II.2-140030 and II.3-
140029), in the unclear individuals (III.1-140031 and III.2-140034) and in the controls (II.1-
140033 and IV.1-140032). The complementary strands chromatograms are depicted in 
Appendix H. 
 
A C C T C C C G G G C C T C [G /A] A T G C T G G C T C C A G G – Family 2 
 
  
 
 
 
 
 
 
 
 
Figure 24. Chromatograms for the c.C53T variant (reverse strand) for family 2. Here is 
shown the ancestral G allele for the c.C53T variant in patients (II.2-140030 and II.3-140029), in 
the unclear individuals (III.1-140031 and III.2-140034) and in the controls (II.1-140033 and 
IV.1-140032). The complementary strands chromatograms are showed in the Appendix H. 
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A T G C C T G G T G T A T C C [A/G] C A A A A G T G A C C C T C – Family 2 
 
 
 
 
 
 
 
 
 
Figure 25. Chromatograms for the c.T566C variant (reverse strand) for family 2. Here is 
shown the ancestral A allele for the c.T566C variant in patients (II.2-140030 and II.3-140029), 
in the unclear individuals (III.1-140031 and III.2-140034) and in the controls (II.1-140033 and 
IV.1-140032). The complementary strands chromatograms are presented in the Appendix H. 
 
 
G G T G T C C A T C A T T A T [G/A] C T G A G C C C G G G C G T – Family 2 
 
 
 
 
 
 
 
 
 
 
Figure 26. Chromatograms for the c.G180A variant (reverse strand) for family 2. Here one 
can see the ancestral G allele for the c.G180A variant in patients (II.2-140030 and II.3-140029), 
in the unclear individuals (III.1-140031 and III.2-140034) and in the controls (II.1-140033 and 
IV.1-140032). The complementary strands chromatograms are presented in the Appendix H. 
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 C C T C C T C C T C C T C C T [C C T C / C] T T C C T C C T C C T G C T – Family 2 
Figure 27. Chromatograms for the c.2163_2168del variant (forward strand) for family 2. 
Here one can see the deletion CTC for the 6.529.187/6.529.190 bp position in chromosome 1 in 
the controls (II.1-140033 and IV.1-140032), absent in patients (II.2-140030 and II.3-140029) 
and in the unclear individuals (III.1-140031 and III.2-140034). The complementary strands 
chromatograms are showed Appendix H. 
 
In Table 22 is summarized the inconsistencies between the BAM files, 
bioinformatics analysis and Sanger sequencing. 
 
Table 22. Summary of the differences observed between the WES analysis, bioinformatics 
re-analysis and the Sanger sequencing. Here is shown the genotype present for both affected 
and unnafected individuals when we visualized the BAM files in IGV, the bioinformatics 
analysis and Sanger sequencing. Discordant results are highlited in bold. 
CDS change Family 1 relative ID 
Bioinformatics 
analysis 
IGV 
Sanger 
sequencing 
c.C4786T 
Affected individuals CT CT CT 
Control IV.1-080002 CC CC CT 
c.C53T 
Affected individuals GA GA GA 
Control IV.1-080002 GG GG GA 
c.T566C 
Affected individuals AG AG AG 
Control IV.1-080002 AA AA AG 
c.G180A 
Affected individuals GA GA GA 
Control IV.1-080002 GG GG GA 
Control IV.3-090095 GG GG GG 
c.2163_2168del 
Affected individuals TCCTCC/- TCCTCC/- CTCCTC/- 
Control IV.1-080002 TCCTCC TCCTCC CTCCTC/- 
Control IV.3-090095 TCCTCC TCCTCC TCCTCC 
CDS change: Coding DNA sequence change. 
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4.5 Exonic Variants in PDB-associated genes 
 
Since none of the four novel variants studied previously appeared to co-
segregated with PDB with an autosomal dominant mode of inheritance (with complete 
penetrance), the evolution of variants reported in the dbSNP or 1000 GP databases may 
have been too restrictive. To test the possibility that the disease-causing mutation in 
family 1 is in a gene previously associated with PDB (Table 1 and 2) we investigated if 
any of the variants detected in these genes (Table I.1, Appendix I) co-segregated with 
PDB in one of the analysis models. Using this selection criteria only one variant in PML 
(c.T1933C) present in an exonic region co-segregated with disease according to model 
2, and was further confirmed by Sanger sequencing. 
The amplification of the region of interest was confirmed using PCR as before 
(Figure 28). Then, this variant was observed in all the family members sequenced by 
WES via IGV (Figure 29). This way it has been confirmed visually if they were really 
present in the BAM files (originated after the alignment process) and confirm the 
coverage for each mutation in the six family members. Afterwards, the validation of 
these variant were performed by Sanger sequencing and tested the segregation in the 
other relatives from family 1 and in family 2.  
The chromatogram is shown in Figure 29B for the reverse strand (and the 
respective forward strands are in Appendix H). One can see that four patients (family 1) 
are heterozygous as well, having the reference allele (T) and the alternate (C) alleles for 
the 74.336.633 bp position in chromosome 15 supporting our results (Figure 29B). In 
the unclear individual IV.3-090095 the mutation was not identified as it was expected. 
However, in the control individual IV.1-080002 the variant was supposed to be absent, 
but that was not confirmed by our sequencing. In addition, the variant was present in 
control III.8-090043 and in all the relatives (affected and unaffected) from family 2 
(Figure 30). 
In Table I.1, Appendix I we can see that all six family members sequenced by 
WES have mutations in genes associated to PDB, even the control (IV.1-080002). 
Additionally, our bioinformatics pipeline also identified common variants present in 
intronic, intergenic and splicing regions in our study individuals (results in Table I.1, 
Appendix I). Since PDB is a complex disease, with incomplete penetrance and several 
causal genes, it is possible that non affected individuals have the casual genes but do not 
express the PDB phenotype. Numerous variants are located in regulatory regions. Most 
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of the NSV were predicted to be not damaging for the protein function the in silico 
SIFT and Polyphen-2 tools (Table I.1, Appendix I). 
 
 
 
 
1 – NZYDNALadder VI             10 – Negative Control 
2 – III.4-080001               11 – II.3-140029 
3 – IV.1-080002              12 – II.2-140030 
4 – III.1-080003  13 – III.1-140031 
5 – III.2-080004  14 – IV.1-140032 
6 – III.6-080005  15 – II.1-140033 
7 – IV.3-090095  16 – III.2-140034 
8 – III.8-090043 
9 – IV.9-090044 
Figure 28. PCR amplification of the c.T1933C variant (model 2). This product was 
run in a 2% agarose gel and has 350 bp as was expected. 
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A T C C A G C C T G A A G C C [T/C] T C T T C A G C A T C T A C  – Family 1 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. c.T1933C variant according to IGV (A) and chromatograms obtained through 
Sanger sequencing (reverse strand – B). A - Here one can see the mutated C allele present in 
the four PDB patients (III.2-080004, III.4-080001, III.6-080005 and IV.9-090044) and absent in 
the two controls (IV.1-080002 and IV.3-090095), using IGV. B - Here is shown the mutated C 
allele for c.T1933C variant in patients (III.1-080003, III.2-080004, III.4-080001, III.6-080005 
and IV.9-090044), also present in controls III.8-090043 and IV.1-080002 from family 1. The 
variant is absent in the unclear individual IV.3-090095. The complementary strands 
chromatograms are showed Appendix H. 
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A T C C A G C C T G A A G C C [T/C] T C T T C A G C A T C T A C  – Family 2 
 
 
 
 
 
 
 
 
 
Figure 30. Chromatograms for the c.T1933C variant (reverse strand) for family 2. Here is 
shown the mutated C allele, for c.T1933C variant in patients (II.2-140030 and II.3-140029), 
also present in probable PDB affected (III.1-140031 and III.2-140034) and in both controls 
(II.1-140033 and IV.1-140032) from family 2. The complementary strands chromatograms are 
showed in the Appendix H. 
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5. Discussion  
 
5.1 WES data quality control 
 
5.1.1 BGI selected variants    
 
WES is a robust approach to search for disease-related variants, however it still 
presents with important bioinformatics challenges, such as variant detection and 
annotation, which ultimately lead to high error rates
61,79
. Moreover, variant annotation 
tools usually have a strong impact in creating errors due to variant analysis, creating the 
possibility that we are discarding important variants
97
.  
Even though chromatograms for the quality control variants (Figures 9B, 10B 
and 11B) do not have a good quality because the primers used mapped too close to the 
variant of interest, one can see the presence/absence of the variant. From the four 
variants selected for the QC, only the “good” quality variant (c.C8800T – Figure 9B) 
was validated successfully in both individuals. In addition, the result obtained by Sanger 
sequencing for c.C871T (“medium” quality) for individual IV.1-080002 (control – 
where the mutation is present – see Figure 11) is confirmed by what one can see using 
BGI bam files in IGV. Additionally, this variant was present in patient IV9-090044. 
However, in the VCF files (created by GATK Unified Genotyper) this variant was not 
present for the control. This contradiction might be explained by the fact that this region 
has a low MAPQ and did not fulfill the minimum score to proceed in the BGI 
bioinformatics analysis, most likely being filtered out. 
The MAPQ scores for the c.C8800T and c.C2264T variants indicate a good 
confidence in the alignment (MAPQ ~60), contrasting to c.C871T and c.C478G that 
have a lower MAPQ (MAPQ ~36.98 and 24.94, respectively). Lastly, c.C478G had a 
low coverage (DP ~10x), which along with the low MAPQ (~24.94) can be suggestive 
of a false positive result. One possible explanation for the low MAPQ scores rely on the 
regions where the variants are inserted being highly repetitive, which can normally 
result in alignment errors. A possible solution to increase the coverage in regions with 
low mappability is increasing the read length, thus improving the specificity
98
. 
There is a balance between the alleles observed in the forward and reverse 
strands for c.C8800T. However, for c.T1933C, c.C2264T, c.C871T and c.C478G 
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variants we observed an unbalanced strand bias, which in turn can be an indicator of a 
false positive SNP. Strand bias can be explained by the fact that c.C2264T is inserted in 
the extremities of the reads being harder to sequence this region. Also, since the MAPQ 
for both c.C871T and c.C478G is low, the unbalanced strand bias is possibly due to 
errors in the read alignment resulting in the observation of more reference or alternate 
alleles in one of the strands than expected. This way, we can infer that variants with 
high MAPQ, high coverage, and also with no strand bias are less susceptible to false 
positive/negative results. 
 
5.1.2 BGI versus our bioinformatics pipeline 
 
As carefully analyzed the BGI bioinformatics results several errors were found. 
Thus, we decided to perform a new entire bioinformatics analysis at this point using 
only the raw FASTQ files sent by BGI. To minimize errors we performed quality 
control analyses at three stages of the bioinformatics pipeline: (1) raw data (FASTAQ 
files), (2) alignment (BAM files) and (3) variant calling (VCF files).  
In the first stage (1), we used FastQC to check the GC content and base quality.  
The GC content for an exome region is usually reported to be between 49 and 51%, and 
abnormal deviations indicate DNA contamination
79
. We verified that the confidence in 
our base call is high (Figure G.1, Appendix G) and the GC content is approximately 45 
and 48%, indicating that our samples have a good quality to proceed through the 
pipeline.  
In the second stage, we used Qualimap to check both the mapping and 
duplication rate. These parameters are a good indicator to perceive if the variant call 
will be accurate. If the mapping and duplication mark is done incorrectly it can affect 
the subsequent analysis, such as the coverage that could be overestimated if the 
duplicates do not get marked. The mappability is also a source of false negative 
variants, being however more challenging to detect. In our dataset approximately 2% of 
the reads did not map with the human reference (hg19). Since reports indicate that 
approximately 1-10% of the reads usually do not map with the reference sequence
79
, 
this means that our 2% of unmapped reads are within the expected range. In addition, 
we used the graphs created by BGI to assess the sequencing depth and we visualized 
that there is no variation between samples, suggesting that there seems to be no problem 
with the DNA sequencing itself.  
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In the third stage, to identify the best approach to proceed in the pipeline, we 
calculated the Ti/Tv ratio for each of the four variant calling tools used and for the 
combined analysis. We found that the Unified Genotyper (GATK) and Samtools 
mpileup had worst scores than the Haplotype Caller (GATK) and Freebayes. Thus, by 
using the combined analysis we decreased the false positive rate (Ti/Tv ratio = 2.30), 
since when we combined only the variants that are equal between the four variants 
calling tools we increased the probability that these variants are true positives. 
Consequently, we chose the combined analysis to proceed with the bioinformatics 
analysis.  
 
5.1.3 QC of the variants highlited by our bioinformatics analysis 
 
Efforts to understand association between human genetic variants and their 
phenotype effects have been made since it is believed that genetic variation is a major 
factor that stimulates the diversity between individuals. Recent studies have reported 
that the number of genetic variants in the genome is higher than 3.5 million per 
individual, making the identification of causative variants an extremely challenging 
task
36
. Approximately 20.000 SNVs are identified by a WES approach and ~95% of 
these variants are already known
56
.  
The number of novel and known SNPs was assessed in the CDS region studied. 
The number of novel NSVs can be a good indicator of the false positive SNPs present in 
the study sample
79
. Bamshad et al. showed that only 200 novel NSVs are usually 
expected per individual through a WES approach. Higher numbers are indicative of a 
high false positive rate. There was ~20.838 SNPs in average called per individual, of 
which 259 were novel (Table 15). From these, approximately 150 novel SNPs are NSVs 
against the 192 novel SNPs obtained by Bamshad et al. for European Americans (Table 
15). Our results indicate that our sample has a low false positive rate as the number of 
novel NSVs obtained should be smaller since we used a new version of dbSNP 
(containing a higher number known SNPs).  
In addition, we also calculated the Ti/Tv ratio for all the SNPs (known and 
novel) and also for the novel SNPs only to confirm the rate of false positive in our 
samples (Table 16). We obtained a Ti/Tv ratio of 2.37 for all SNPs and 2.11 for novel 
SNPs. When we compared these with the scores from the literature (Ti/Tv of 3.0 for 
WES
75
) we verify that our rate of false positive is higher. This can be due to the novel 
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SNPs that reduce the global Ti/Tv ratio obtained for all the variants in the sample. Also, 
this score can be undervalued because most of the exome capture kits do not capture 
only the exonic region. So, it is expected the Ti/Tv ratio to vary between 2.0 and 3.0 for 
SNPs inside these target regions, with the value depending on the fraction of exons 
inside the target regions
99
. 
 
5.1.4 Validation of variants of interest 
 
The most interesting mutations to follow-up (variants present in affected 
individuals and absent from unaffected relatives), were validated by Sanger sequencing. 
Introduction of novel next-generation sequencing techniques has dramatically reduced 
the cost for DNA sequencing, however these techniques have a higher error rate when 
compared to the tradicional Sanger sequencing
66
. NGS differs from Sanger sequencing 
in several aspects, including producing 100 times more data in a short time (high-
throughput) and depending on the detection of pyrophosphate release on nucleotide 
incorporation, rather than chain termination with dideoxynucleotides
100
. Furthermore, 
the NGS technique produces shorter reads (~100bp) but with lower quality when 
compared to Sanger sequencing
100,101
. 
MAPQ for the novel variants selected for both models achieved the highest 
score (MAPQ ~60) indicating good confidence in the alignment. However, the coverage 
was lower for c.C4786T (DP ~27), c.C53T (DP ~31) and c.G180A (DP ~13) when 
compared with the coverage achieved for c.T566C variant (DP ~113) and 
c.2163_2168del (DP ~54). A mean coverage of 60x was requested to BGI to obtain 
more confident results in the variant calling. A coverage above 30 already indicates a 
good confidence in the variant call, but below this score the confidence diminishes, 
suggesting a harder region to sequence. Additionally, for each variant we counted how 
many reference / observed alleles were seen in the reverse and forward strands to 
analyze the strand bias (Tables 19 and 21). When the strand bias is significantly 
different, it is an indication of a false positive call (e.g. for SNPs a strand bias above 60 
is excluded from the call set)
79
. A 50% allele balance between the positive (or forward) 
and negative (or reverse) strands for heterozygous calls is desirable in sequencing data. 
The bias between the two strands is affected by the preferential reference allele bias 
caused by the alignment algorithm that penalizes a mismatch from the reference 
sequence, lowering in turn the percentage of alternate alleles in the reads
79
. For c.T566C 
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(model 1), we observed a slight strand bias when compared with the other two variants 
(c.C4786T and c.C53T). One possible explanation to this bias is that novel rare variants 
are less specific to exome capture itself being more difficult to sequence. Additionally, 
strand bias can be due to PCR duplications that did not get marked, originating a higher 
coverage than would be expected. For model 2, we observed a slight strand bias in 
c.2163_2168del. This region is highly repetitive, which can lead to misalignments. 
Our validation stage was very successful in the sense that four variants 
(c.C4786T, c.C53T, and c.T566C – model 1, and c.G180A – model 2) identified in 
affected individuals by WES were in fact present and confirmed with our Sanger 
sequencing. However, it did not validate the WES results for the control individual 
IV.1-080002 in both models.  
In model 1, the regions were succesfully amplified with the variant of interest 
and the reference and alternate alleles for each variant were observed in all affected 
individuals in family 1. Nonetheless, these three variants are also present in the control 
individual IV.1-080002 and the other control individual III.8-090043 (family 1). 
Moreover, in family 2 these variants are always absent and so are not causal in this 
family. While looking for novel variants it was already expected that this could happen, 
since mutations may be different from family to family, particularly because their 
frequency is unknown in the population. However, since the two families originate from 
the same Portuguese region (Alentejo), it is expected that they may share the same 
pathogenic mutation through a distant relative (these two families are not known to be 
related). 
For model 2, all PDB patients from family 1 and both controls (IV.1-080002 and 
III.8-090043) have the c.G180A variant. However, the c.2163_2168del deletion mapped 
to a different location when compared to its WES results, and is a known deletion 
already reported in public databases (present both in affected and control individuals 
according to Sanger sequencing). As for the control IV.3-090095, the variants analyzed 
were not present (as expected by the WES results), indicating that this individual is not 
a carrier. Additionally, in family 2, these variants follow the same pattern as in model 1. 
Still, for model 2 c.2163_2168del, when looked at the agarose gel (Figure 17) it was 
seen that three instead of one region of interest were amplifying in four affected 
relatives (family 1 - III.1-080003, III.2-080004, III.4-080001, III.6-080005 and IV.9-
090044) and also in the control (IV.1-080002, Figure 17). For family 2, we also 
observed that more than one region was being amplified but the distance between the 
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PCR fragments is smaller when compared to the PCR fragments in family 1. However, 
when we designed the primers we confirmed their uniqueness with BLAT and an in 
silico PCR (UCSC - http://genome.ucsc.edu).  
The chromatogram in Figure 22B shows that variant c.2163_2168del is not 
localized in the amplified region that we were expecting through the bioinformatics 
analysis (TCCTCC – 6.529.182/6.529.188 bp). Instead, we observed two different 
deletions in both families. For family 1, the deletion (CTCCTC) was localized in 
chromosome 1 from 6.529.184 bp until 6.529.190 bp position being present in all 
affected individuals and also in control IV.1-080002. Additionally, in the control IV.3-
090095, we did not identify the mutation as expected. For family 2, we observed a 
deletion localized from 6.529.187 bp until 6.529.190 bp position (CTC) only present in 
the healthy controls (II.1-140033 and IV.1-140032). Nonetheless, the three different 
regions amplified in individuals (family 1 - III.1-080003, III.2-080004, III.4-080001, 
III.6-080005 and IV.9-090044) and also in the control (IV.1-080002, Figure 23) were 
not explained with the results obtained. But, for family 2, it is possible that the two 
regions amplified in individuals IV.1-140032 and II.1-140033 are possibly due to the 
deletion since the distance between PCR fragments is smaller when compared to the 
PCR fragments in family 1. Additionaly, we investigated this region in more detail and 
we found several polymorphisms in the region where the two different deletions are 
inserted. Two frameshifts and five non-frameshifts are described in this region. Only 
found reported in dbSNP the deletion present in individuals from family 1 
(rs375111412 – c.2143_2148del), but until now there are not reports associating this 
variant with PDB. InDels are more challenging to detect and validate since the InDel 
calling is more imprecise and inaccurate
74
. Since c.2143_2148del is too close from the 
supposed variant found through our bioinformatic analysis (c.2163_2168del), it is 
possible that the result obtained was due to a misalignment.  
False negatives present in control IV.1-080002 have several possible 
explanations. c.C4786T and c.C53T are located in the extremities of the reads, which 
result in a lower coverage (< 30). Also, c.G180A has low coverage (DP ~13), which 
indicates a lower confidence in the variant call. Positions with lower coverage are 
harder to call with confidence
102
. A technical limitation of the WES approach is that the 
probes that hybridize with the DNA are designed based on the reference sequence, so 
they capture preferentially the regions with the reference allele
103
. There are a high 
number of common SNPs around the variants analyzed that may perturb the sequencing 
Family Genetics of Paget’s Disease of Bone                                                          5. Discussion  
 
89 
 
of these target regions. Regions with a higher number of SNPs when compared to the 
reference sequence can failed in the hybridization step, consequently being missed in 
the sequencing
56,103
. Furthermore, besides c.T566C, the rest of the variants analyzed had 
a high GC content, which prevents proper hybridization and results in a low capture and 
coverage of these regions
104
.  
It is also possible that some reads are mapping in the wrong location originating 
false negative results. This can happen around repeat regions. One approach to avoid 
these errors is to increase the quality values selected when we use BWA for mapping 
the reads.   
 
5.2 Variants in genes associated to PDB 
 
There are several genes described in the literature that may play a role in the 
genetic susceptibility to PDB. We found in all six family relatives analyzed by WES 
mutations in 11 genes previously associated with PDB (Table I.1, Appendix I). One of 
the variants that we found was c.T1933C (PML - rs5742915). This variant was 
associated in the literature, and is also present in all four PDB patients and absent from 
the two unaffected relatives IV.1-080002 and IV.3-090095 through WES analysis. 
Sanger sequencing confirms the presence of the mutation in all four PDB patients and 
control individual IV.1-080002 (family 1) and absent in the control IV.3-090095 
(Figure 29B). However, for family 2 we observe the variant in all the relatives (affected 
and unaffected – Figure 30). So, it is possible that PML is increasing the risk for PDB in 
family 1.  
The most significant association reported was seen with rs5742915 in PML 
resulting in a phenylalanine to leucine amino acid change at codon 645 of PML
23
. Its 
function in bone metabolism is at the moment unknown, but it is known to be involved 
in TGF-β signal, which has a role in the regulation of bone remodeling23.  
Additionally, there are three NSVs in CSF1, NUP205 and OPTN present in all 
family relatives studied, with a MAF < 5%. Since GWAS does not detect variants with 
MAF < 5% these are not yet reported and would be interesting to validate them in these 
family relatives and others PDB patients. These three genes are implicated in osteoclast 
formation (CSF1), transporting proteins between the nucleus and cytosol (NUP205) and 
regulation of NFκB signaling and autophagy (OPTN)2,7,24. 
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Disease severity can be related with the number and type of genetic variants 
segregating in the family relatives 
6
. PDB affected family members can carry different 
combinations of variants that contribute to disease risk
6
. There are also numerous 
variants located in regulatory regions within known genes (Table I.1, Appendix I), 
pointing to a possible relation between these and PDB, so future studies are warranted 
to clarify their role. 
Also, PDB is a complex disease with a late age-at-onset, so healthy controls can 
have causal variants. This could be affecting our results because the control IV.1-
080002 is younger, and so could still develop PDB. 
 
5.3 Novel variants associated to PDB 
 
As previously mentioned, it was necessary create two models to analyze the 
bioinformatics results since a final diagnosis of one individual (IV.3-090095) was not 
available until the end of this thesis. Since the interest were in novel rare alleles shared 
only among affected individuals, variants that are absent from the unaffected relative 
and present in all affected individuals were selected. Also, variants present in dbSNP 
and 1000 GP were excluded. Then, the variants putative impact on protein function was 
assessed using mainly two prediction tools, SIFT and Polyphen-2. Additionally, we 
watched their level of constraint of our candidate regions to see if they are less 
conserved, tolerating better mutations when compared to conserved sites, possibly 
implicating them in key biological processes
84
. 
 
For the model 1, we obtained three novel NSVs (Table 18), c.C4786T 
(KIAA1875), c.C53T (NLRC3) and c.T566C (SRL). Variants c.C4786T and c.T566C 
were predicted to be probably damaging to the protein function. Moreover, these two 
variants are inserted in conserved sites, not tolerating mutations and possibly being 
involved in key biological processes related to PDB. c.C53T was predicted to have no 
negative impact in protein function and also it is inserted in a less conserved site, which 
will likely tolerate mutations.  
c.4786T is localized at 8q24.3 in KIAA1875 (exon 24), which has an unknown 
function. This gene belongs to the WD-repeat domain family which is involved in a 
wide range of cellular functions, such as gene regulation, vesicular trafficking and cell 
cycle regulation
105,106
. An association with bone metabolism is yet unknown. The region 
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amplified (containing 394 bp – Table 3) was investigated and found four SNPs. Two of 
them (rs4977193 and113230) are present in all family relatives from family 1 and 2. 
These variants do not change the results obtained in the PCR not being relevant for the 
study performed. 
c.C53T is inserted at 16p13.3 in NLRC3 (exon 1). The NLRC3 protein is part of 
the nucleotide-binding leucine-rich repeat (LRR)-containing (NLR) family of sensors, 
attenuating immune-cell activation by interacting with receptors or their downstream 
adaptors to inhibit signaling molecules
107,108
. NLRC3 interacts with TRAF6 to attenuate 
Lys63 (K63)-linked ubiquitination of TRAF6 and activation of NFκB. Since NFκB is 
expressed in osteoclast progenitor cells and induces osteoclastogenesis by binding to 
RANKL
109
, it is possible that an association between PDB and NLRC3 could be 
mediated by an effect in TRAF6, which in turn is an intermediary of the NFκB 
activation. According to dbSNP
110
, for the region amplified (444 bp - Table 4), we 
found 14 known variants which include one insertion and two deletions. One SNP 
(rs758747) is present in all family relatives from family 1 and 2. Also, there is one SNP 
described in databases localized next to our variant. Neverthless, this has no impact in 
the region amplified and in the results obtained for the variant under study. 
c.T566C is also located at 16p13.3, in exon 5 of SRL. SRL is located in the 
lumen of the longintudinal sarcoplasmaticum reticulum, which is associated with the 
inner side of these membranes through calcium bridges
111
. Reports have shown that 
Ca
++
-activated ATPase (correlated with Ca
++
 transport) is part of the Ca
++
-transport 
system of sarcoplasmaticum reticulum
112
. A modification in calcium transport could 
result in changes in bone metabolism, given that it is important for maintaining bone 
mass. A bone metabolism imbalance could then lead to an increased risk for PDB. 
According to dbSNP
110
 there are 16 SNPs in the region amplified (417 bp – Table 4). 
SNP (rs10852643) segregates in all relatives from family 2, but in family 1 is absent for 
individuals III.1-080003, III.2-080004 and III.8-090043. However, this has no impact in 
the results obtained for the variant under study. 
c.C4786T, c.C53T and c.T566C are co-segregating in all affected individuals 
being also present in unaffected III.8-090043, IV.1-080002 and IV.3-090095. It is 
possibly that these unaffected individuals are PDB affected but have not yet received a 
diagnosis or they could be carriers only. These variants can be increasing the risk 
disease since the genes functions are possibly associated with bone metabolism but only 
explain a minor portion of the variability.  
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For model 2, we obtained one novel NSV, c.G180A (SERINC2), and one non-
frameshift deletion, c.2163_2168del (PLEKHG5) (Table 20). For the c.G180A, SIFT 
and PolyPhen-2 show ambiguous scores. SIFT indicated that the mutation is deleterious 
and the Polyphen-2 that it is benign for protein function. GERP++ showed that this 
variant is inserted in a conserved site indicating that it will possibly not tolerate 
mutations and is probably involved in key biological processes. With the SIFT and 
GERP++ scores we conclude that probably the mutation is deleterious since it is 
inserted in a site that do not tolerate mutations.  
c.G180A is localized at 1p35.1 in SERINC2 (exon 24). SERINC2 belongs to the 
SERINC family of transmembrane proteins that facilitates incorporation of serine into 
phosphatidylserine and sphingolipids, being related to neural activity and lipid 
biosynthesis
113,114
. Lipids have an important role in the biomineralization process. The 
early formation of crystal nuclei within the matrix vesicles is enhanced by the activity of 
specific enzymes, such as alkaline phosphatase
115
. Moreover, it is reported that 
phosphatidylserine has an association with calcium deposition and alkaline phosphatase 
activity. Thus, it is likely that mutations in SERINC2 can modify the activity of alkaline 
phosphatase, which is related to PDB causing changes in the biomineralization process 
leading to deficiencies in bone metabolism. The region amplified (460 bp – Table 4) has 
21 known SNPs according to dbSNP
110
, absent in all family relatives from family 1 and 
2. These polymorphisms have no impact in the results achieved for the variant analyzed. 
c.2163_2168del is localized at 1p36.31 in PLEKHG5 (exon 20). PLEKHG5 
activates the NFκB signaling pathway, which seems to be involved in 
osteoclastogenesis
116
. Mutations in this gene can lead to modifications in the NFκB 
pathway, inducing osteoclast activity and resulting in a higher susceptibility to PDB. 
Several polymorphisms (dbSNP) have been described in the region that we amplified 
(379 bp – Table 4), which may explain the different results obtained through WES and 
Sanger sequencing, as discussed in sub-chapter 5.1.4. The 6 bp deletion that are actually 
present in the affected individuals and control IV.1-080002 from family 1 
(c.2143_2148del) is described in dbSNP (rs375111412l), so it does not co-segregate 
with disease. We also found in the same position a deletion of 3 bp in two healthy 
controls from family 2 that may be related with a protective function, however more 
studies are warranted to confirm this.   
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PDB segregation in family 1 is consistent with an autosomal dominant model of 
inheritance with incomplete penetrance since all mutations for both models were found 
in the heterozygous state (with presence of both reference and alternate alleles) and 
segregate in all family relatives (for family 1), being also present in the two unaffected 
individuals (III.8-090043 and IV.1-080002). Although we cannot formaly exclude the 
possibility of an autosomal recessive inheritance of PDB in family 1, it is highly 
unlikely since there are affected individuals in two consecutive generations, which is 
more compatible with an autosomal dominant inheritance. Also, the disease segregates 
in both males and females excluding an X-linked recessive model. This results supports 
the findings that suggest that familial PDB is inherited in an autosomal dominant 
fashion
8,15,21,22
. Since we have a family with few individuals genes that cause an 
autosomal dominant disease are more difficult to identify especially when there is a 
large number of heterozygous candidate variants
55
.  
PDB is a complex disease of late onset being more challenging to study since it 
was difficult to find controls in this family. The family members available in our study 
only allowed us to select controls who had not reached yet the usual age of disease 
onset. So, the controls used can still develop the disease in the future. Also, there is a 
high rate of patients that do not have a diagnosis since they did not develop any 
symptoms. Moreover, our control IV.1-080002 has not yet reached the age of risk. 
Thus, we may be assigning a control status to an individual that is actually a PDB 
patient, and disregarding causal variants in our analysis because of this. Moreover, 
variants located in regulatory and/or intronic regions can explain part of the genetic 
variability to PDB and further study on these is now warranted.   
Rare variants can have larger effects sizes in complex diseases when compared 
to common variants identified, helping to identify the causal loci 
53
. Allele penetrance is 
also important for the risk of developing the disease, even though it is known that 
combination of common and rare variants, environmental factors and their interactions 
are important for the PDB risk
53
. Studies reported that PDB has a highly variable 
penetrance, so it is possible that unaffected individuals carrying the novel rare-variants 
identified do not express a phenotype
8,15,21,22
. This may support the unaffected status of 
individual III.8-090043, since our results shows that she inherited the possible causal 
alleles and she passed it on to her daughter, which is PDB affected (IV.9-090043).  
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Also, the causal variant may be outside the exome, not being identified with our 
WES approach. So, additional studies are needed search for novel rare-variants inserted 
in regions that were not mapped. 
This is the 1
st
 study that aimed to identify novel variants in the exome of PDB 
families. There is only one study of novel rare genetic variants in PDB to the best of our 
knowledge, however they only searched for variants located in PDB associated loci 
reported in other studies
25
. We also searched for the Beauregard et al. 
25
 rare variants in 
our data but did not find any of the variants identified in their PDB study, which is not 
unexpected since these studies were performed in different populations. 
Further studies are needed to explain the possible association between the novel 
variants identified in this study and PDB, as well as explain their role in PDB 
pathogenesis. 
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6. Conclusion/Future work 
 
In this study, we described two Portuguese multiplex PDB families from 
Alentejo. This region as a high prevalence of PDB patients but until now there is no 
explanation for this fact. 
We started to emphasize the importance of the three quality control stages in the 
bioinformatics analysis of the WES data, since this approach has a high error rate that 
can impact the power to detect novel rare variants. The error rate can be increased by 
multiple factors, such as the sample quality, exome capture bias, sequencing errors, 
mapping errors and PCR duplications not marked. In order to obtain more confident 
results in the WES approach, the DNA must be freshly extracted prior to analysis. In the 
bioinformatics analysis, the quality values should be more stringent to avoid detection 
of false positive/negative variants, especially in the alignment. However, false negatives 
are more challenging to detect than false positive variants. Other scores should be used, 
such as VQSLOD (variant quality score recalibration), to assess the WES variants 
quality and improve the variant call. 
We validated the three novel variants identified for model 1 (c.C4786T, c.C53T 
and c.T566C) and one novel variant for model 2 (c.G180A). For model 1, the three 
variants are present in all PDB patients from family 1. However, for individual IV.1-
080002 and III.8-090043 (control individuals) the variants are also present. Moreover, 
Sanger sequencing did not confirm the results obtained for individual IV.1-080002 in 
the WES analysis. For model 2, variant c.2163_2168del (PLEKHG5) was possibly 
misaligned and the real variant observed through Sanger sequencing was in fact a 
known deletion reported in dbSNP. The variant c.G180A is present in all affected 
individuals and in both controls (III.8-090043 and IV.1-080002) as before, and it is 
absent from the additional control (IV.3-090095). Moreover, family 2 present none of 
the five variants studied. The control IV.1-080002 used to perform this study has not 
reached the average age of disease onset, so it is possible that she may come to develop 
the disease or have a misdiagnosis. So, it is possible that we had eliminated variants that 
can increase the predisposition to PDB. Moreover, control III.8-090043 is possibly a 
carrier or was misdiagnosed since present all the variants analyzed and also has a 
daughter with PDB. So, we may be assigning a control status to family relatives that are 
actually PDB patients.  
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Taken all togheter, one can conclude the results obtained support the hypothesis 
that point out for familial PDB to be inherited in an autosomal dominant mode with 
incomplete penetrance.  
Future studies should extend to low-frequency variants (MAF between 1% and 
5%) present in dbSNP (which contain a large number of pathogenic alleles). Also, the 
study sample should be bigger to improve the identification of causal variants and with 
healthy controls above the average age-at-onset. There are also numerous variants 
located in regulatory regions pointing to a possible presence of novel variants 
implicated in this region, so future studies are warranted to clarify their role in PDB. 
Further studies are now warranted to discover if the four novel variants 
identified are in fact absent from further true controls individuals and if so, to uncover 
their role in PDB pathogenesis. 
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Appendix A - Scripts used in the bioinformatics analysis 
 
1. Data pre-processing 
a) Raw reads (FASTQ files) – FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/download.html#fastqc) to all files  
 
b) Map to reference with BWA 
# Prepare reference genome file to BWA (approximately 1h20min)  
1 bwa index hg19.fa 
 
# Align FASTQ1 with reference genome (approximately 44 min)  
2 bwa aln -o1 -e50 -m100000 -t4 -i15 -q10 -I hg19.fa fastaq1.fq > fastaq1.fq.aln 
 
# Align FASTQ2 with reference genome 
3 bwa aln -o1 -e50 -m100000 -t4 -i15 -q10 -I hg19.fa fastaq2.fq > fastaq2.fq.aln  
 
# With FASTQ1 and FASTQ2 aligned, combine the two FASTQ files and create a sam 
file (use the sampe option when reads are pair-end) (approximately 31 min)  
4 bwa sampe hg19.fa fastaq1.fq.aln fastaq2.fq.aln fastaq1.fq fastaq2.fq > P1.sam 
 
c) Mark duplicates and sort with Picard 
# Convert from sam to bam  
5 samtools view -S -b P1.sam > P1.bam 
6 java -jar picard-tools-1.111/SortSam.jar VALIDATION_STRINGENCY=LENIENT 
INPUT=P1.bam OUTPUT=P1.sort_picard.bam SORT_ORDER=coordinate 
 
# Mark duplicates 
7 java -jar picard-tools-1.111/MarkDuplicates.jar INPUT=P1.sort_picard.bam 
OUTPUT=P1rmdup.bam METRICS_FILE=P1metricsfile.txt 
VALIDATION_STRINGENCY=LENIENT  
 
d) InDel realignment using GATK (and Samtools & Picard for some steps) 
# Create a .fai  filev for GATK RealignerTargetCreator  
8 samtools faidx hg19.fa 
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# Create a .dict filev for GATK RealignerTargetCreator  
9 java -jar picard-tools-1.111/CreateSequenceDictionary.jar R=hg19.fa O=hg19.dict 
 
# Add ReadGroup  
10 java -jar picard-tools-1.111/AddOrReplaceReadGroups.jar INPUT=P1rmdup.bam 
OUTPUT=P1readgroup.bam PL=illumina LB=unknown PU=unknown SM=unknown 
VALIDATION_STRINGENCY=LENIENT 
11 java -jar picard-tools-1.111/ReorderSam.jar I=P1readgroup.bam O=P1reorder.bam 
REFERENCE=hg19.fa VALIDATION_STRINGENCY=LENIENT  
 
# Create a index file for GATK RealignerTargetCreator  
12 java -jar picard-tools-1.111/BuildBamIndex.jar INPUT=P1reorder.bam 
VALIDATION_STRINGENCY=LENIENT  
 
# Download of known sites for indel realignment 
ftp://ftp.broadinstitute.org/bundle/2.8/hg19/ 
 
# GATK RealignerTargetCreator  
13 java –jar GATK_2.4.3/GenomeAnalysisTK-2.4-3-g2a7af43/GenomeAnalysisTK.jar 
-T RealignerTargetCreator -R hg19.fa -I P1reorder.bam -o P1realigner.intervals –known 
Mills_and_1000G_gold_standard.indels.hg19.vcf 
 
# Indel Realigner  
14 java -jar GATK2.4.3/GenomeAnalysisTK-2.4-3-g2a7af43/GenomeAnalysisTK.jar -
T IndelRealigner -R hg19.fa -I P1reorder.bam –known 
Mills_and_1000G_gold_standard.indels.hg19.vcf -targetIntervals P1realigner.intervals -
o P1realigned.bam  
 
e) Base recalibration using GATK 
# Builds recalibration model  
15 java -jar GATK2.4.3/GenomeAnalysisTK-2.4-3-g2a7af43/GenomeAnalysisTK.jar -
T BaseRecalibrator -R hg19.fa -I P1realigned.bam -knownSites 
dbsnp_138.hg19.chrM_reordered.vcf -knownSites 
Mills_and_1000G_gold_standard.indels.hg19.vcf -o P1recal.table  
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# Print reads  
16 java -jar GATK2.4.3/GenomeAnalysisTK-2.4-3-g2a7af43/GenomeAnalysisTK.jar -
T PrintReads -R hg19.fa -I P1realigned.bam -BQSR P1recal.table -o P1recal.bam  
 
# Base recalibrator - second pass, which evaluates how the data looks like after 
recalibration  
17 java -jar GATK2.4.3/GenomeAnalysisTK-2.4-3-g2a7af43/GenomeAnalysisTK.jar -
T BaseRecalibrator -R hg19.fa -I P1realigned.bam -knownSites 
dbsnp_138.hg19.chrM_reordered.vcf -knownSites 
Mills_and_1000G_gold_standard.indels.hg19.vcf -BQSR P1recal.table -o 
P1after_recal.table  
 
2. Variant discovery 
2.1 Unified Genotyper - GATK 
2.1.1 SNPs 
a) Variant calling  
1 java -jar GATK_2.4.3/GenomeAnalysisTK-2.4-3-g2a7af43/GenomeAnalysisTK.jar -
T UnifiedGenotyper -R hg19.fa -I P1recal.bam -o P1.vcf -stand_call_conf 50 -
stand_emit_conf 10.0 -A Coverage -A RMSMappingQuality -baq 
CALCULATE_AS_NECESSARY 
 
2.1.2 InDels  
a) Variant calling   
2 java -jar GATK_2.4.3/GenomeAnalysisTK-2.4-3-g2a7af43/GenomeAnalysisTK.jar -
T UnifiedGenotyper -R hg19.fa -I P1recal.bam -o P1indel.vcf -stand_call_conf 50 -
stand_emit_conf 10.0 -A Coverage -A RMSMappingQuality -baq 
CALCULATE_AS_NECESSARY -glm INDEL  
 
# The previous step (2) has given an error so the procedure from PrintReads was 
repeated with the –DIQ option  
3 java -jar GATK_2.4.3/GenomeAnalysisTK-2.4-3-g2a7af43/GenomeAnalysisTK.jar -
T PrintReads -R hg19.fa -I P1realigned.bam -BQSR P1recal.table -o P1recal_indel.bam 
–DIQ 
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# VariantCalling - with PrintReads -DIQ  
4 java -jar GATK_2.4.3/GenomeAnalysisTK-2.4-3-g2a7af43/GenomeAnalysisTK.jar -
T UnifiedGenotyper -R hg19.fa -I P1recal_indel.bam -o P1indel.vcf -stand_call_conf 50 
-stand_emit_conf 10.0 -A Coverage -A RMSMappingQuality -baq 
CALCULATE_AS_NECESSARY -glm INDEL 
 
2.2 Haplotype Caller – GATK 
a) Variant calling 
5 java -jar GATK_3.1.1/GenomeAnalysisTK.jar -T HaplotypeCaller -R hg19.fa -I 
P1recal.bam -o P1_HC.vcf -stand_call_conf 50 -stand_emit_conf 10 -minPruning 3 -A 
Coverage -A RMSMappingQuality   
  
2.2.1 SNPs  
a) Select variants  
6 java -jar Paget/Softwares/GATK_2.4.3/GenomeAnalysisTK-2.4-3-
g2a7af43/GenomeAnalysisTK.jar -T SelectVariants -R hg19.fa -V P1_HC.vcf -
selectType SNP -o P1_raw_snps.vcf 
  
2.2.2 InDels      
a) Select variants   
7 java -jar GATK_2.4.3/GenomeAnalysisTK-2.4-3-g2a7af43/GenomeAnalysisTK.jar -
T SelectVariants -R hg19.fa -V P1_HC.vcf -selectType INDEL -o P1_raw_indels.vcf 
 
2.3 Freebayes  
a) Variant calling (approximately 10h)  
# create bam.bai file 
8 samtools index P1recal.bam 
9 freebayes -f hg19.fa -b P1recal.bam -v P1_freebayes.vcf -0 --genotype-qualities  
  
2.3.1 SNPs  
a) Select variants  
10 java -jar GATK_2.4.3/GenomeAnalysisTK-2.4-3-g2a7af43/GenomeAnalysisTK.jar -
T SelectVariants -R hg19.fa -V P1_freebayes.vcf -selectType SNP -o 
P1_fb_raw_snps.vcf 
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2.3.2 InDels        
a) Select variants    
11 java -jar GATK_2.4.3/GenomeAnalysisTK-2.4-3-g2a7af43/GenomeAnalysisTK.jar -
T SelectVariants -R hg19.fa -V P1_freebayes.vcf -selectType INDEL -o 
P1_fb_raw_indels.vcf 
 
2.4 Samtools mpileup   
a) Variant calling (approximately 6h)  
12 samtools mpileup -C50 -ugf hg19.fa P1recal.bam | bcftools view -bvcg - > 
P1_samtools.bcf  
 
# Convert from bcf to vcf  
13 bcftools view P1_samtools.bcf > P1_samtools.vcf 
 
# Select variants - SNPs      
14  java -jar GATK_2.4.3/GenomeAnalysisTK-2.4-3-g2a7af43/GenomeAnalysisTK.jar 
-T SelectVariants -R hg19.fa -V P1_samtools.vcf -selectType SNP -o 
P1_raw_snps_sam.vcf     
 
# Select variants - INDELs       
15 java -jar GATK_2.4.3/GenomeAnalysisTK-2.4-3-g2a7af43/GenomeAnalysisTK.jar -
T SelectVariants -R hg19.fa -V P1_samtools.vcf -selectType INDEL -o 
P1_raw_indels_sam.vcf  
 
2.5 Combined analysis 
 2.5.1 SNPs  
# Compare the output files obtained with the 4 variant call tools and create a final file 
only with the common variants between the 4 tools, for each individual – to construct a 
combined analysis  
16 awk 'NR==FNR{a[$2];next} $2 in a‘P1_fb_raw_snps.vcf P1_HCfilter_snp_chrA.vcf 
> P1_1.vcf      
17 awk 'NR==FNR{a[$2];next} $2 in a' P1_raw_snps_sam.vcf P1filter_snp_chrA.vcf > 
P1_2.vcf      
18 awk 'NR==FNR{a[$2];next} $2 in a' P1_1.vcf P1_2.vcf > P1_snps.vcf  
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b) VariantRecalibrator      
19 java -jar GATK_3.1.1/GenomeAnalysisTK.jar -T VariantRecalibrator -R hg19.fa -
input P1_snps.vcf -resource:hapmap,known=false,training=true,truth=true,prior=15.0 
hapmap_3.3.hg19.chrM_reordered.vcf -
resource:omni,knwon=false,training=true,truth=true,prior=12.0 
1000G_omni2.5.hg19.vcf -
resource:1000G,known=false,training=true,truth=false,prior=10.0 
Mills_and_1000G_gold_standard.indels.hg19.vcf -
resource:dbsnp,known=true,training=false,truth=false,prior=2.0 
dbsnp_138.hg19.chrM_reordered.vcf -an DP -an QD -an FS -an MQ -an MQRankSum -
mode SNP -recalFile P1raw.SNPs.recal -tranchesFile P1raw.SNPs.tranches -rscriptFile 
P1recalSNP.plots.R      
 
# ApplyRecalibration  
20 java -jar GATK_3.1.1/GenomeAnalysisTK.jar -T ApplyRecalibration -R hg19.fa -
input P1_snps.vcf -mode SNP --ts_filter_level 99.0 -recalFile P1raw.SNPs.recal -
tranchesFile P1raw.SNPs.tranches -o P1recalibrated_snps.vcf 
 
c) VariantFiltration       
21 java -jar GATK_3.1.1/GenomeAnalysisTK.jar -T VariantFiltration -R hg19.fa -V 
P1recalibrated_snps.vcf --filterExpression "QD < 2.0 || FS > 60.0 || MQ < 40.0 || 
HaplotypeScore > 13.0 || MQRankSum < -12.5 || ReadPosRankSum < -8.0" --
filterName "Hard_to_Validate" -o P1filter_snps_1.vcf      
22 java -jar GATK_3.1.1/GenomeAnalysisTK.jar -T VariantFiltration -R hg19.fa -V 
P1filter_snps_1.vcf --filterExpression "DP < 4" --filterName "Low_Read_Support" -o 
P1filter_snps_2.vcf 
 
# Remove variants present in chrX, chrY and chrM      
23 cat P1filter_snps_2.vcf | grep -v '^chrX' | grep -v '^chrY' | grep -v '^chrM' | grep -v 
'Hard_to_Validate' | grep -v 'Low_Read_Support' | grep -v 'LowQual' > 
P1_snp_chrA_combined.vcf 
 
2.5.2 InDels  
# Compare the output files obtained with the 4 variant call tools and create a final file 
only with the common variants between the 4 tools, for each individual – to construct a 
combined analysis    
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24 awk 'NR==FNR{a[$2];next} $2 in a' P1_fb_raw_indels.vcf 
P1_HCfilter_indel_chrA.vcf > P1_1.vcf      
25 awk 'NR==FNR{a[$2];next} $2 in a' P1_raw_indels_sam.vcf 
P1filter_indel_chrA.vcf > P1_2.vcf      
26 awk 'NR==FNR{a[$2];next} $2 in a' P1_1.vcf P1_2.vcf > P1_indels.vcf 
 
b) VariantRecalibrator      
27 java -jar GATK_3.1.1/GenomeAnalysisTK.jar -T VariantRecalibrator -R hg19.fa -
input P1_indels.vcf -resource:mills,known=true,training=true,truth=true,prior=12.0 
Mills_and_1000G_gold_standard.indels.hg19.vcf -an DP -an FS -an MQRankSum -an 
ReadPosRankSum -mode INDEL --maxGaussians 4 -recalFile 
P1recalibrated_INDEL.recal -tranchesFile P1recalibrated_INDEL.tranches -rscriptFile 
P1recalibrated_INDEL.plots.R 
 
# ApplyRecalibration      
29 java -jar GATK_3.1.1/GenomeAnalysisTK.jar -T ApplyRecalibration -R hg19.fa -
input P1_indels.vcf -mode INDEL --ts_filter_level 99.0 -recalFile 
P1recalibrated_INDEL.recal -tranchesFile P1recalibrated_INDEL.tranches -o 
P1recalibrated_indel.vcf 
 
c) VariantFiltration      
30 java -jar GATK_3.1.1/GenomeAnalysisTK.jar -T VariantFiltration -R hg19.fa -V 
P1recalibrated_indel.vcf --filterExpression "QD < 2.0 || FS > 200.0 || ReadPosRankSum 
< -20.0" --filterName "Hard_to_Validate" -o P1filter_indels_1.vcf      
 
31 java -jar GATK_3.1.1/GenomeAnalysisTK.jar -T VariantFiltration -R hg19.fa -V 
P1filter_indels_1.vcf --filterExpression "DP < 4" --filterName "Low_Read_Support" -o 
P1filter_indels_2.vcf 
 
# Remove variants present in chrX, chrY and chrM  
32 cat P1filter_indels_2.vcf | grep -v '^chrX' | grep -v '^chrY' | grep -v '^chrM' | grep -v 
'Hard_to_Validate' | grep -v 'Low_Read_Support' | grep -v 'LowQual' > 
P1_indel_chrA_combined.vcf 
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3. Variant annotation 
3.1 Functional analysis 
# Link to download dbNSFP in SnpEff     
http://sourceforge.net/projects/snpeff/files/databases/dbNSFP/dbNSFP2.4.txt.gz/downlo
ad     
http://sourceforge.net/projects/snpeff/files/databases/dbNSFP/dbNSFP2.4.txt.gz.tbi/dow
nload 
 
# Link to dbSNP 
ftp://ftp.ncbi.nih.gov/snp/organisms/human_9606_b141_GRCh37p13/VCF/All.vcf.gz 
 
# Link refseq to VEP ensembl 
ftp://ftp.ensembl.org/pub/release-75/variation/VEP/homo_sapiens_refseq_vep_75.tar.gz  
ftp://ftp.ensembl.org/pub/release-75/variation/VEP/homo_sapiens_vep_75.tar.gz 
 
3.1.1 SnpSift 
a) Annotation with SnpSift    
1 java -jar snpEff/SnpSift.jar dbnsfp -v snpEff/dbNSFP2.4.txt.gz 
P1_snp_chrA_combined.vcf > P1_snps_dbnsfp.vcf 
 
b) Annotation dbSNP 141 
2 java –jar snpEff/SnpSift.jar annotate dbSNP141.vcf P1_snps_dbnsfp.vcf > 
P1_snps_dbsnp.vcf 
  
3.1.2 VEP ensembl (approximately 1h)  
a) Annotation with VEP      
3 perl variant_effect_predictor.pl --cache --everything --pick -i 
P1_snp_chrA_combined.vcf -o P1_annot_vep.vcf
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Appendix B - Fisher Strand Bias calculation example 
2 x 2 frequency table: 
  
    Contingency tables – all configurations with the same frequencies 
 
Table A  Table B  Table C  Table D  Table E  Table F  Table G 
9 6 15 
 
10 5 15 
 
11 4 15 
 
12 3 15 
 
13 2 15 
 
14 1 15 
 
15 0 15 
16 0 16 
 
15 1 16 
 
14 2 16 
 
13 3 16 
 
12 4 16 
 
11 5 16 
 
10 6 16 
25 6 31 
 
25 6 31 
 
25 6 31 
 
25 6 31 
 
25 6 31 
 
25 6 31 
 
25 6 31 
 
Fisher probability: 
Table A – Fisher probability = 0.0068 
Table B – Fisher probability = 0.0653   
Table C – Fisher probability = 0.222  
Table D – Fisher probability = 0.346  
Table E – Fisher probability = 0.260  
Table F – Fisher probability = 0.0890  
Table G – Fisher probability = 0.0109  
p-value = 0.0068 + 0.0653 + 0.222 + 0.260 + 0.0890 + 0.0109 = 0.6539 (the probability for the Table D is not included because it is more 
probable than the observed frequency configuration) 
Fisher strand bias = -10log100.6539 = 1.8446 
NLRC3 Strand (+) Strand (-) Sum 
ref alleles 13 2 15 
obs alleles 12 4 16 
Sum 25 6 31 
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Appendix C –Results for the two models from our WES analysis 
 
Table C.1. Variants obtained from the SNPs category from our bioinformatics pipeline (model 1). We applied three filters (as described in sub-chapter 
3.6) and identified 16 variants. These are absent from the unaffected (ID IV.1-080002) but present in all five affected individuals. Also, these variants are not 
present in public databases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chr: Chromosome; Ref: Reference; Obs: Observed; CDS change: Coding DNA sequence change; NSV: Non-synonymous Variants.  
 
 
Chr Position (bp) 
Ref 
allele 
Obs 
allele 
Gene CDS change Variant classification SIFT score PolyPhen-2 score 
2 1.457.407 T C TPO c.483-59T>C Intron  - - 
2 171.702.584 C T GAD1 c.1002+11C>T Intron  - - 
6 32.609.813 T C HLA-DQA1 c.396T>C Synonymous  - - 
6 32.709.346 T C HLA-DQA2 c.82+44T>C Intron  - - 
6 32.709.370 T C HLA-DQA2 c.82+68T>C Intron  - - 
8 145.171.113 C T KIAA1875 c.4786C>T NSV 0.000 0.996 
9 85.622.564 T C RASEF c.960-144A>G Intron  - - 
12 121.097.538 A G CABP1 c.655-143A>G Intron  - - 
16 2.105.335 C G TSC2 c.482-68C>G Intron  - - 
16 3.627.162 G A NLRC3 c.53C>T NSV 0.920 0.000 
16 4.245.598 A G SRL c.566T>C NSV 0.000 0.948 
16 4.513.886 G A NMRAL1 c.530-35C>T Intron  - - 
16 1.330.7046 G A SHISA9 c.848-64G>A Intron  - - 
17 43.924.412 T C SPPL2C c.*85T>C 3’UTR - - 
21 9.912.194 T C TEKT4P2 n.130-2917A>G Intron  - - 
21 9.914.197 C T TEKT4P2 n.130-4920G>A Intron  - - 
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Table C.2. Variants obtained from the InDels category from our bioinformatics pipeline (model 1). We applied three filters (as described in sub-chapter 
3.6) and identified one variant. These are absent from the unaffected (ID IV.1-080002) but present in all five affected individuals. Also, these variants are not 
present in public databases. 
Chr Position (bp) Ref allele Obs allele Gene CDS change Variant classification 
SIFT 
score 
PolyPhen-2 
score 
16 2.115.413 
CAAAAAAA
AAAAAAAA 
C TSC2 
c.1600-106_1600-
92delAAAAAAAAAAAAAAA 
Intron  - - 
Chr: Chromosome; Ref: Reference; Obs: Observed; CDS change: Coding DNA sequence change.  
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Table C.3. Variants obtained from the SNPs category from our bioinformatics pipeline (model 2). We applied three filters (as described in sub-chapter 
3.6) and identified eight variants. These are absent from the two unaffected relatives (ID IV.1-080002 and IV.3-090095) but present in all four affected 
individuals. Also, these variants are not present in public databases. 
Chr Position (bp) 
Ref 
allele 
Obs 
allele 
Gene CDS change Variant classification SIFT score 
PolyPhen-2 
score 
1 26.863.294 G A RPS6KA1 c.64-122G>A Intron  - - 
1 31.896.668 G A SERINC2 c.195G>A NSV 0.030 0.068 
4 69.540.024 T C UGT2B15 - Upstream - - 
12 58.218.301 A G CTDSP2 c.412-199T>C Intron  - - 
19 32.130.944 T C - - Intergenic  - - 
19 35.530.272 C G HPN - Upstream - - 
19 36.018.347 G T SBSN c.837C>A Synonymous  - - 
21 9.913.829 C T TEKT4P2 n.130-4552G>A Intron  - - 
Chr: Chromosome; Ref: Reference; Obs: Observed; CDS change: Coding DNA sequence change; NSV: Non-synonymous Variants.  
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Table C.4. Variants obtained from the InDels category from our bioinformatics pipeline (model 2). We applied three filters (as described in sub-chapter 
3.6) and identified two variants. These are absent from the two unaffected relatives (ID IV.1-080002 and IV.3-090095) but present in all four affected 
individuals. Also, these variants are not present in public databases. 
Chr Position (bp) Ref allele Obs allele Gene CDS change Variant classification 
SIFT 
score 
PolyPhen-2 
score 
1 6.529.182 TTCCTCC T PLEKHG5 c.2400_2405delGGAGGA NFD - - 
12 6.909.380 TG T CD4 c.49+28delG Intron  - - 
Chr: Chromosome; Ref: Reference; Obs: Observed; CDS change: Coding DNA sequence change; NFD: Non-Frameshift Deletion.  
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Appendix D - PCR conditions 
 
Variants Stepdown PCR conditions 
c.C8800T (G/A) and c.C871T (G/A) 
25 cycles 
94 o /30 seconds 
70 o /30 seconds (-1 o C/cycle) 
72 o /60 seconds 
30 cycles 
94 o /10 seconds 
55 o /45 seconds 
72 o /60 seconds 
72 o /7 minutes 
4 o /∞ 
c.T1933C (T/C) and c.2163_2168del 
(TTCCTCC/T) 
20 cycles 
94 o /30 seconds 
70 o /30 seconds (-1 o C/cycle) 
72 o /60 seconds 
30 cycles 
94 o /10 seconds 
55 o /45 seconds 
72 o /60 seconds 
72 o /7 minutes 
4 o /∞ 
c.C2264T (G/A) 
20 cycles 
94 o /30 seconds 
70 o /30 seconds (-0.5 o C/cycle) 
72 o /60 seconds 
30 cycles 
94 o /10 seconds 
60 o /45 seconds 
72 o /60 seconds 
72 o /7 minutes 
4 o /∞ 
c.C4786T (C/T) 
20 cycles 
94 o /30 seconds 
65 o /30 seconds (-0.5 o C/cycle) 
72 o /60 seconds 
30 cycles 
94 o /10 seconds 
53 o /45 seconds 
72 o /60 seconds 
72 o /7 minutes 
4 o /∞ 
c.C53T (G/A) 
20 cycles 
94 o /30 seconds 
70 o /30 seconds (-1 o C/cycle) 
72 o /30 seconds 
30 cycles 
94 o /10 seconds 
55 o /45 seconds 
72 o /60 seconds 
72 o /7 minutes 
4 o /∞ 
c.T566C (A/G) 
20 cycles 
94 o /30 seconds 
65 o /30 seconds (-0.5 o C/cycle) 
72 o /60 seconds 
30 cycles 
94 o /10 seconds 
52 o /45 seconds 
72 o /60 seconds 
72 o /7 minutes 
4 o /∞ 
c.G180A (G/A) 
20 cycles 
94 o /30 seconds 
70 o /30 seconds (-0.5 o C/cycle) 
72 o /60 seconds 
42 cycles 
94 o /10 seconds 
50 o /45 seconds 
72 o /60 seconds 
72 o /7 minutes 
4 o /∞ 
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Appendix E - Ethics committee approval 
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Appendix F – Quality control 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure F.1. Bioanalyzer results. A – After running the three PDB samples and nine controls, in 
the DNA LabChip, a gel-like image of the ladder and all DNA samples was obtained. B – 
Electropherograms of the ladder and three PDB samples. These graphs depicted the 
fluorescence units (FU) per base pair. Two markers bracketing the overall sizing range were run 
with each sample. The two peaks represented in the electropherograms are the “lower” (50 bp) 
and “upper” (10380 bp) markers (internal standards). 
B 
A 
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Appendix G – Sequence Quality graphs 
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Figure G.1.  Sequence quality graphs per base for the six individuals exome-sequenced using the 
FASTQ1 (A1 through F1) and the FASTQ2 (A2 through F2) files. A1 and A2 – III.2-080004; B1 and 
B2 – IV.1-080002; C1 and C2 – IV.9-090044; D1 and D2 – IV.3-090095; E1 and E2 – III.4-080001; F1 
and F2 – III.6-080005. The x-axis shows the position in the read (in base pairs) and the y-axis shows the 
quality score across all bases. The graph is divided into three colours: green, orange and red represent the 
calls with good, reasonable and bad quality, respectively. The higher the quality score the better the base 
call. The quality of the calls typically degrades as the run progresses. At each position a whisker box-plot 
was drawn. The yellow box represents the inter-quartile range of each position (from 25 to 75%). The 
upper and lower whiskers represent the 10% and 90% points. Central red line is the median value and the 
blue line represents the mean quality.  
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Figure G.2. Sequencing and cumulative sequencing depth graphs for the six individuals 
exome-sequenced. A: III.2-080004; B: IV.1-080002; C: IV.9-090044; D: IV.3-090095; E: 
III.4-080001; F: III.6-080005).  
E 
F 
Family Genetics of Paget’s Disease of Bone                                                          Appendix H 
 
126 
 
A 
B 
Appendix H – Sanger Sequencing chromatograms 
 
T G G C C T A T G C C C C C G [C/T] G C C C C G C T G C C C C C G – Family 1 
 
 
 
 
 
 
 
 
 
 
 
 
T G G C C T A T G C C C C C G [C/T] G C C C C G C T G C C C C C G – Family 2 
 
 
 
 
 
 
 
 
 
Figure H.1. Chromatograms for the c.C4786T variant (reverse strand). A – Family 1: the 
mutated T allele for the c.C4786T variant was detected in patients (III.1-080003, III.2-080004, 
III.4-080001, III.6-080005, IV.3-090095 and IV.9-090044), and in the controls (III.8-090043 
and IV.1-080002). B – Family 2: the ancestral C allele for the c.C4786T variant was detected in 
patients (II.2-140030 and II.3-140029), in the unclear individuals (III.1-140031 and III.2-
140034) and in controls (II.1-140033 and IV.1-140032). 
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A 
B 
 
A C C T C C C G G G C C T C [G /A] A T G C T G G C T C C A G G – Family 1 
 
 
 
 
 
 
 
 
 
 
 
 
A C C T C C C G G G C C T C [G /A] A T G C T G G C T C C A G G – Family 2 
 
 
 
 
 
 
 
 
 
 
Figure H.2. Chromatograms for the c.C53T variant (forward strand). A – Family 1: the 
mutated A allele for the c.C53T variant was detected in patients (III.1-080003, III.2-080004, 
III.4-080001, III.6-080005, IV.3-090095 and IV.9-090044), and in the controls (III.8-090043 
and IV.1-080002). B – Family 2: the ancestral G allele for the c.C53T variant was detected in 
patients (II.2-140030 and II.3-140029), in the unclear individuals (III.1-140031 and III.2-
140034) and in controls (II.1-140033 and IV.1-140032). 
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A 
B 
 
 
A T G C C T G G T G T A T C C [A/G] C A A A A G T G A C C C T C – Family 1 
 
 
 
 
 
 
 
 
 
 
 
 
A T G C C T G G T G T A T C C [A/G] C A A A A G T G A C C C T C – Family 2 
 
 
 
 
 
 
 
 
 
Figure H.3. Chromatograms for the c.T566C variant (forward strand). A – Family 1: the 
mutated G allele for the c.T566C variant was detected in patients (III.1-080003, III.2-080004, 
III.4-080001, III.6-080005, IV.3-090095 and IV.9-090044), and in the controls (III.8-090043 
and IV.1-080002). B – Family 2: the ancestral A allele for the c.T566C variant was detected in 
patients (II.2-140030 and II.3-140029), in unclear individuals (III.1-140031 and III.2-140034) 
and in controls (II.1-140033 and IV.1-140032). 
 
 
 
 
 
Family Genetics of Paget’s Disease of Bone                                                          Appendix H 
 
129 
 
A 
B 
 
G G T G T C C A T C A T T A T [G/A] C T G A G C C C G G G C G T – Family 1 
 
 
 
 
 
 
 
 
 
 
 
 
G G T G T C C A T C A T T A T [G/A] C T G A G C C C G G G C G T – Family 2 
 
 
 
 
 
 
 
 
 
Figure H.4. Chromatograms for the c.G180A variant (forward strand). A – Family1: the 
mutated A allele for the c.G180A variant was detected in patients (III.1-080003, III.2-080004, 
III.4-080001, III.6-080005 and IV.9-090044), and in the controls (III.8-090043 and IV.1-
080002). The variant is absent in the unclear individual IV.3-090095. B – Family 2: the 
ancestral G allele for the c.G180A variant was detected in patients (II.2-140030 and II.3-
140029), in the unclear individuals (III.1-140031 and III.2-140034) and in controls (II.1-140033 
and IV.1-140032). 
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C T C C T C C T C C T C C T [C C T C C T C / C] T T C C T C C T C C T G C T – Family 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C C T T C C T C C T C C T C C T C C T C C T C C T [C C T C C T C / C] T T C – Family 2 
 
Figure H.5. Chromatograms for the c.2163_2168del variant (reverse strand). A – Family 1: 
the deletion CTCCTC for the 6.529.184/6.529.190 bp position in chromosome 1 was detected in 
patients (III.1-080003, III.2-080004, III.4-080001, III.6-080005 and IV.9-090044), and in the 
controls (III.8-090043 and IV.1-080002). The deletion is absent in the unclear individual IV.3-
090095. B – Family 2: the deletion CTC for the 6.529.187/6.529.190 bp position in 
chromosome 1 was detected in the controls (II.1-140033 and IV.1-140032), and was absent in 
patients (II.2-140030 and II.3-140029) and in the unclear individuals (III.1-140031 and III.2-
140034).  
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A T C C A G C C T G A A G C C [T/C] T C T T C A G C A T C T A C  – Family 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
A T C C A G C C T G A A G C C [T/C] T C T T C A G C A T C T A C  – Family 2 
 
Figure H.6. Chromatograms for the c.T1933C variant (forward strand). A –the mutated C 
allele for c.T1933C variant was detected in patients (III.1-080003, III.2-080004, III.4-080001, 
III.6-080005 and IV.9-090044), and in controls (III.8-090043 and IV.1-080002) from family 1. 
The variant is absent in the unclear individual IV.3-090095 from family 1. B –the mutated C 
allele, for c.T1933C variant was detected in patients (II.2-140030 and II.3-140029), in the 
unclear individuals (III.1-140031 and III.2-140034) and in both controls (II.1-140033 and IV.1-
140032) from family 2. 
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Appendix I – Variants in genes associated with PDB 
 
Table I.1. Exonic, regulatory, intronic, intergenic and splicing variants in PDB-associated genes. Variants present at least one individual from family 1. 
Individual 
Variant 
classification 
Gene CDS change dbSNP 
1000 GP 
(MAF) 
SIFT 
score 
PolyPhen-2 
score 
Chr 
Start position 
(bp) 
Ref 
allele 
Obs 
allele 
P2, C, U Upstream  
CSF1 
- rs1999714 0.556 - - 1 110.450.033 G T 
U Upstream - rs1999713 0.551 - - 1 110.450.177 T C 
U Intron c.162+65G>A . - - - 1 110.457.068 G A 
P1, P3, P4, C, U Intron  c.226-142C>T rs333967 0.699 - - 1 110.459.773 C T 
C Intron  c.396+1569G>A rs333969 0.001 - - 1 110.461.654 G A 
P2, U Synonymous  c.1095C>A rs333970 0.553 - - 1 110.466.338 C A 
P1, P2, P3, P4, C, U NSV c.1223T>C rs1058885 0.574 0.300 0.011 1 110.466.466 T C 
P1, P2, P3, P4, C, U NSV c.1466T>C rs333971 0.002 0.970 0.003 1 110.466.709 T C 
P1, P2, P3, P4, C, U Intron  c.1623-24A>G rs333972 0.002 - - 1 110.467.745 A G 
P2 Splice region c.*13+7T>A rs41313284 0.993 - - 1 110.467.831 T A 
P1, P2, P3, P4, C, U Intron  c.*13+185C>A rs3138072 0.905 - - 1 110.468.009 C A 
P1 Upstream 
CaSR 
- rs6776158 0.411 - - 3 121.901.849 G A 
U Intron  c.-243+6512A>G rs73858157 0.855 - - 3 121.909.888 A G 
U Intron  c.-243+7319C>G rs1553308 0.254 - - 3 121.910.695 C G 
U Intron  c.-243+7330A>G rs1553309 0.662 - - 3 121.910.706 A G 
C Intron  c.-243+10478_-243+10479insCTC rs111507015 - - - 3 121.913.854 G GCTC 
U Intron  c.-243+19950G>A rs62271400 0.628 - - 3 121.923.326 G A 
U Intron  c.-243+32891A>G rs11721042 0.321 - - 3 121.936.267 A G 
U Intron  c.-243+32902T>C rs11717321 0.322 - - 3 121.936.278 T C 
U Intron  c.-243+34086_-243+34088delAGA rs34710605 0.335 - - 3 121.937.461 TAGA T 
C Intron  c.-242-3948T>G rs2173961 0.369 - - 3 121.968.847 T G 
C, U Intron  c.-242-1436_-242-1433delAGAA rs141055482 0.375 - - 3 121.971.358 GAGAA G 
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C Intron  
CaSR 
c.-242-1283G>T rs937625 0.175 - - 3 121.971.512 G T 
P1, P2, P3, P4, C, U Intron  c.492+19G>A rs9869985 0.078 - - 3 121.976.253 G A 
P1, P2, U Intron  c.493-133T>C rs3749207 0.465 - - 3 121.980.242 T C 
P2 Intron  c.493-91C>T rs3749208 0.666 - - 3 121.980.284 C T 
U Intron  c.1377+2546C>T rs36060529 0.799 - - 3 121.983.805 C T 
P2 Intron  c.1378-1185C>T rs35780274 0.747 - - 3 121.993.474 C T 
P1, P2, P3, U Intron  c.1609-59C>T rs4678174 0.468 - - 3 122.000.871 C T 
P3, P4 Intron  c.1762+16T>C rs2270916 0.821 - - 3 122.001.099 T C 
P1, U Intron  c.1762+163C>T rs2270917 0.468 - - 3 122.001.246 C T 
P1, P2, P3, P4, C, U Synonymous c.2274G>C rs2036400 0.025 - - 3 122.003.045 G C 
P2 NSV c.2986G>T rs386545639 0.924 0.170 0.012 3 122.003.757 G T 
P1, P2, P3, P4, C, U NSV c.3061G>C rs1801726 0.077 0.910 0.000 3 122.003.832 G C 
P1, P2, P3, P4, U 3’UTR c.*60A>T rs4677948 0.078 - - 3 122.004.098 A T 
U Intron  
SQSTM1 
c.-48+2228A>C rs10516140 0.259 - - 5 179.240.910 A C 
U Upstream - rs172057 0.008 - - 5 179.245.959 C T 
U Intron  c.673+152T>G rs55993594 0.440 - - 5 179.251.475 T G 
P3 Intron  c.755-23G>A rs386562270 0.599 - - 5 179.260.009 G A 
P3, U Synonymous c.876C>T rs4935 0.317 - - 5 179.260.153 C T 
P3, U Synonymous c.936G>A rs4797 0.420 - - 5 179.260.213 G A 
P3 Intron  c.970-109C>G rs2241350 0.859 - - 5 179.260.478 C G 
P1, P2, P3, P4 Intron  c.970-93G>A rs155787 0.388 - - 5 179.260.494 G A 
U 3’UTR c.*1322G>T rs1065154 0.306 - - 5 179.264.915 G T 
U Intron  
ESR1 
n.73+1350A>G rs851969 0.857 - - 6 151.979.248 A G 
U Intron  n.73+8791T>C rs1293959 0.000 - - 6 151.986.689 T C 
U Intron  n.73+8837G>T rs1293958 0.000 - - 6 151.986.735 G T 
P1 Intron  n.73+9908C>A rs7745737 0.748 - - 6 151.987.806 C A 
U Intron  c.-71+41215G>A rs1999806 0.609 - - 6 152.064.355 G A 
U Intron  c.-71+46651A>G rs2982575 0.607 - - 6 152.069.791 A G 
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U Intron  
ESR1 
c.-70-31281C>G rs2504068 0.376 - - 6 152.097.697 C G 
P2, P4, C Synonymous c.30T>C rs386556657 0.568 - - 6 152.129.077 T C 
U Intron  c.453-8005A>T rs827424 0.179 - - 6 152.155.727 A T 
P1, P2, P3, P4, C, U Synonymous c.729T>C rs4986934 0.018 - - 6 152.201.875 T C 
P1, P2, P3, P4 Intron  c.760+101T>C rs3757323 0.558 - - 6 152.202.007 T C 
P2 Intron  c.760+22195A>G rs12215922 0.841 - - 6 152.224.101 A G 
P2 Intron  c.760+27539T>C rs1514347 0.273 - - 6 152.229.445 T C 
P1, P2 Intron  c.761-26_761-25insT rs55740371 0.512 - - 6 152.265.282 A AT 
P1, P2, P3, P4, C, U Synonymous c.975G>C rs1801132 0.262 - - 6 152.265.522 G C 
C, U Synonymous c.1782G>A rs2228480 0.821 - - 6 152.420.095 G A 
P3 Upstream 
NUP205 
- rs4728356 0.015 - - 7 135.240.927 C T 
C Intron  c.28+27T>C rs117892953 0.988 - - 7 135.242.747 T C 
P1, P3, P4, C Intron  c.28+190C>T rs6961420 0.494 - - 7 135.242.910 C T 
P1, P3, P4, C Intron  c.649-11T>C rs10252250 0.659 - - 7 135.262.533 T C 
P1 Intron  c.1218+819A>G rs7781687 0.001 - - 7 135.270.574 A G 
P1, P3, P4, C Intron  c.1219-53T>C rs10271506 0.758 - - 7 135.272.270 T C 
P1, P2, P3, P4, C, U Intron  c.1624+137G>A rs4410839 0.000 - - 7 135.276.485 G A 
P1, P3, P4, C Synonymous c.1851A>C rs7800214 0.653 - - 7 135.279.315 A C 
P1, P2, P4, C, U Intron  c.2374+71T>C rs4296989 0.009 - - 7 135.285.788 T C 
U Intron  c.3310+307G>A rs4316099 0.016 - - 7 135.299.328 G A 
P1, P2, P3, P4, C, U NSV c.4066G>C rs7810767 0.014 0.730 0.001 7 135.304.273 G C 
P1, P3, P4, C, U Intron  c.4671+102A>G rs6972359 0.663 - - 7 135.310.205 A G 
P1, P2, P3, P4, C, U Intron  c.4672-128G>A rs10085457 0.728 - - 7 135.310.860 G A 
P2 Intron  c.4793+11G>A rs7810260 0.586 - - 7 135.311.120 G A 
P1, P2, P3, P4, C, U Intron  c.4793+58G>A rs10234309 0.282 - - 7 135.311.167 G A 
P1, P2, P3, P4, C, U Splice region c.5559+4C>T rs10260691 0.720 - - 7 135.328.110 C T 
P2, P3, P4, U Intron  c.5813-77C>A rs62479523 0.885 - - 7 135.330.829 C A 
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P4, U Splice region 
TNFRSF11B 
c.817+8A>C rs7844539 0.935 - - 8 119.938.725 T G 
P4, U Synonymous  c.768A>G rs2228568 0.928 - - 8 119.938.782 T C 
P4, U Intron  c.592+55_592+56delCT rs10554146 0.822 - - 8 119.940.920 CAG C 
P1, P2, P3, P4, C, U Splice region c.401-5T>C rs3134046 0.084 - - 8 119.941.173 A G 
P3 Intron  c.401-109T>C rs4876869 0.677 - - 8 119.941.277 A G 
U Intron  c.401-1477C>T rs11573916 0.929 - - 8 119.942.645 G A 
P4, U Splice region c.400+4C>T rs1564858 0.928 - - 8 119.945.166 G A 
U Intron  c.30+4374G>A rs3134063 0.408 - - 8 119.959.657 C T 
P2, P3, U Intron  c.30+188C>A rs386513902 0.801 - - 8 119.963.843 G T 
P1, P2, P3, P4, C, U NSV c.9C>G rs2073618 0.357 1.000 0.000 8 119.964.052 G C 
P1, P2, P3, P4, C, U 5’UTR c.-223C>T rs2073617 0.408 - - 8 119.964.283 G A 
C 5’UTR c.-266C>A . - - - 8 119.964.326 G T 
P3, P4, C, U 3’UTR 
VCP 
c.*153G>T rs1053318 0.826 - - 9 35.056.961 C A 
C, U Intron  c.2161-241C>T rs12686362 0.823 - - 9 35.057.768 G A 
P1, P2, P4 Synonymous c.1704A>G rs142577424 0.998 - - 9 35.059.790 T C 
P1, P2, P3, P4, C, U Splice region c.1695+8A>G rs684562 0.573 - - 9 35.060.302 T C 
P1, P2, P3, P4, U Intron  c.1482+52T>C rs562381 0.306 - - 9 35.060.746 A G 
P1, P2, P3, P4, C, U Intron  c.1360-35A>G rs2258240 0.296 - - 9 35.060.955 T C 
P1, P3, P4 Intron  c.1194+71A>G rs2074549 0.859 - - 9 35.061.503 T C 
P1, P2, P3, P4, C, U Splice region 
c.1082-18_1082-
8dupTTGTGTACTGT 
rs11272867 0.590 - - 9 35.061.693 G 
GACAGT 
ACACAA 
P1, P2, P3, P4, C, U Splice region c.811+3G>A rs514492 0.298 - - 9 35.062.972 C T 
P1, P2, P4 Intron  c.446-140G>A rs41274873 0.997 - - 9 35.065.518 C T 
P1, P3, P4, C, U Intron  c.129+47G>A rs10972300 0.844 - - 9 35.068.201 C T 
P1, P2, U Upstream 
OPTN 
- rs642347 0.009 - - 10 13.138.143 A C 
P1, P2, P4 Synonymous c.102G>A rs2234968 0.820 - - 10 13.151.224 G A 
P1, P2, P3, P4 Intron  c.166+66A>G rs10906303 0.815 - - 10 13.151.354 A G 
P1, P4, C, U Intron  c.167-157A>G rs60399947 0.861 - - 10 13.152.117 A G 
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P1, P4, C, U Intron  
OPTN 
c.167-150C>T rs60221241 0.882 - - 10 13.152.124 C T 
P2 Intron  c.369+29delT rs398096802 - - - 10 13.152.504 GT G 
C Intron  c.369+190T>G rs7921853 0.681 - - 10 13.152.666 T G 
P1, P2, P3, P4, C, U Splice region c.553-5C>T rs2244380 0.205 - - 10 13.158.262 C T 
P1 Intron  c.780-165T>C . - - - 10 13.164.220 T C 
P3 Intron  c.780-53T>C rs765884 0.809 - - 10 13.164.332 T C 
P1, P2, P3, P4, C, U Intron  c.882+109A>G rs489040 0.517 - - 10 13.164.596 A G 
P2 Intron  c.882+196G>T rs59554572 0.950 - - 10 13.164.683 G T 
P1, P2, P3, P4, C, U NSV c.964A>G rs523747 0.009 1.000 0.000 10 13.166.076 A G 
P1, P2, P3, P4, C, U Intron  c.1149-86G>T rs676302 0.199 - - 10 13.167.860 G T 
P3 Intron  c.1401+389A>C rs7919563 0.710 - - 10 13.170.292 A C 
P3, P4 Intron  c.1402-253A>G rs3740209 0.704 - - 10 13.173.814 A G 
P2 Intron  c.1532+72G>A rs77873111 0.978 - - 10 13.174.269 G A 
P1, P2, P3, P4, C, U Intron  c.1612+101A>C rs7086894 0.675 - - 10 13.175.682 A C 
U Intron  c.1612+279G>C rs7068612 0.698 - - 10 13.175.860 G C 
P1 Intron  c.1613-554G>A rs11258219 0.789 - - 10 13.178.191 G A 
P1 Intron  c.1613-544T>A rs7078784 0.226 - - 10 13.178.201 T A 
P1, P2, P3, P4, C, U Intron  c.1613-48C>A rs10906310 0.734 - - 10 13.178.697 C A 
P1, P4, U Intron  
RIN3 
c.44+233C>A rs71430764 0.978 - - 14 92.980.553 C A 
U Intron  c.44+10859A>G rs11622288 0.603 - - 14 92.991.179 A G 
P1 Intron  c.44+18651C>T rs6575265 0.296 - - 14 92.998.971 C T 
P3 Intron  c.45-10541T>C rs7142824 0.230 - - 14 93.011.555 T C 
P1 Intron  c.249+56G>A rs74072951 0.865 - - 14 93.022.356 G A 
U Intron  c.367+214G>A rs7159046 0.800 - - 14 93.044.036 G A 
P3 Intron  c.367+862A>G rs7159925 0.449 - - 14 93.044.684 A G 
P2 Intron  c.367+8645C>A rs10136857 0.005 - - 14 93.052.467 C A 
P3 Intron  c.367+13849G>A rs4904952 0.005 - - 14 93.057.671 G A 
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P1 Intron  
RIN3 
c.368-13818T>C rs2146499 0.014 - - 14 93.067.934 T C 
P3 Intron  c.368-3046A>G rs2181380 0.014 - - 14 93.078.706 A G 
P2, U Intron  c.368-99C>T rs75641131 0.927 - - 14 93.081.653 C T 
U Intron  c.440+10873A>G rs7151638 0.0060 - - 14 93.092.697 A G 
C Intron  c.441-5011_441-5008delAGAA rs142704371 0.850 - - 14 93.102.571 CAGAA C 
U Intron  c.533-139_533-134delCAACCT rs11278705 0.012 - - 14 93.117.787 ACAACCT A 
P1, P2, P3, P4, C, U NSV c.644A>G rs3829947 0.566 - 0.000 14 93.118.038 A G 
U Synonymous c.804C>T rs3814830 0.735 - - 14 93.118.198 C T 
C, U NSV c.1274C>T rs3742717 0.725 0.270 0.014 14 93.118.668 C T 
P1, P3, P4, C, U Synonymous c.1275G>A rs3742716 0.717 - - 14 93.118.669 G A 
C Synonymous c.2013C>T rs3818321 0.860 - - 14 93.119.407 C T 
P1, C Intron  c.2027-2929C>T rs8013795 0.011 - - 14 93.122.577 C T 
P1 Intron  c.2027-224G>T rs12885166 0.714 - - 14 93.125.282 G T 
P2, C Intron  c.2027-91G>C rs2295991 0.686 - - 14 93.125.415 G C 
P2 Intron  c.2336-326A>G rs2273926 0.720 - - 14 93.142.494 A G 
P2 Intron  c.2336-286T>C rs2273925 0.746 - - 14 93.142.534 T C 
P2, C, U Intron  c.2336-183G>A rs2273924 0.719 - - 14 93.142.637 G A 
P2, C, U Intron  c.2336-175T>C rs2273923 0.720 - - 14 93.142.645 T C 
P1, P4 Intron  c.2336-169G>A rs733447 0.790 - - 14 93.142.651 G A 
P2 NSV c.2377T>C rs147042536 0.997 0.000 0.999 14 93.142.861 T C 
U Intron  c.2632-859G>A rs61994063 0.763 - - 14 93.153.412 G A 
P1, P4, C, U NFD c.2899_2901delGGC rs71698059 0.331 - - 14 93.154.537 TGGC T 
P2 Intron  
PML 
c.602+206G>A rs3784562 0.410 - - 15 74.291.023 G A 
P1, P2, C Intron  c.1184-155T>C rs2277599 0.440 - - 15 74.317.043 T C 
C Intron  c.1254+603C>G rs12902857 0.437 - - 15 74.317.871 C G 
P3 Intron  c.1398+126A>G rs2304716 0.401 - - 15 74.325.182 A G 
P1, P3 Intron  c.1658-108G>A rs2304718 0.506 - - 15 74.326.711 G A 
P1, P2, P3, C Intron  c.1710+1245A>G rs743580 0.451 - - 15 74.328.116 A G 
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CDS change: Coding DNA sequence change; Chr.: Chromosome; Ref.: Reference; Obs.: Observed; NSV: Non-synonymous Variants; NFD: Non-Frameshift Deletion.  
Note – Individual: P1 - III.2-080004; P2 - IV.9-090044; P3 - III.4-080001; P4 - III.6-080005; C - IV.1-080002; U - IV.3-090095. 
Individual IV.1-080002 is a control, the remaining (III.4-080001, III.2-080004, III.6-080005, IV.9-090044 and IV.3-090095) are PDB affected, for model 1.  
Individuals IV.1-080002 and IV.3-090095 are controls, the remaining (III.4-080001, III.2-080004, III.6-080005 and IV.9-090044) are PDB affected, for model 2. 
C Intron  
PML 
c.1710+1270G>T rs743581 0.613 - - 15 74.328.141 G T 
P1, P2, P3 Intron  c.1710+1335G>C rs743582 0.882 - - 15 74.328.206 G C 
P1, P3 Intron  c.1710+1705A>G rs9479 0.466 - - 15 74.328.576 A G 
P1, P2, P3, P4 Intron  c.1862-168C>T rs8032123 0.059 - - 15 74.336.394 C T 
P1, P2, P3, P4 NSV c.1933T>C rs5742915 0.773 0.900 0.001 15 74.336.633 T C 
P3, U Intron  GOLGA6A c.1593+81A>G rs79015760 0.802 - - 15 74.364.478 T C 
P1, P2 Intron  
TNFRSF11A 
c.76-194G>C rs11152342 0.697 - - 18 60.015.207 G C 
P2 Intron  c.284-120T>G rs3826620 0.339 - - 18 60.021.504 T G 
P3, P4, U NSV c.421C>T rs35211496 0.920 0.130 0.762 18 60.021.761 C T 
P2 Intron  c.428-22delT . - - - 18 60.025.458 GT G 
U Intron  c.428-22_428-21delTT rs71160827 - - - 18 60.025.458 GTT G 
P3, P4 Intron  c.522-183T>A rs6567270 0.528 - - 18 60.027.005 T A 
P1, P3, P4, C, U Intron  c.522-39T>A rs6567271 0.395 - - 18 60.027.149 T A 
P1, P3, P4, C, U Intron  c.522-17C>T rs6567272 0.395 - - 18 60.027.171 C T 
P1, P3, P4, C, U NSV c.575C>T rs1805034 0.395 1.000 0.000 18 60.027.241 C T 
P1, P3, P4, C, U Intron  c.616+79G>A rs9653064 0.433 - - 18 60.027.361 G A 
U Intron  c.617-258A>C rs8083511 0.657 - - 18 60.028.655 A C 
P1, P3, C, U Intron  c.617-151G>A rs8099222 0.769 - - 18 60.028.762 G A 
C Intron  c.730+212G>C rs7239667 0.547 - - 18 60.029.238 G C 
P1, P2, P3, P4, C, U Synonymous c.933A>G rs8092336 0.022 - - 18 60.036.083 A G 
C NSV c.1519G>A rs61751992 0.996 0.040 0.276 18 60.036.669 G A 
C Intron  c.1568-399A>T rs9956633 0.015 - - 18 60.051.585 A T 
P1, C Intron  c.1568-43C>T rs56231704 0.876 - - 18 60.051.941 C T 
